

August 26, 2026

To,
Listing Department,
National Stock Exchange Limited
Exchange Plaza, C-1, Block-G,
Bandra Kurla Complex, Bandra (E),
Mumbai-400 051

Scrip Code – INFLUX

Dear Sir/Ma'am,

Sub: Notice of 6th Annual General Meeting and Annual Report for the Financial Year 2025-2026
Ref: Regulation 34 (1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

In compliance with Regulation 34 (1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Annual Report of the Company for the financial year 2025-2026, to be approved and adopted by the Members of the Company in the 6th Annual General Meeting to be held on **Friday, September 18, 2026**, at 12:00 P.M. through video conferencing ("VC") /other Audio - Visual Means ("OAVM").

The Notice along with the Annual Report will be sent to the registered email-ids of the Shareholders who holds shares of the company as on August 21, 2026, being the cut-off date for dispatch of Notice and Annual Report. The same is also available on the website of the Company at www.influxhealthtech.com.

Key Information relating to AGM are as under:

Date and time of AGM	Friday, September 18, 2026, at 12:00 P.M.
Mode of Meeting	VC/ OAVM
Cut-off date for e-voting	Friday, September 11, 2026
E-voting start date and time	September 15, 2026 09:00 A.M
E-voting end date and time	September 17, 2026 05:00 P.M

Further, Kindly note that the equity shares of the Company are listed on the NSE Emerge (SME) Platform. Accordingly, in terms of Regulation 15(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Regulation 24A concerning Secretarial Auditor and Secretarial Compliance Report is not



Regd. Office : 109, Ghanshyam Enclave, Link Road, Lalipada, Kandivali (W), Mumbai : 400067.

Factory : Plot No. 9, 10, Phase II, Genesis Ind. Estate, Kolgaon, Palghar - 401 404. Maharashtra.

Contact No. : +91 9820201063 / 8080333319 / 8411879521

Email : influxhealthtech@gmail.com / influxhealthcare1@gmail.com

Website : www.influxhealthcare.com

CIN : L24299MH2020PLC346825

applicable to companies listed on the SME Exchange. Consequently, the Company is not required to take approval of shareholders at the said Annual General Meeting for appointment of Secretarial Auditor.

Please take the same on your records.

Thanking you,

For Influx Healthtech Limited,

Munir Abdul

Ganee

Chandniwala

Digitally signed by Munir
Abdul Ganee Chandniwala
Date: 2026.08.26 15:43:13
+05'30'

Munir Abdul Ganee Chandniwala

Managing Director

DIN: 08459582



Celebrate each day of healthiness

ANNUAL REPORT 2025-26

6th Annual General Meeting



Strengthening **Health**.



Enriching **Lives**.



Building a
Better **Tomorrow**.



COSMETICS &
PERSONAL CARE



VETERINARY
NUTRITION

(6th) Sixth Annual General Meeting of the Company:

Date: September 18, 2026

Day: Friday

Time: 12:00 P.M. through Video Conferencing (“VC”)/ Other Audio-Visual Means (“OAVM”) facility

CONTENTS

1. GENERAL INFORMATION	2
2. NOTICE OF 6 th ANNUAL GENERAL MEETING	5
3. DIRECTOR’S REPORT	19
4. ANNEXURE-I Form AOC - 1	40
5. ANNEXURE-II Form MR – 3 (Secretarial Audit Report)	42
6. ANNEXURE-III Annual Report on Corporate Social Responsibility (CSR) Activities.....	47
7. ANNEXURE- IV Form AOC - 2	51
8. ANNEXURE- V Information Required Under Section 197 of Companies act, 2013	53
9. ANNEXURE – VI Declaration Regarding Code of Conduct.....	55
10. MANAGEMENT DISCUSSION AND ANALYSIS REPORT	56
11. FINACIAL INFORMATION	60

GENERAL INFORMATION

NAME OF THE ENTITY:

Influx Healthtech Limited

ISIN:

INE0MYZ01012

CORPORATE IDENTITY NUMBER:

L24299MH2020PLC346825

WEBSITE:

www.influxhealthtech.com

INVESTORS SERVICE MAIL ID:

cs@influxhealthtech.com

REGISTERED OFFICE:

109, Ghanshyam Enclave Premises Co-op Soc Plot No. 856, Laljipada, Kandivali West, Mumbai - 400067 Maharashtra, India.

Email: influxhealthtech@gmail.com

Website: www.influxhealthtech.com

REGISTRAR AND SHARE TRANSFER AGENT:

[Maashitla[®] Securities Private Limited](#)

451, Krishna Apra Business Square Netaji Subhash Place, Pitampura, North west, New Delhi, Delhi - 110034, India

Email: contact@maashitla.com

Contact Number: 011-45121798

Website: www.maashitla.com

SEBI Registration No.: INR000004370

FACTORY:

Plot No. 9, 10, Phase II, Genesis Ind. Estate, Kolgaon, Palghar - 401 404. Maharashtra.

BANKER:

Axis Bank Limited

STATUTORY AUDITOR:

M/s V.B. Goel & Co.

Chartered Accountants

Simba Tower, 6th Floor, Vishveshwar Nagar, Goregaon (East), Mumbai – 400 063

SECRETARIAL AUDITOR:

M/s. PNK & Co.

Company Secretaries

805, Arizona, Nr. Hotel Hyatt Regency, Opp Gujarat Vidhyapith, Usmanpura, Ashram Road, Ahmedabad - 380014

INTERNAL AUDITOR:

M/s. Phirodia Bafna & Associates

Chartered Accountants

212, Ghanshyam Enclave, New Link Road, Near Lalji Pada Police Chowky, Kandivali (West), Mumbai 400067

Board of Directors:

Sr. No.	Name	DIN	Category	Designation	Date of Appointment
1	Mr. Munir Abdul Ganee Chandniwala	08459582	Executive	Chairman & Managing Director	September 28, 2020
2	Mrs. Shirin Munir Ahmed Chandniwala	08459623	Executive	Whole-time Director	September 28, 2020
3	Mr. Abdul Ganee Abdul Rasul Chandniwala	09573672	Non-Executive	Director	April 18, 2022
4	Mr. Vipul Balubhai Patel	08091260	Non-Executive	Independent Director	July 13, 2024
5	Mr. Mohmad Saleh Mutvalli ⁽¹⁾	07361078	Non-Executive	Independent Director	March 31, 2026
6	Mr. Ashok Kumar Jain ⁽¹⁾	00251096	Non-Executive	Independent Director	July 26, 2024

⁽¹⁾ Mr. Ashok Kumar Jain resigned from the position of Non-Executive Independent Director w.e.f. March 31, 2026 and Mr. Mohmad Saleh Mutvalli was appointed as Non-Executive Independent Director w.e.f March 31, 2026

KEY MANAGERIAL PERSONNEL:

Company Secretary & Compliance Officer:

Mr. Atul Kumar Ashok Kumar Shukla

Chief Financial Officer:

Mr. Ashish Ghanshyam Shah

AUDIT COMMITTEE:

Mr. Mohmad Saleh Mutvalli ⁽¹⁾

Chairperson

Mr. Ashok Kumar Jain ⁽¹⁾

Chairperson

Mr. Vipul Balubhai Patel

Member

Mrs. Shirin Munir Ahmed Chandniwala

Member

NOMINATION & REMUNERATION COMMITTEE:

Mr. Mohmad Saleh Mutvalli ⁽²⁾	Chairperson
Mr. Ashok Kumar Jain ⁽²⁾	Chairperson
Mr. Vipul Balubhai Patel	Member
Mr. Abdul Ganee Abdul Rasul Chandniwala	Member

STAKEHOLDERS RELATIONSHIP COMMITTEE:

Mr. Vipul Balubhai Patel	Chairperson
Mr. Munir Abdul Ganee Chandniwala	Member
Mr. Shirin Munir Ahmed Chandniwala	Member

CORPORATE SOCIAL RESPONSIBILITY COMMITTEE:

Mr. Munir Abdul Ganee Chandniwala	Chairperson
Mr. Mohmad Saleh Mutvalli ⁽³⁾	Member
Mr. Ashok Kumar Jain ⁽³⁾	Member
Mr. Shirin Munir Ahmed Chandniwala	Member

⁽¹⁾ Mr. Ashok Kumar Jain (Non-Executive Independent Director) resigned from the position of Chairperson of the committee w.e.f. March 31, 2026 and Mr. Mohmad Saleh Mutvalli (Non-Executive Independent Director) was appointed as Chairperson of the committee w.e.f March 31, 2026

⁽²⁾ Mr. Ashok Kumar Jain (Non-Executive Independent Director) resigned from the position of Chairperson of the committee w.e.f. March 31, 2026 and Mr. Mohmad Saleh Mutvalli (Non-Executive Independent Director) was appointed as Chairperson of the committee w.e.f March 31, 2026

⁽³⁾ Mr. Ashok Kumar Jain (Non-Executive Independent Director) resigned from the position of Member of the committee w.e.f. March 31, 2026 and Mr. Mohmad Saleh Mutvalli (Non-Executive Independent Director) was appointed as Member of the committee w.e.f March 31, 2026

NOTICE OF 6th ANNUAL GENERAL MEETING

Notice is hereby given that the Sixth (6th) Annual General Meeting (AGM) of Influx Healthtech Limited to be held on **Friday, September 18, 2026, at 12:00 P.M. IST** through Video Conferencing (“VC”)/ Other Audio-Visual Means (“OAVM”) facility to transact the following businesses.

ORDINARY BUSINESSES:

- 1. To consider and adopt the Annual Audited Financial Statements (Standalone and Consolidated) of the Company for the financial year ended March 31, 2026 including the Balance Sheet as on March 31, 2026, the Statement of Profit and Loss and the Cash Flow Statement for the financial year ended on that date and the Reports of the Board of Directors and Auditors thereon.:**

*In this regard, to consider and if thought fit, to pass, with or without modification(s), the following resolution as **Ordinary Resolution**;*

“RESOLVED THAT the audited standalone and consolidated financial statement of the Company for the financial year ended March 31, 2026, and the reports of the Board of Directors and Auditors thereon, as circulated to the members, be and are hereby considered and adopted.”

- 2. To appoint Mrs. Shirin Munir Ahmed Chandniwala (DIN: 08459623) as a Whole time Director of the Company, who retires by rotation and being eligible offers herself for re-appointment.**

*In this regard, to consider and if thought fit, to pass, with or without modification(s), the following resolution as **Ordinary Resolution**;*

“RESOLVED THAT in accordance with the provisions of Section 152 and other applicable provisions of the Companies Act, 2013, Mrs. Shirin Munir Ahmed Chandniwala (DIN: 08459623), who retires by rotation at this meeting, be and is hereby appointed as a Director of the Company.”

Registered Office:

109, Ghanshyam Enclave Premises Co-op Soc Plot No.
856, Laljipada, Kandivali West, Mumbai - 400067
Maharashtra, India.

Date: August 26, 2026

Place: Mumbai

**By Order of the Board of Directors of
Influx Healthtech Limited**

Sd/-

**Munir Abdul Ganee Chandniwala
Chairman and Managing Director
DIN: 08459582**

IMPORTANT NOTES

1. In compliance with General Circular Nos. 14/2020 dated April 08, 2020, 17/2020 dated April 13, 2020, 20/2020 dated May 05, 2020, 33/2020 dated September 28, 2020, 39/2020 dated December 31, 2020, 10/2021 dated June 23, 2021, 20/2021 dated December 08, 2021, 10/2022 dated December 28, 2022, 09/2023 dated September 25, 2023, 09/2024 dated September 19, 2024 and 03/2025 dated September 22, 2025 issued by the Ministry of Corporate Affairs (“MCA”) and SEBI/HO/CFD/CFDPoD-2/P/CIR/2023/167 dated October 07, 2023 issued by Securities and Exchange Board of India (hereinafter collectively referred to as “Circulars”), the provisions of the Companies Act, 2013 (“the Act”) and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), the 6th (Sixth) Annual General Meeting (“AGM”) of the Company is being held through VC/OAVM without the physical presence of Members at a common venue. The deemed venue for the 6th (Sixth) AGM will be the Registered Office of the Company– 109, Ghanshyam Enclave Premises Co-op Soc Plot No. 856, Laljipada, Kandivali West, Mumbai - 400067 Maharashtra, India.
2. A Statement pursuant to the provisions of Section 102 of the Companies Act, 2013 and additional information of the Directors seeking re-appointment as required under Regulation 36(3) of the Listing Regulations and Secretarial Standard on General Meetings issued by The Institute of Company Secretaries of India (‘Secretarial Standard’) are annexed.
3. In terms of the MCA Circulars since the physical attendance of Members has been dispensed with, there is no requirement of appointment of proxies. Accordingly, the facility of appointment of proxies by Members under Section 105 of the Act will not be available for the AGM and hence the Proxy Form and Attendance Slip are not annexed to this Notice. However, in pursuance of Section 113 of the Act, representatives of the Institutional/Corporate Members may be appointed for the purpose of voting through remote e-Voting, for participation in the AGM through VC/OAVM Facility and e-Voting during the AGM. The said Resolution/Authorization shall be sent to the Scrutinizer by email through its registered email address to info@csnayan.com with a copy marked to contact@maashitla.com.
4. The attendance of the Members participating in the AGM through VC/OAVM will be counted for the purpose of reckoning the quorum under Section 103 of the Companies Act, 2013. In case of joint holders, the Member whose name appears as the first holder in the order of names as per the Register of Members of the Company will be entitled to vote at the AGM.
5. In line with the MCA Circulars and SEBI Circular, the notice of the AGM along with the Annual Report are being sent only by electronic mode to those Members whose e-mail addresses are registered with the Company/Depositories. Members may please note that this Notice and Annual Report will also be available on the Company’s website www.influxhealthtech.com, website of the Stock Exchange i.e., National Stock Exchange of India Limited at www.nseindia.com and also on the website of the RTA at www.maashitla.com.
6. Since the AGM is being held through VC/OAVM Facility, the route map of the venue of the Meeting is not annexed hereto.

7. The Members may join the AGM in the VC/OAVM mode thirty (30) Minutes before the scheduled time of the commencement of the Meeting by following the procedure mentioned in this Notice.
8. Since no shares of the Company are held in physical form, the provisions relating to closure of the Register of Members and Share Transfer Books shall not be applicable, in terms of Section 91 of the Companies Act, 2013 and Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
9. Pursuant to the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014 (as amended), Secretarial Standard on General Meetings (SS-2) issued by the Institute of Company Secretaries of India (“ICSI”) and Regulation 44 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI circular no. SEBI/HO/ CFD/CMD/CIR/P/2020/242 dated December 09, 2020, the Company is providing remote e- Voting facility to its Members in respect of the business to be transacted at the AGM and facility for those Members participating in the AGM to cast vote through e-Voting system during the AGM.
10. The Company has availed the services of Central Depository Services (India) Limited, as the authorized agency for conducting of the AGM through VC/OAVM and providing e- Voting facility.
11. The e-voting period commences on Tuesday, September 15, 2026 (9:00 A.M. IST) and ends on Thursday, September 17, 2026 (5:00 P.M. IST). The e-voting module will be disabled by Central Depository Services (India) Limited thereafter. The voting rights of members shall be proportionate to their share of the paid-up equity share capital of the Company as on the cut-off date, i.e. September 11, 2026.
12. Members joining the meeting through VC/OAVM, who have not already cast their vote by means of remote e-Voting, shall be able to exercise their right to vote through e-Voting at the AGM. The Members who have cast their vote by remote e-Voting prior to the AGM may also attend the AGM but shall not be entitled to cast their vote again.
13. A person who is not a member as on the cut-off date should treat this Notice of AGM for information purpose only.
14. A person, whose name is recorded in the Register of Members or in the Register of Beneficial Owners maintained by the depositories as on the cut-off date i.e. September 11, 2026 only shall be entitled to avail the facility of remote e-voting as well as e-voting at the AGM.
15. The Board of Directors have appointed M/s. PNK & Co. (Previously known as M/s. Pitroda Nayan & Co.), Practicing Company Secretaries (Membership No. FCS: 58473, COP: 23912) as Scrutinizer for the e-Voting process. The Scrutinizer shall, after the conclusion of AGM, unblock the votes in the presence of at least two witnesses who are not in employment of the Company and shall within a period of 2 (Two) working days from the conclusion of the AGM, prepare a Scrutinizer’s Report of the votes cast in favour or against, if any, and submit it to the Chairman of the meeting.

-
16. The results of the e-Voting will be declared within 2 (Two) working days from the conclusion of the AGM. The results declared along with the Scrutinizer's Report shall be placed on the Company's website at www.influxhealthtech.com and on the website of Central Depository Services (India) Limited and shall be communicated to National Stock Exchange of India Limited (NSE).
 17. The register of directors and key managerial personnel (KMP) and their shareholding, maintained under Section 170 of the Act, and the register of contracts or arrangements in which the directors are interested, maintained under Section 189 of the Act, will be available electronically for inspection by the members during the AGM. All documents referred to the Notice will also be available for electronic inspection without any fee from the date of circulation of this Notice up to the date of AGM. Members seeking to inspect such documents can send an email to cs@influxhealthtech.com.

18. Procedure for Remote e-Voting:

Procedure for Login for e-Voting and Attending AGM through VC/OAVM for Individual Shareholders holding securities in Demat mode. In terms of SEBI circular dated December 09, 2020, on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in Demat mode are allowed to vote through their Demat account maintained with Depositories and Depository Participants. Shareholders are advised to update their mobile number and email Id in their Demat accounts to access e-Voting facility.

THE INTRUCTIONS OF SHAREHOLDERS FOR E-VOTING AND JOINING VIRTUAL MEETINGS ARE AS UNDER:

Step 1 : Access through Depositories CDSL/NSDL e-Voting system in case of individual shareholders holding shares in demat mode.

- (i) The voting period begins on Tuesday, September 15, 2026 (9:00 A.M. IST) and ends on Thursday, September 17, 2026 (5:00 P.M. IST). During this period shareholders of the Company, holding shares either in physical form or in dematerialized form, as on the cut-off date (record date) of Friday, September 11, 2026 may cast their vote electronically. The e-voting module shall be disabled by CDSL for voting thereafter.
- (ii) Shareholders who have already voted prior to the meeting date would not be entitled to vote at the meeting venue.
- (iii) Pursuant to SEBI Circular No. **SEBI/HO/CFD/CMD/CIR/P/2020/242 dated 09.12.2020**, under Regulation 44 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, listed entities are required to provide remote e-voting facility to its shareholders, in respect of all shareholders' resolutions. However, it has been observed that the participation by the public non-institutional shareholders/retail shareholders is at a negligible level.

Currently, there are multiple e-voting service providers (ESPs) providing e-voting facility to listed entities in India. This necessitates registration on various ESPs and maintenance of multiple user IDs and passwords by the shareholders.

In order to increase the efficiency of the voting process, pursuant to a public consultation, it has been decided to enable e-voting to **all the demat account holders, by way of a single login credential, through their demat accounts/ websites of Depositories/ Depository Participants**. Demat account holders would be able to cast their vote without having to register again with the ESPs, thereby, not only facilitating seamless authentication but also enhancing ease and convenience of participating in e-voting process.

- (iv) In terms of **SEBI circular no. SEBI/HO/CFD/CMD/CIR/P/2020/242 dated December 9, 2020**, on e - Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are advised to update their mobile number and email Id in their demat accounts in order to access e-Voting facility.

Pursuant to the above-said SEBI Circular, Login method for e-Voting and joining virtual meetings **for Individual shareholders holding securities in Demat mode CDSL/NSDL** is given below:

Type of shareholders	Login Method
----------------------	--------------

Individual Shareholders holding securities in Demat mode with CDSL Depository	1) Users who have opted for CDSL Easi / Easiest facility, can login through their existing user id and password. The option will be made available to reach e-Voting page without any further authentication. The users to login to Easi / Easiest are requested to visit CDSL website www.cdslindia.com and click on login icon & My Easi New (Token) Tab. 2) After successful login the Easi / Easiest user will be able to see the e-Voting option for eligible companies where the evoting is in progress as per the information provided by company. On clicking the evoting option, the user will be able to see e-Voting page of the e-Voting service provider for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. Additionally, there is also links provided to access the system of all e-Voting Service Providers, so that the user can visit the e-Voting service providers' website directly. 3) If the user is not registered for Easi/Easiest, option to register is available at cdsi website www.cdslindia.com and click on login & My Easi New (Token) Tab and then click on registration option. 4) Alternatively, the user can directly access e-Voting page by providing Demat Account Number and PAN No. from an e-Voting link available on www.cdslindia.com home page. The system will authenticate the user by sending OTP on registered Mobile & Email as recorded in the Demat Account. After successful authentication, users will be able to see the e-Voting option where the evoting is in progress and also able to directly access the system of all e-Voting Service Providers.
Individual Shareholders holding securities in demat mode with NSDL Depository	1) If you are already registered for NSDL IDeAS facility, please visit the e-Services website of NSDL. Open web browser by typing the following URL: https://eservices.nsdl.com either on a Personal Computer or on a mobile. Once the home page of e-Services is launched, click on the "Beneficial Owner" icon under "Login" which is available under 'IDeAS' section. A new screen will open. You will have to enter your User ID and Password. After successful authentication, you will be able to see e-Voting services. Click on "Access to e-Voting" under e-Voting services and you will be able to see e-Voting page. Click on company name or e-Voting service provider name and you will be re-directed to e-Voting service provider website for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. 2) If the user is not registered for IDeAS e-Services, option to register is available at https://eservices.nsdl.com. Select "Register Online for IDeAS "Portal or click at https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp 3) Visit the e-Voting website of NSDL. Open web browser by typing the following URL: https://www.evoting.nsdl.com/ either on a Personal Computer or on a mobile. Once the home page of e-Voting system is launched, click on the icon

	“Login” which is available under ‘Shareholder/Member’ section. A new screen will be opened. You will have to enter your User ID (i.e. your sixteen-digit demat account number hold with NSDL), Password/OTP and a Verification Code as shown on the screen. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or e-Voting service provider name and you will be redirected to e-Voting service provider website for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. 4) For OTP based login you can click on https://eservices.nsdl.com/SecureWeb/evoting/evotinglogin.jsp. You will have to enter your 8-digit DP ID, 8-digit Client Id, PAN No., Verification code and generate OTP. Enter the OTP received on registered email id/mobile number and click on login. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on the company name or e-Voting service provider name and you will be re-directed to e-Voting service provider website for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.
Individual Shareholders (holding securities in demat mode) login through their Depository Participants (DP)	You can also login using the login credentials of your demat account through your Depository Participant registered with NSDL/CDSL for e-Voting facility. After Successful login, you will be able to see e-Voting option. Once you click on e-Voting option, you will be redirected to NSDL/CDSL Depository site after successful authentication, wherein you can see e-Voting feature. Click on company name or e-Voting service provider name and you will be redirected to e-Voting service provider website for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.

Important note: Members who are unable to retrieve User ID/ Password are advised to use Forget User ID and Forget Password option available at abovementioned website.

Helpdesk for Individual Shareholders holding securities in demat mode for any technical issues related to login through Depository i.e. CDSL and NSDL

Login type	Helpdesk details
Individual Shareholders holding securities in Demat mode with CDSL	Members facing any technical issue in login can contact CDSL helpdesk by sending a request at helpdesk.evoting@cdslindia.com or contact at toll free no. 1800 21 09911
Individual Shareholders holding securities in Demat mode with NSDL	Members facing any technical issue in login can contact NSDL helpdesk by sending a request at

	evoting@nsdl.co.in or call at: 022 - 4886 7000 and 022 - 2499 7000
--	---

Step 2 : Access through CDSL e-Voting system in case of non-individual shareholders holding shares in demat mode.

(v) Login method for e-Voting and joining virtual meetings for **shareholders other than individual holding in Demat form.**

- 1) The shareholders should log on to the e-voting website www.evotingindia.com.
- 2) Click on “Shareholders” module.
- 3) Now enter your User ID
 - a. For CDSL: 16 digits beneficiary ID,
 - b. For NSDL: 8 Character DP ID followed by 8 Digits Client ID,
 - c. Shareholders holding shares in Physical Form should enter Folio Number registered with the Company.
- 4) Next enter the Image Verification as displayed and Click on Login.
- 5) If you are holding shares in demat form and had logged on to www.evotingindia.com and voted on an earlier e-voting of any company, then your existing password is to be used.
- 6) If you are a first-time user follow the steps given below:

	For shareholders other than individual shareholders holding shares in Demat.
PAN	Enter your 10-digit alpha-numeric *PAN issued by Income Tax Department (Applicable for both demat shareholders as well as physical shareholders) Shareholders who have not updated their PAN with the Company/Depository Participant are requested to use the sequence number sent by Company/RTA or contact Company/RTA.
Dividend Bank Details OR Date of Birth (DOB)	Enter the Dividend Bank Details or Date of Birth (in dd/mm/yyyy format) as recorded in your demat account or in the company records in order to login. If both the details are not recorded with the depository or company, please enter the member id / folio number in the Dividend Bank details field.

(vi) After entering these details appropriately, click on “SUBMIT” tab.

-
- (vii) Shareholders holding shares in demat form will now reach ‘Password Creation’ menu wherein they are required to mandatorily enter their login password in the new password field. Kindly note that this password is to be also used by the demat holders for voting for resolutions of any other company on which they are eligible to vote, provided that company opts for e-voting through CDSL platform. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential.
- (viii) Click on the EVSN for the Influx Healthtech Limited on which you choose to vote.
- (ix) On the voting page, you will see “RESOLUTION DESCRIPTION” and against the same the option “YES/NO” for voting. Select the option YES or NO as desired. The option YES implies that you assent to the Resolution and option NO implies that you dissent to the Resolution.
- (x) Click on the “RESOLUTIONS FILE LINK” if you wish to view the entire Resolution details.
- (xi) After selecting the resolution, you have decided to vote on, click on “SUBMIT”. A confirmation box will be displayed. If you wish to confirm your vote, click on “OK”, else to change your vote, click on “CANCEL” and accordingly modify your vote.
- (xii) Once you “CONFIRM” your vote on the resolution, you will not be allowed to modify your vote.
- (xiii) You can also take a print of the votes cast by clicking on “Click here to print” option on the Voting page.
- (xiv) If a demat account holder has forgotten the login password, then Enter the User ID and the image verification code and click on Forgot Password & enter the details as prompted by the system.
- (xv) There is also an optional provision to upload BR/POA if any uploaded, which will be made available to scrutinizer for verification.
- Non-Individual shareholders (i.e. other than Individuals, HUF, NRI etc.) and Custodians are required to log on to www.evotingindia.com and register themselves in the “Corporates” module.
 - A scanned copy of the Registration Form bearing the stamp and sign of the entity should be emailed to helpdesk.evoting@cdslindia.com.
 - After receiving the login details a Compliance User should be created using the admin login and password. The Compliance User would be able to link the account(s) for which they wish to vote on.
 - The list of accounts linked in the login will be mapped automatically & can be delink in case of any wrong mapping.
 - It is Mandatory that, a scanned copy of the Board Resolution and Power of Attorney (POA) which they have issued in favour of the Custodian, if any, should be uploaded in PDF format in the system for the scrutinizer to verify the same.
 - Alternatively Non Individual shareholders are required mandatory to send the relevant Board Resolution/ Authority letter etc. together with attested specimen signature of the duly authorized signatory who are authorized to vote, to the Scrutinizer and to the Company at the email address viz;

cs@influxhealthtech.com, if they have voted from individual tab & not uploaded same in the CDSL e-voting system for the scrutinizer to verify the same.

INSTRUCTIONS FOR SHAREHOLDERS ATTENDING THE AGM THROUGH VC/OAVM & E-VOTING DURING THE MEETING ARE AS UNDER:

1. The procedure for attending meeting & e-Voting on the day of the AGM is same as the instructions mentioned above for e-voting.
2. The link for VC/OAVM to attend meeting will be available where the EVSN of Company will be displayed after successful login as per the instructions mentioned above for e-voting.
3. Shareholders who have voted through Remote e-Voting will be eligible to attend the meeting. However, they will not be eligible to vote at the AGM.
4. Shareholders are encouraged to join the Meeting through Laptops / IPads for better experience.
5. Further shareholders will be required to allow Camera and use Internet with a good speed to avoid any disturbance during the meeting.
6. Please note that Participants Connecting from Mobile Devices or Tablets or through Laptop connecting via Mobile Hotspot may experience Audio/Video loss due to Fluctuation in their respective network. It is therefore recommended to use Stable Wi-Fi or LAN Connection to mitigate any kind of aforesaid glitches.
7. Shareholders who would like to express their views/ask questions during the meeting may register themselves as a speaker by sending their request in advance atleast **2 days prior to meeting** mentioning their name, demat account number/folio number, email id, mobile number at cs@influxhealthtech.com. The shareholders who do not wish to speak during the AGM but have queries may send their queries in advance **2 days prior to meeting** mentioning their name, demat account number/folio number, email id, mobile number at cs@influxhealthtech.com. These queries will be replied to by the company suitably by email.
8. Those shareholders who have registered themselves as a speaker will only be allowed to express their views/ask questions during the meeting.
9. Only those shareholders, who are present in the AGM through VC/OAVM facility and have not casted their vote on the Resolutions through remote e-Voting and are otherwise not barred from doing so, shall be eligible to vote through e-Voting system available during the AGM.
10. If any Votes are cast by the shareholders through the e-voting available during the AGM and if the same shareholders have not participated in the meeting through VC/OAVM facility, then the votes cast by such shareholders may be considered invalid as the facility of e-voting during the meeting is available only to the shareholders attending the meeting.

PROCESS FOR THOSE SHAREHOLDERS WHOSE EMAIL/MOBILE NO. ARE NOT REGISTERED WITH THE COMPANY/DEPOSITORIES.

11. For Physical shareholders- please provide necessary details like Folio No., Name of shareholder, scanned copy of the share certificate (front and back), PAN (self-attested scanned copy of PAN card), AADHAR (self-attested scanned copy of Aadhar Card) by email to **Company/RTA email id i.e. cs@influxhealthtech.com** and contact@maashitla.com.
12. For Demat shareholders -, Please update your email id & mobile no. with your respective **Depository Participant (DP)**
13. **For Individual Demat shareholders – Please update your email id & mobile no. with your respective Depository Participant (DP) which is mandatory while e-Voting & joining virtual meetings through Depository.**

EXPLANATORY STATEMENT PURSUANT TO SECTION 102 OF THE COMPANIES ACT, 2013

ITEM NO.02: TO RE-APPOINT MRS. SHIRIN MUNIR AHMED CHANDNIWALA (DIN: 08459623) AS A WHOLE TIME DIRECTOR OF THE COMPANY, WHO RETIRES BY ROTATION AND BEING ELIGIBLE OFFERS HERSELF FOR RE-APPOINTMENT.

Mrs. Shirin Munir Ahmed Chandniwala is the Whole-Time Director and Co-founder of the Company. She has been associated with the Company since its inception and has played a significant role in the financial planning, business operations and growth of the Company.

Mrs. Shirin Munir Ahmed Chandniwala holds a Bachelor of Commerce and Master of Commerce degree from Hemchandracharya North Gujarat University. She has over 12 (twelve) years of experience in financial management and business operations. She is responsible for overseeing the Company's financial strategy, data analysis, budgeting and financial systems. She has also been actively involved in formulating and implementing the Company's growth strategies and has contributed significantly to its financial planning and operational functions.

She possesses more than 3 (three) years of experience in the nutraceutical, cosmetics and healthcare industries, which has enabled her to develop relevant knowledge and understanding of the Company's business and the industry in which it operates.

In accordance with the provisions of the Companies Act, 2013 and the Articles of Association of the Company, the Company proposes to make Mrs. Shirin Munir Ahmed Chandniwala liable to retire by rotation. Accordingly, the resolution set out at Item No. 2 is proposed for approval of the Members.

Mrs. Shirin Munir Ahmed Chandniwala is interested in the proposed resolution as it pertains to her continuation as a Whole Time Director of the Company. Mr. Munir Abdul Ganee Chandniwala, Managing Director of the Company and spouse of Mrs. Shirin Munir Ahmed Chandniwala, and Mr. Abdul Ganee Abdul Rasul Chandniwala, Director of the Company and father-in-law of Mrs. Shirin Munir Ahmed Chandniwala, may be deemed to be concerned or interested, financially or otherwise, in the proposed resolution. Save and except the aforesaid persons, none of the other Directors, Key Managerial Personnel of the Company or their respective relatives is concerned or interested, financially or otherwise, in the said resolution.

The Board recommends the resolution set out at Item No. 2 for approval of the Members by way of an Ordinary Resolution.

The profile, specific areas of expertise, and other disclosures required under the SEBI Listing Regulations and Secretarial Standard-2 (SS-2) are provided in the annexure to this Notice.

ANNEXURE TO NOTICE

Details of Directors seeking appointment / re-appointment at the Annual General Meeting
[In pursuance of Clause 36 (3) of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 and SS-2 -Secretarial Standard on General Meetings]

Particulars	Mrs. Shirin Munir Ahmed Chandniwala
Director Identification Number	08459623
Date of Birth	July 29,1984
Age	41 years
Justification for Appointment	Mrs. Shirin Munir Ahmed Chandniwala is proposed to be re-appointed by considering her leadership role in the business of the company.
Educational Qualification.	She holds a Bachelor of Commerce and a Master of Commerce degree from Hemchandracharya North Gujarat University.
Number of Board meetings attended during the FY 2025- 26	Entitled and attended 8 Board Meetings
Details of last drawn remuneration	Rs. 24,00,000/- per Annum
Skills and capabilities required for the role and the manner in which the proposed person meets such requirements	She possesses the requisite skills and capabilities for the role, with expertise in financial management, business operations, financial strategy, data analysis and budget management, enabling her to effectively contribute to the Company's strategic and operational growth.
Experience (No. of Years)	12 Years
Business field in which Experience.	Financial Management, Business Operations, Oversees Financial Strategy, Data Analysis, And Budget Management
Date of Initial Appointment	September 28, 2020
Directorship held in any other Company (Including any Listed Company).	Yes, Mrs. Shirin Munir Ahmed Chandniwala is Director in Following Companies: 1. Olahey Wellness Private Limited 2. Influx Foundation
Member of any Committees of the Directors in the Company.	Yes, The Director is a member of the following Committees of the Board: 1. Audit Committee - Member 2. Stakeholders Relationship Committee - Member 3. Corporate Social Responsibility Committee - Member

Member of any committees of the Directors in other Companies with names of the Company.	Nil
No. of Shares Held as on August 21, 2026 in the Company.	880638 Shares
Relationship with other Directors/KMPs	She is the wife of Mr. Munir Abdul Ganee Chandniwala, Chairman and Managing Director and Daughter-in-law of Mr. Abdul Ganee Abdul Rasul Chandniwala, Director of the Company.

The nature of concern or interest, financial or otherwise, if any, in respect of the ordinary business proposed is mentioned as follows:

1. every Director and the manager, if any: Mr. Munir Abdul Ganee Chandniwala, Chairman and Managing Director and Mr. Abdul Ganee Abdul Rasul Chandniwala, Director of the Company.
2. every other key managerial personnel: none interested.
3. relatives of the persons mentioned in 1 and 2 above: Relatives of Mr. Munir Abdul Ganee Chandniwala, Chairman and Managing Director and Mr. Abdul Ganee Abdul Rasul Chandniwala, Director of the Company.

Registered Office:

109, Ghanshyam Enclave Premises Co-op Soc Plot No.
856, Laljipada, Kandivali West, Mumbai - 400067
Maharashtra, India.

Date: August 26, 2026

Place: Mumbai

**By Order of the Board of Directors of
Influx Healthtech Limited**

Sd/-

**Munir Abdul Ganee Chandniwala
Chairman and Managing Director
DIN: 08459582**

DIRECTOR'S REPORT

Dear Members,

On behalf of the Board of Directors, it is our pleasure to present the 6th Director's Report of the Company together with the Audited Standalone and Consolidated Financial Statements for the financial year ended March 31, 2026 ("FY 2025-26") along with the Auditors' Report thereon.

The Board places on record its sincere appreciation and gratitude to all the shareholders for their continued trust and support in the Company. Your confidence has been instrumental in enabling the Company to pursue its strategic objectives and strengthen its market position. The Board remains committed to maintaining the highest standards of corporate governance, transparency and accountability, while focusing on sustainable growth, long-term value creation and safeguarding the interests of all stakeholders.

1. KEY FINANCIAL HIGHLIGHTS (STANDALONE AND CONSOLIDATED):

The key financial highlights of the Company for FY 2025-26 as compared to the preceding FY 2024-25, on a standalone and consolidated basis are summarized below:

(Rs. in lakhs, unless otherwise stated)

Particulars	Standalone		Consolidated	
	Year ended 31/03/2026	Year ended 31/03/2025	Year ended 31/03/2026	Year ended 31/03/2025*
Revenue from Operations	14,683.36	10,485.36	14,683.36	-
Other Income	133.49	13.31	133.49	-
Total Income	14,816.85	10,498.68	14,816.85	-
Total Expenses	12,093.45	8,727.27	12,093.80	-
Profit/(loss) before Tax (EBT)	2,723.40	1,771.41	2,723.05	-
Less: Provision for Income Tax				
(i) Current Tax	710.47	440.99	710.47	-
(ii) Deferred Tax	(42.93)	10.32	(43.02)	-
(iii) Short/Excess Provision for Income Tax	1.73	(7.22)	1.73	-
Net Profit/(Loss) After Tax	2,054.13	1,327.32	2,053.87	-
Earnings per equity share:				
Basic	9.35	7.31	9.35	-
Diluted	9.35	7.31	9.35	-

* Consolidated financial figures for the financial year ended March 31, 2025 were not applicable to the Company, as its wholly owned subsidiary, Olahey Wellness Private Limited, was incorporated on February 03, 2026. Figures in brackets represents negative figures

2. STATE OF THE COMPANY'S AFFAIRS

The Company is engaged in the development and manufacturing of a diverse range of healthcare products, including dietary and nutritional supplements (tablets, capsules, soft gels, liquid orals, oral powders, effervescent tablets,

gummies), cosmetic and personal care formulations (creams, gels, external oils, soaps), Ayurvedic and herbal products, veterinary feed supplements, and homecare items, all produced in GMP, HACCP, ISO 22000, Halal and US FDA registered facilities to ensure stringent quality control and regulatory compliance. There has been no change in the nature of the Company's business during the financial year ended March 31, 2026.

On a standalone basis, The highlights of the Company's performance are as under:

- i. Revenue from operations for the year ended on March 31, 2026 and March 31, 2025 is INR 14,683.36 Lakhs and INR 10,485.36 Lakhs.
- ii. Other incomes for the year ended for the year ended on March 31, 2026 and March 31, 2025 is INR 133.49 Lakhs and INR 13.31 Lakhs.
- iii. Net profit for the year ended for the year ended on March 31, 2026 and March 31, 2025 is INR 2,054.13 Lakhs and INR 1,327.32 Lakhs.

On a Consolidated basis, The highlights of the Company's performance are as under:

- i. Revenue from operations for the year ended on March 31, 2026 is INR 14,683.36 Lakhs.
- ii. Other incomes for the year ended for the year ended on March 31, 2026 is INR 133.49 Lakhs.
- iii. Net profit for the year ended for the year ended on March 31, 2026 is INR 2,053.87 Lakhs.

3. RESERVE & SURPLUS

The Board of Directors have decided to retain the entire amount of profit under Retained Earnings.

4. COMPANY AFFAIRS

- i. **Business Segments:** The Company operates in the following business segments:
 - Nutraceuticals
 - Cosmetics
 - Ayurvedic & Herbal Products
 - Veterinary Feed Supplements
 - Homecare Products
- ii. **Change in status of the Company:** Status of the Company is Public Limited. During the financial year under review, the Company successfully listed its equity shares on the NSE EMERGE Platform of the National Stock Exchange of India Limited with effect from June 25, 2025. Accordingly, the status of the Company changed from an unlisted public company to a listed public company.
- iii. **Key Business Developments:** During the financial year under review, The Company did come up with Initial Public Offer and had raised ₹4800.38 Lakhs by issuing 50,00,400 Fresh Equity Shares and 11,00,400 Equity Shares by way of an Offer for Sale by the selling shareholder, Mr. Munir Abdul Ganee Chandniwala. The equity shares of the company got listed on NSE Emerge w.e.f. June 25, 2025.
- iv. **Change in FY:** There is no change in Financial Year.

-
- v. **Capex Programmes:** During the Financial Year under review, the Company has made capital expenditure (CAPEX) on various assets in the ordinary course of its business, The details of such capital expenditure are set out in Note No. 10 to the Audited Standalone Financial Statements of the Company.

5. CHANGE IN NATURE OF BUSINESS, IF ANY:

There is no change in the nature of the business of the Company during current financial year under Review.

6. CONSOLIDATED FINANCIAL STATEMENT:

The company has incorporated a Wholly Owned Subsidiary Company dated on February 3, 2026 named “Olahey Wellness Private Limited”. Accordingly, the company has prepared consolidated financial statements of the Company and its subsidiaries for FY 2025-26 in compliance with the applicable provisions of the Companies Act, 2013 ('the Act') and as stipulated under Regulation 33 of SEBI Listing Regulations as well as in accordance with the Indian Accounting Standards notified under the Companies (Indian Accounting Standards) Rules, 2015. The audited consolidated financial statements together with the Independent Auditor’s Report thereon form part of this Annual Report.

7. MATERIAL CHANGES AND COMMITMENT IF ANY AFFECTING THE FINANCIAL POSITION OF THE COMPANY OCCURRED BETWEEN THE END OF THE FINANCIAL YEAR TO WHICH THIS FINANCIAL STATEMENTS RELATE AND THE DATE OF THE REPORT

Between the end of the financial year to which the financial statements relate and the date of this Report, the Company conducted a Postal Ballot through remote e-voting. The remote e-voting facility remained open from 9:00 A.M. (IST) on April 2, 2026 to 5:00 P.M. (IST) on May 1, 2026, for seeking the approval of the Members on the following special businesses:

- i. Alteration in the Objects of the Initial Public Offer ("Offer") for which the amount was raised; and
- ii. Appointment of Mr. Mohmad Saleh Mutvalli (DIN: 07361078) as an Independent Director of the Company and approval of the payment of sitting fees to him.

8. DETAILS OF REVISION OF FINANCIAL STATEMENT OR THE REPORT

The Company, during past 3 FYs, have not revised its financial statements, either voluntarily or due to order of any court or authority or tribunal.

9. CREDIT RATING

The Company has not taken any Credit Rating in respect of any securities during the period under review.

10. DIVIDEND

In order to conserve the resources of the Company, the Board did not recommend any dividend for the financial year under review. Although FY 2025-26 was a profitable year for the Company, given that the Company is still in the growth phase, the Board plans to re-invest the profits back into the Company to support its growth objectives and does not recommend any dividend for the financial year ended March 31, 2026.

Further, no interim dividend was declared during the FY financial year 2025-26.

The Company has Dividend Declaration policy and is available at website of company at <https://influxhealthtech.com/investor-relations/>.

11. INVESTOR EDUCATION AND PROTECTION FUND (IEPF)

No amounts, declared as dividend in past years became due to be transferred to the IEPF.

12. SHARE CAPITAL OF THE COMPANY

Sr. No.	Particulars	Amount (₹)
A.	AUTHORISED SHARE CAPITAL	
	2,50,00,000 Equity Shares of face value of Rs.10/- each	25,00,00,000
B.	ISSUED, SUBSCRIBED AND PAID-UP SHARE CAPITAL	
	2,31,50,400 Equity Shares of face value of Rs.10/- each	23,15,04,000⁽¹⁾

⁽¹⁾ During the financial year under review, The Company conducted its initial public offering (IPO) of 61,00,800 Equity Shares, each with a face value of ₹ 10/- in accordance with SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018. The shares were offered at a price of ₹ 96/- per share, including a premium of ₹ 86/- per share.

The IPO was open for subscription from June 18, 2025, to June 20, 2025. The shares were allotted to applicants on June 23, 2025, at the offer price of ₹ 96/- per share. The Company's equity shares began trading on the SME Platform (EMERGE) of the National Stock Exchange of India Limited (NSE) from June 25, 2025.

The Company, vide its Prospectus dated June 23, 2025 ("Prospectus") raised ₹4800.38 Lakhs by issuing 50,00,400 Fresh Equity Shares and 11,00,400 Equity Shares by way of an Offer for Sale by the selling shareholder, Mr. Munir Abdul Ganee Chandniwala.

13. CHANGE IN NAME OF THE COMPANY

During the year under review, Company has not changed its Name.

14. CHANGE IN REGISTERED OFFICE

During the year under review, the Company has not changed its Registered Office.

15. DIRECTORS AND KEY MANAGERIAL PERSONNEL

The Board of Directors of the Company as on March 31, 2026 comprised of Five (5) Directors out of which Two (2) are Executive Directors and One (1) is Non-Executive Non-Independent Director and Two (2) are Non-Executive Independent Directors. The composition of the Board of Directors of the Company is in accordance with the provisions of Section 149 of the Companies Act, 2013 and Regulation 17 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 with an appropriate combination of Executive, Non-Executive and Independent Directors.

Changes During the Financial Year 2025–2026

During the financial year under review, the following changes occurred regarding the Directors and Key Managerial Personnel (KMP):

Name of Directors/KMP	DIN/PAN	Position	Date of appointment	Date of cessation	Applicability of rotation
Ashok Kumar Jain	00251096	Non- Executive Independent Director	26/07/2024	31/03/2026	Not Applicable
Mohmad Saleh Mutvalli	07361078	Non- Executive Independent Director	31/03/2026	-	Not Applicable

Composition as of March 31, 2026

As of the closure of the financial year on March 31, 2026, the Directors and Key Managerial Personnel of the Company were as follows:

Sr. No.	Name of Directors/KMP	Designation	DIN/PAN	Date of appointment	Date of cessation	Applicability of rotation
1	Munir Abdul Ganee Chandniwala	Managing Director	08459582	28/09/2020	-	NA
2	Shirin Munir Ahmed Chandniwala	Whole Time Director	08459623	28/09/2020	-	Applicable
3	Abdul Ganee Abdul Rasul Chandniwala	Non-executive Director	09573672	18/04/2022	-	Applicable
4	Mohmad Saleh Mutvalli	Independent Director	07361078	31/03/2026	-	NA
5	Vipul Balubhai Patel	Independent Director	08091260	13/07/2024	-	NA
6	Ashish Ghanshyam Shah	Chief Financial Officer	*****7652R	02/05/2024	-	NA

7	Atul Kumar Ashok Kumar Shukla	Company Secretary	*****3079E	02/05/2024	-	NA
8	Ashok Kumar Jain	Independent Director	00251096	26/07/2024	31/03/2026	NA

Note: There have been no changes in the composition of the Board of Directors and Key Managerial Personnel between the end of the financial year March 31, 2026 and the date of signing this Board Report.

Key Managerial Personnel (KMP)

In terms of the provisions of Sections 2(51) and 203 of the Companies Act, 2013 ('the Act'), the following are the KMPs of the Company:

- Munir Abdul Ganee Chandniwala - Managing Director
- Shirin Munir Ahmed Chandniwala – Whole Time Director
- Ashish Ghanshyam Shah - Chief Financial Officer
- Atul Kumar Ashok Kumar Shukla - Company Secretary and Compliance Officer

16. DECLARATION BY INDEPENDENT DIRECTORS

Directors who are Independent, have submitted a declaration as required under Section 149(7) of the Act that each of them meets the criteria of Independence as provided in Sub Section (6) of Section 149 of the Act and under Regulation 16 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended from time to time and there has been no change in the circumstances which may affect their status as independent Director during the year. In the opinion of the Board, the Independent Directors possess an appropriate balance of skills, experience and knowledge, as required.

Further, in terms of Section 150 of the Companies Act, 2013 read with Rule 6 of the Companies (Appointment and Qualification of Directors) Rules, 2014, Independent Directors of the Company have confirmed that they have registered themselves with the databank maintained by the Indian Institute of Corporate Affairs (IICA).

17. DETAILS OF MEETINGS OF BOARD OF DIRECTORS AND COMMITTEES

A. BOARD OF DIRECTORS

During the financial year 2025-26, 8 (Eight) meetings of the Board of Directors were held and the details of meetings attended by the Directors are as follows:

Sr. No.	Date of Meeting	Number of Directors Present
1	May 07, 2025	5
2	May 28, 2025	5
3	July 19, 2025	5
4	August 14, 2025	5

5	September 17, 2025	5
6	November 12, 2025	5
7	January 30, 2026	5
8	March 31, 2026	4

The details of meetings attended by the Directors and KMP are as follows:

Sr. No.	Name of Director/KMP	No. of Meetings entitled to attend	No. of meetings attended
1	Munir Abdul Ganee Chandniwala	8	8
2	Shirin Munir Ahmed Chandniwala	8	8
3	Abdul Ganee Abdul Rasul Chandniwala	8	8
4	Ashok Kumar Jain	7	7
5	Vipul Balubhai Patel	8	8
6	Mohmad Saleh Mutvalli*	-	-

*During the year, Mohmad Saleh Mutvalli was appointed as an Independent director w.e.f. March 31, 2026.

B. AUDIT COMMITTEE OF BOARD OF DIRECTORS

As a measure of good Corporate Governance and to provide assistance to the Board of Directors in overseeing the Board's responsibilities, an Audit Committee was formed as a sub-committee of the Board. The Committee is in line with the requirements of Section 177 of the Companies Act, 2013 and Regulation 18 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The terms of reference of the Audit Committee covers all matters specified in Part C of Schedule II of Regulation 18 (3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and also those specified in Section 177 of the Companies Act, 2013.

The detailed composition of the members of the Audit Committee during the financial year is outlined below:

DIN	Name of Directors	Nature of Directorship	Status in Committee	Date of Appointment	Date of Cessation
07361078	Mr. Mohmad Saleh Mutvalli	Non-Executive Independent Director	Chairman	March 31, 2026	-
00251096	Mr. Ashok Kumar Jain	Non-Executive Independent Director	Chairman	August 9, 2024	March 31, 2026
08459623	Mrs. Shirin Munir Ahmed Chandniwala	Whole Time Director	Member	August 9, 2024	-
08091260	Mr. Vipul Balubhai Patel	Non-Executive Independent Director	Member	August 9, 2024	-

Reconstitution of the Committee During the Year

The Board of Directors approved the reconstitution of the Audit Committee on following occasion during the year:

- March 31, 2026: Mr. Mohmad Saleh Mutvalli joined the committee as a Chairman, taking the place of Mr. Ashok Kumar Jain, who has resigned with effect from March 31, 2026.

All the members possess sound accounting and financial management knowledge.

During the period under review, a total of 5 (Five) Audit Committee Meetings were held dated: May 28, 2025, August 14, 2025, November 12, 2025, January 30, 2026 and March 31, 2026.

Attendance for Audit Committee Meeting:

Sr. No.	Name of Committee Member	No. of Meeting	
		Entitled to Attend	Attended
1.	Mr. Mohmad Saleh Mutvalli	0	0
2.	Mr. Ashok Kumar Jain (Resigned w.e.f. March 31, 2026)	5	5
3.	Mrs. Shirin Munir Ahmed Chandniwala	5	5
4.	Mr. Vipul Balubhai Patel	5	5

C. NOMINATION & REMUNERATION COMMITTEE

In compliance with Regulation 19 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Section 178 of the Companies Act, 2013, the Board has constituted the “Nomination and Remuneration Committee”.

The detailed composition of the members of the Nomination and Remuneration Committee at present is given below:

DIN	Name of Directors	Nature of Directorship	Status in Committee	Date of Appointment	Date of Cessation
00251096	Mr. Ashok Kumar Jain	Non-Executive Independent Director	Chairman	August 9, 2024	March 31, 2026
07361078	Mr. Mohmad Saleh Mutvalli	Non-Executive Independent Director	Chairman	March 31, 2026	-
08091260	Mr. Vipul Balubhai Patel	Non-Executive Independent Director	Member	August 9, 2024	-
09573672	Mr. Abdul Ganee Abdul Rasul Chandniwala	Non-Executive Director	Member	August 9, 2024	-

Reconstitution of the Committee During the Year

The Board of Directors approved the reconstitution of the Nomination & Remuneration Committee on following occasion during the year:

March 31, 2026: Mr. Mohmad Saleh Mutvalli joined the committee as a Chairman, taking the place of Mr. Ashok Kumar Jain, who has resigned with effect from March 31, 2026.

During the period under review, total 2 (Two) Nomination and Remuneration Committee Meetings were held dated: August 14, 2025 and March 31, 2026.

Attendance of Nomination & Remuneration Committee Meeting:

Sr. No.	Name of Committee Member	No. of Meeting	
		Entitled to Attend	Attended
1.	Mr. Ashok Kumar Jain	2	2
2.	Mr. Mohmad Saleh Mutvalli	-	-
3.	Mr. Vipul Balubhai Patel	2	2
4.	Mr. Abdul Ganee Abdul Rasul Chandniwala	2	2

D. STAKEHOLDER RELATIONSHIP COMMITTEE

In compliance with the provisions of Section 178 of the Companies Act, 2013 and Regulation 20 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, the Board has constituted the “Stakeholders’ Relationship Committee”.

The Stakeholders’ Relationship Committee has been formed for the effective redressal of the investors’ complaints and reporting of the same to the Board periodically.

The detailed composition of the members of the Stakeholders Relationship Committee at present is given below:

DIN	Name of Directors	Nature of Directorship	Status in Committee	Date of Appointment	Date of Cessation
08091260	Mr. Vipul Balubhai Patel	Non-Executive Independent Director	Chairman	August 9, 2024	-
08459582	Mr. Munir Abdul Ganee Chandniwala	Managing Director	Member	August 9, 2024	-
08459623	Mrs. Shirin Munir Ahmed Chandniwala	Whole Time Director	Member	August 9, 2024	-

During the period under review, a total of 3 (Three) Stakeholders Relationship Committee Meetings were held dated July 25, 2025, October 28, 2025 and January 23, 2026.

Attendance of Stakeholder Relationship Committee Meeting:

Sr. No.	Name of Committee Member	No. of Meeting	
		Entitled to Attend	Attended
1.	Mr. Vipul Balubhai Patel	3	3
2.	Mr. Munir Abdul Ganee Chandniwala	3	3

3.	Mrs. Shirin Munir Ahmed Chandniwala	3	3
----	-------------------------------------	---	---

E. CORPORATE SOCIAL RESPONSIBILITY COMMITTEE

In compliance with the provisions of Section 135 of the Companies Act, 2013, the Board has constituted the “Corporate Social Responsibility Committee”.

The detailed composition of the members of the Corporate Social Responsibility Committee at present is given below:

DIN	Name of Directors	Nature of Directorship	Status in Committee	Date of Appointment	Date of Cessation
08459582	Mr. Munir Abdul Ganee Chandniwala	Managing Director	Chairman	August 9, 2024	-
00251096	Mr. Ashok Kumar Jain	Non-Executive Independent Director	Member	August 9, 2024	March 31, 2026
07361078	Mr. Mohmad Saleh Mutvalli	Non-Executive Independent Director	Member	March 31, 2026	-
08459623	Mr. Shirin Munir Ahmed Chandniwala	Whole Time Director	Member	August 9, 2024	-

Reconstitution of the Committee During the Year

The Board of Directors approved the reconstitution of the Nomination & Remuneration Committee on following occasion during the year:

March 31, 2026: Mr. Mohmad Saleh Mutvalli joined the committee as a Chairman, taking the place of Mr. Ashok Kumar Jain, who has resigned with effect from March 31, 2026.

During the period under review, total 2 (Two) Nomination and Remuneration Committee Meetings were held dated: August 14, 2025 and March 31, 2026.

Attendance of Nomination & Remuneration Committee Meeting:

Sr. No.	Name of Committee Member	No. of Meeting	
		Entitled to Attend	Attended
1.	Mr. Ashok Kumar Jain	2	2
2.	Mr. Mohmad Saleh Mutvalli	-	-
3.	Mr. Vipul Balubhai Patel	2	2
4.	Mr. Abdul Ganee Abdul Rasul Chandniwala	2	2

18. BOARD EVALUATION:

The board of directors has carried out an annual evaluation of its own performance, board committees and individual directors pursuant to the provisions of the Act and SEBI Listing Regulations.

The performance of the Board was evaluated after seeking input from all the directors on the basis of criteria such as board composition and structure effectiveness of board process, information and functioning etc. The performance of the committees was evaluated by the board after seeking input from committee members on the basis of criteria such as composition of committees, effectiveness of committee meetings etc.

In separate meeting of Independent Directors, performance of the non-independent directors, performance of the board as a whole and the Chairman was evaluated, taking into account the views of the executive directors and non-executive directors.

The board and nomination and remuneration committee reviewed the performance of the individual directors on the basis of criteria such as contribution of the individual director to the board and committee meetings preparedness on the issues to be discussed meaningful and constructive contribution and inputs in the meeting etc.

The evaluation of the Independent Directors was carried out by the entire Board excluding the Director being evaluated and that of the Non-Independent Directors was carried out by the Independent Directors in their separate meeting held on March 31, 2026.

19. VIGIL MECHANISM

The Company has whistle blower policy for Directors and employees to report their genuine concerns regarding unethical behaviour; actual or suspected fraud or violation of the Company's Code of Conduct and Ethics Policy. The said mechanism also provides for adequate safeguard against victimization of persons who use such mechanism and makes provision for direct access to the chairman of the Audit Committee in the appropriate or exceptional cases. We affirm that no employee of the company was denied access to the Audit Committee.

The Whistle Blower Policy is available on the website of the Company at <https://influxhealthtech.com/wp-content/uploads/2024/08/Whistle-Blower-Policy.pdf>

20. COMPANY'S POLICY RELATING TO DIRECTORS' APPOINTMENT, PAYMENT OF REMUNERATION AND DISCHARGE OF THEIR DUTIES

Your Company has formulated and published The Nomination & Remuneration Policy for Directors, Key Managerial Personnel and Senior Management. The provisions of this policy are in line with the provisions of Section 178(1) of the Act. The Policy is uploaded on the website of the company. The web link is <https://influxhealthtech.com/wp-content/uploads/2024/08/Nomination-and-Remuneration-Policy-1.pdf>

21. DIRECTORS' RESPONSIBILITY STATEMENT

Pursuant to Section 134(3)(c) & 134(5) of the Companies Act, 2013, the Board of Directors of the Company hereby confirm that:

-
- a) In preparation of the annual accounts, the applicable Accounting Standards have been followed, along with proper explanation relating to material departures, if any;
 - b) Such Accounting Policies have been selected and applied consistently, and judgements and estimates have been made that are reasonable and prudent to give a true and fair view of the Company's state of affairs as on March 31, 2026, and of the Company's profit or loss for the year ended on that date;
 - c) Proper and sufficient care has been taken for the maintenance of adequate accounting records, in accordance with the provisions of the Companies Act, 2013 for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;
 - d) The annual Financial Statements have been prepared on a Going Concern Basis.
 - e) Internal financial controls have been laid down to be followed by the Company and that such internal financial controls were adequate and operating effectively.
 - f) Proper systems were devised to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

22. ADEQUACY OF INTERNAL FINANCIAL CONTROLS

The Company has in place adequate internal financial controls with reference to financial statement across the organization. The same is subject to review periodically by the internal auditors for its effectiveness. During the financial year, such controls were tested and no reportable material weaknesses in the design or operations were observed. The Statutory Auditors of the Company also test the effectiveness of Internal Financial Controls in accordance with the requisite standards prescribed by ICAI. Their expressed opinion forms part of the Independent Auditor's report.

Internal Financial Controls are an integrated part of the risk management process, addressing financial and financial reporting risks. The internal financial controls have been documented, digitized and embedded in the business processes.

Assurance on the effectiveness of internal financial controls is obtained through management reviews, control self-assessment, continuous monitoring by functional experts. We believe that these systems provide reasonable assurance that our internal financial controls are designed effectively and operate as intended. During the year, no reportable material weakness was observed.

23. APPOINTMENT OF DESIGNATED PERSON (MANAGEMENT AND ADMINISTRATION) RULES 2014 - RULE 9 OF THE COMPANIES ACT 2013

In accordance with Rule 9 of the Appointment of Designated Person (Management and Administration) Rules 2014, it is essential for the company to designate a responsible individual for ensuring compliance with statutory obligations.

The company had appointed Mr. Munir Abdul Ganee Chandniwala (DIN: 08459582) as a Designated person in the Board meeting held on August 26, 2026 and the same will be reported in Annual Return of the company.

24. SUBSIDIARY, JOINT VENTURE AND ASSOCIATE COMPANIES

As of March 31, 2026, the Company has one (1) Wholly-Owned Subsidiary. The details of the Company's holding in this entity are as follows:

Sr. No.	Name of the Wholly Owned Subsidiary Company	Percentage holding
1	Olahey Wellness Private Limited*	100%

- *Olahey Wellness Private Limited* was incorporated on February 3, 2026.

During the financial year under review, the Company did not have any associate companies and has not entered into any joint ventures with other entities.

Pursuant to the first proviso of Section 129(3) of the Companies Act, 2013, read with Rule 5 of the Companies (Accounts) Rules, 2014, a statement containing the salient features of the financial statements of the Company's subsidiaries, associate companies, and joint ventures is provided in **Form AOC-1**, which is appended to this report as '**Annexure - I**'.

25. MATERIAL SUBSIDIARIES

In terms of Regulation 16 of the Listing Regulations, a subsidiary shall be considered material subsidiary if, its turnover or net worth exceeds 10% of the consolidated turnover or net worth respectively, of the listed entity and its subsidiaries in the immediately preceding accounting year. Basis this definition and audited financial statements of the Company of March 31, 2026, the Company had no material subsidiaries during the period under review.

26. SIGNIFICANT & MATERIAL ORDERS PASSED BY THE REGULATORS

During the year, no significant and material orders were passed by the regulators or courts or tribunals impacting the going concern status and company's operations in the future.

27. EXTRACT OF ANNUAL RETURN

The Annual return referred to in Sub Section (3) of Section 92 read with Section 134(3)(a) of the Companies Act, 2013, for the financial year ended March 31, 2026 is placed on the website of the company at www.influxhealthtech.com.

28. AUDITORS AND AUDITOR'S REPORT

A. STATUTORY AUDITOR

The Auditor, M/s V.B. Goel & Co., Chartered Accountants, (FRN: 115906W) were appointed as Statutory Auditor of the Company to hold office from September 30, 2024 for a term of five years in terms of Section 139 of the Companies Act, 2013.

STATUTORY AUDITOR'S OBSERVATION IN AUDIT REPORT

The Auditors' Report for the Financial Year ended March 31, 2026 does not contain any qualification, reservation, adverse remark, or disclaimer. The Notes on financial statements referred to in the Auditor's Report are self-explanatory and do not call for any further comments.

B. SECRETARIAL AUDITOR

In terms of Section 204 of the Companies Act, 2013, every listed company is required to annex a Secretarial Audit Report issued by a Practicing Company Secretary to its Board's Report.

Accordingly, being a listed company, the provisions relating to Secretarial Audit are applicable to the Company for the financial year 2025-26.

Further, pursuant to Regulation 15(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Regulation 24A relating to Secretarial Compliance Report is not applicable to companies listed on the SME Exchange. Accordingly, approval of shareholders for appointment of Secretarial Auditor under Regulation 24A is not applicable to the Company.

In compliance with the provisions of Section 204 of the Companies Act, 2013, the Audit Committee and the Board of Directors, at their respective meetings held on March 31, 2026, approved the appointment of M/s. PNK & Co. (Earlier Pitroda Nayan & Co., Practicing Company Secretaries, as Secretarial Auditor of the Company for the financial year 2025-26.

SECRETARIAL AUDITOR'S OBSERVATION IN SECRETARIAL AUDIT REPORT

The Secretarial Audit Report in the prescribed Form No. MR-3 is annexed as '**Annexure II**' and forms an integral part of this Report. The Secretarial Auditor has not made any qualifications, observations or adverse remarks in the said Report for the year under review. Accordingly, no comments of the Board of Directors are required in this regard.

Being a SME Listed Company, Pursuant to Regulation 24A of the Listing Regulations read with SEBI Circular No. CIR/CFD/CMD1/27/2019 dated 08 February 2019, the Annual Secretarial Compliance Report is not applicable to our Company.

C. INTERNAL AUDITOR

In terms of Section 138 of the Companies Act, 2013, every listed company and such other class of companies as prescribed by the Ministry of Corporate Affairs is required to appoint an internal auditor. In compliance with the

applicable provisions of Section 138 of the Companies Act, 2013, the Company appointed M/s. Phirodia Bafna & Associates as the Internal Auditor of the Company for the financial year 2025–26 on August 14, 2025.

D. COST AUDITOR

Pursuant to the provisions of Section 148 of the Companies Act, 2013 read with the Companies (Cost Records and Audit) Rules, 2014, the provisions relating to the appointment of a Cost Auditor are not applicable to the Company for the Financial Year 2025-26, as the Company does not fall within the prescribed criteria for mandatory cost audit. Accordingly, the Board of Directors has not appointed a Cost Auditor for the Financial Year 2025-26.

E. FRAUD'S REPORTED BY AUDITORS OTHER THAN THOSE WHICH ARE REPORTABLE TO THE CENTRAL GOVERNMENT U/S 143(12)

During the year under review, the Statutory Auditors, Internal Auditor and Secretarial Auditor have not reported any instances of frauds committed in the Company by its Officers or Employees, to the Audit Committee or the Board under Section 143 (12) of the Companies Act, 2013.

29. CORPORATE SOCIAL RESPONSIBILITY

In compliance with the provisions of section 135 of Companies Act, 2013 and the Companies (Corporate Social Responsibility Policy) Rules, 2014, the Company has adopted Corporate Social Responsibility Policy. In order to implement CSR Policy, the Company has constituted CSR Committee. The brief outline of the Corporate Social Responsibility (CSR) Policy of the Company, Constitution of Committee, the initiatives undertaken by the Company on CSR activities during the year and other disclosures are set out in **Annexure - III** of this report in the format prescribed in the Companies (Corporate Social Responsibility Policy) Rules, 2014.

The Company remains committed to creating sustainable social value through its Corporate Social Responsibility (CSR) initiatives. During the year under review, the Company, through its implementing agency, undertook CSR activities focused on promoting education and healthcare for underprivileged sections of society, thereby contributing to community development and fulfilling its social responsibility.

30. PARTICULARS OF LOANS, GUARANTEES AND INVESTMENTS

Particulars of loans, Guarantees and investments made by the Company pursuant to Section 186 of the Companies Act, 2013 are given in the notes to Financial Accounts, which forms part of the Annual Report.

31. DEPOSITS FROM PUBLIC

The Company, during the year, has not invited/ accepted any deposit other than the exempted deposit as prescribed under the provision of the Companies Act, 2013, and the rules framed there under, as amended from time to time. Hence there are no particulars to report about the deposit falling under Rule 8 (5) (v) and (vi) of Companies (Accounts) Rules, 2014.

32. RISK MANAGEMENT POLICY

The Company has laid down the procedure to inform the Board about the risk assessment and minimization procedures. These procedures are reviewed by the Board annually to ensure that there are timely identification and assessment of risks, measures to mitigate them, and mechanisms for their proper and timely monitoring and reporting.

The Company does not fall under the ambit of top 1000 listed entities, determined on the basis of market capitalization as at the end of the immediately preceding financial year. Hence, compliance under Regulation 21 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is not applicable.

33. RELATED PARTY TRANSACTIONS

Your Company has adopted a policy on Related Party Transactions under Regulation 23(1) of SEBI Listing Regulations, which is available on the website of your Company at <https://influxhealthtech.com/wp-content/uploads/2024/08/Policy-on-Materiality-of-Related-Party-Transactions.pdf>. All contracts or arrangements or transactions entered during the year with related parties were on arm's length basis and in the ordinary course of business and in compliance with the applicable provisions of the Act and the SEBI Listing Regulations. None of the contract or arrangements or transaction with any of the related parties was in conflict with the interest of the Company.

Since all the transactions with related parties during the year were on arm's length basis and in the ordinary course of business the disclosure of related party transactions as required under Section 134(3)(h) of the Act in Form AOC-2 is not applicable for F.Y. 2025-26. However, the company is voluntarily giving the details pertaining to related party transactions which are not material but are on arm's length basis in AOC-2 as 'Annexure - IV' and same forms part of this report. In terms of Regulation 23 of the SEBI Listing Regulations, your Company submits details of related party transactions on a standalone basis as per the specified format to the stock exchanges on a half-yearly basis.

34. MANAGEMENT'S DISCUSSION AND ANALYSIS

The Management Discussion and Analysis Report for the year under review, as stipulated under Regulation 34(2)(e) read with Schedule V of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 forms part of this Report.

35. CORPORATE GOVERNANCE REPORT

In accordance with Regulation 15(2)(b) SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Corporate Governance provisions are not mandatory for the Company, as it is listed as a Small and Medium-sized Enterprise (SME) Platform of NSE.

36. GENERAL SHAREHOLDER INFORMATION

A	AGM: Day, Date, Time and Venue	Friday, September 18, 2026, at 12:00 P.M through V.C
---	--------------------------------	--

B	Financial Year	2025-26
C	Cut-off date for the purpose of determining shareholders for voting	September 11, 2026
D	Listing on Stock Exchanges	NSE-Emerge
E	Scrip Code/Symbol	INFLUX
F	ISIN	INE0MYZ01012
G	Payment of Listing Fees	The Company confirms that it has paid Annual Listing fees due to the stock exchange.
H	Market Price Data (High, Low during each month in last financial year 2025-26)	*Refer table below
I	Registrar and Share Transfer Agents	Maashitla Securities Private Limited

***MARKET PRICE DATA**

Month	High	Low
June 2025	140.40	120.00
July 2025	184.00	120.50
August 2025	186.50	141.00
September 2025	208.00	164.40
October 2025	190.25	160.60
November 2025	240.65	170.75
December 2025	261.95	210.00
January 2026	236.00	183.05
February 2026	235.90	192.10
March 2026	234.00	196.50

DISTRIBUTION OF SHAREHOLDING AS ON MARCH 31, 2026

Share Holding Range	No. of Shareholders	% of Total numbers	Shareholding Amount (in ₹)	% to Total Amount
1-5000	1,219	90.03	1,63,08,300	7.04
5,001 to 10,000	63	4.65	44,80,380	1.94
10,001 to 20,000	32	2.36	44,63,940	1.93
20,001 to 30,000	11	0.81	26,70,000	1.15
30,001 to 40,000	4	0.30	13,62,000	0.59
40,001 to 50,000	5	0.37	22,68,000	0.98
50,001 to 1,00,000	8	0.59	50,82,000	2.20
1,00,000 and above	12	0.89	19,48,69,380	84.18
Total	1,354	100.00	23,15,04,000	100.00

SHAREHOLDING PATTERN AS ON MARCH 31, 2026

Sr. No.	Category	Shareholders	No of shares held	Percentage of holding
1.	Promoter and Promoter Group	3	1,70,23,464	73.53
2.	Institutions Domestic	8	13,07,400	5.65
3.	Institutions Foreign	3	37,800	0.16
5.	KMP	1	726	0.01
6.	Individual shareholders holding nominal shares Capital upto 2 lakhs	1,180	22,23,210	9.6
7.	Individual Shareholders holding nominal Shares Capital in excess of 2 Lakhs	22	15,12,600	6.53
8.	NRI	38	1,40,400	0.61
9.	Bodies corporate	20	6,28,800	2.72
10.	Any other	60	2,76,000	1.19
	TOTAL	1,335	2,31,50,400	100.00

Note: The shareholding of Directors and Key Managerial Personnel (KMP) is included under the 'Promoter and Promoter Group' category.

37. DISCLOSURE UNDER THE SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013

The Company has zero tolerance towards sexual harassment of women at workplace and values the dignity of individuals and is committed to provide an environment, which is free of discrimination, intimidation and abuse.

As per the requirement of the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 ("POSH Act") and rules made there under, the Company has adopted a Prevention of Sexual Harassment of Women at Workplace Policy to ensure healthy working environment for women without fear of prejudice, gender bias and sexual harassment and the Company is complying with the applicable provisions of the POSH Act.

In terms of the provisions of the POSH Act and rules made thereunder, the Company constituted an Internal Complaints Committee to redress the complaints received regarding sexual harassment.

Number of Complaints of Sexual Harassment Received During the Year	Number of complaints disposed off during the year	Number of Cases Pending for More than Ninety Days
0	0	0

38. COMPLIANCE OF THE PROVISIONS RELATING TO THE MATERNITY BENEFIT ACT, 1961:

The Company is in Compliance with provisions relating to the Maternity Benefit Act, 1961 during the Year under review i.e. FY 2025-26.

39. DETAILS OF CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION, FOREIGN EXCHANGE EARNINGS AND OUTGO:

The information on conservation of energy, technology absorption and foreign exchange earnings and outgo stipulated under Section 134(3)(m) of the Companies Act, 2013 read with Rule, 8 of The Companies (Accounts) Rules, 2014, are as follows:

a). Conservation of energy-

(i)	the steps taken or impact on conservation of energy	Continuous Monitoring on electricity uses to reduce the misuse or wastage of electricity at factory and office premise
(ii)	the steps taken by the company for utilizing alternate sources of energy	NIL
(iii)	the capital investment on energy conservation equipments	NIL

b). Technology absorption-

(i)	the efforts made by the Company towards technology absorption	NIL
(ii)	the benefits derived like product improvement, cost reduction, product development or import substitution	NIL
(iii)	The information regarding imported technology (imported during the last three years)-	NIL
	(a) the details of technology imported	NIL
	(b) the year of import	NIL
	(c) whether the technology been fully absorbed	NIL
	(d) if not fully absorbed, areas where absorption has not taken place, and the reasons thereof	NIL
(iv)	the expenditure incurred on Research and Development	NIL

Foreign exchange earnings and Outgo-

The Foreign Exchange earned in terms of actual inflows during the year and the Foreign Exchange outgo during the year in terms of actual outflows are as follows:

(Rs. In Lakhs, unless otherwise stated)

Particulars	Current Year (2025-26) (INR)	Previous Year (2024-25) (INR)
Export of Goods on F.O.B Basis	21.51	61.03
C.I.F Value of Import	33.68	-
Remittance of Dividend in Foreign Currency	-	-
Expenditure in Foreign Currency	0.90	27.47

40. PARTICULARS REGARDING EMPLOYEES' REMUNERATION

The ratio of remuneration of each Director to the median remuneration of the employees as required under Section 197(12) of the Companies Act, 2013, read with Rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 is annexed herewith as **Annexure - V**.

41. TRANSFER OF UNCLAIMED DIVIDEND TO INVESTOR EDUCATION AND PROTECTION FUND:

The Company did not have any funds lying unpaid or unclaimed for a period of seven year. Therefore, there were no funds which were required to be transferred to Investor Education and Protection Fund (IEPF).

42. COMPLIANCE WITH SECRETARIAL STANDARDS

The Company has complied with the applicable Secretarial Standards issued by the Institute of Company Secretaries of India on the Board Meetings and General Meeting.

43. CODE OF CONDUCT FOR THE BOARD OF DIRECTORS AND SENIOR MANAGEMENT PERSONNEL:

The Board has adopted the Code of Conduct for the Board of Directors and Senior Management Personnel of the Company. The compliance of the said code has been affirmed by them annually. The Code of Conduct also includes the duties of Independent Directors. A copy of the Code has been put up on the Company's website and same may be accessed at <https://influxhealthtech.com/wp-content/uploads/2024/08/Code-of-Conduct-of-Board-Senior-Management.pdf>

A declaration of the Company for compliance with code of conduct is annexed herewith as **Annexure – VI**.

44. DISCLOSURES UNDER THE INSOLVENCY AND BANKRUPTCY CODE, 2016

There are no applications made or any proceeding pending under the Insolvency and Bankruptcy Code, 2016 (31 of 2016) during the year along with their status as at the end of the financial year.

45. DETAILS OF DIFFERENCE BETWEEN AMOUNT OF THE VALUATION DONE AT THE TIME OF ONE TIME SETTLEMENT AND THE VALUATION DONE WHILE TAKING LOAN FROM THE BANKS OR FINANCIAL INSTITUTIONS ALONG WITH THE REASONS THERE OF

As Company has not done any one-time settlement during the year under review, no disclosure is required.

46. OTHER GENERAL DISCLOSURES

The Directors state that no disclosure or reporting is required in respect of the following items as there were no transactions/events of these nature during the year under review:

- Issue of equity shares with differential rights as to dividend, voting or otherwise.
- Voting rights which are not directly exercised by the employees in respect of shares for the subscription/ purchase of which loan was given by the Company (as there is no scheme pursuant to which such persons can beneficially hold shares as envisaged under section 67(3)(c) of the Companies Act, 2013).
- One-time settlement of loan obtained from the Banks or Financial Institutions.
- None of the Directors of the Company has been debarred or disqualified from being appointed or continuing as a Director by SEBI / Ministry of Corporate Affairs / Statutory Authorities.
- Neither the Managing Director nor the Whole- time Directors of the Company, receives any commission from any of its subsidiaries.

47. AUDIT TRAIL APPLICABILITY (AUDIT AND AUDITORS) RULES 2014 - RULE 11 OF THE COMPANIES ACT 2013

The Company has used accounting software for maintaining its books of account for the financial year ended March 31, 2026 which has a feature of recording audit trail (edit log) facility and the same has operated throughout the year for all relevant transactions recorded in the softwares.

48. ACKNOWLEDGEMENTS

The Directors wish to place on record their sincere appreciation for excellent support received from the Banks and financial institutions during the financial year under review. Your directors also express their warm appreciation to all employees for their contribution to your Company's performance and for their superior levels of competence, dedication and commitment to the growth of the Company. The Directors are also grateful to you, the Shareholders, for the confidence you continue to repose in the Company.

Registered Office:

109, Ghanshyam Enclave
Premises Co-op Soc Plot No.
856, Laljipada, Kandivali
West, Mumbai - 400067
Maharashtra, India.

**By Order of the Board of Directors of
Influx Healthtech Limited**

Sd/-

Mrs. Shirin Munir Ahmed Chandniwala
Whole-time Director
DIN: 08459623

Sd/-

Mr. Munir Abdul Ganee Chandniwala
Chairman and Managing Director
DIN: 08459582

Date: August 26, 2026

Place: Mumbai

ANNEXURE-I

On Subsidiaries, Associate Companies and Joint Venture forming part of Board's Report for F.Y
2025-26.

Form AOC-1

*(Pursuant to first proviso to Sub-Section (3) of Section 129 read with Rule 5 of Companies
(Accounts) Rules, 2014)*

Part "A": Subsidiaries

Sr. No.	Particulars	Details
1	Name of the subsidiary	Olahey Wellness Private Limited
2	Reporting period for the subsidiary concerned, if different from the holding company's reporting period	NA
3	The date since when subsidiary was acquired	February 3, 2026
4	Reporting currency and Exchange rate as on the last date of the relevant financial year in the case of foreign subsidiaries	NA
5	Share capital (In amount)	1,00,000
6	Reserves & surplus	(26,150)
7	Total assets	88,850
8	Total Liabilities	15,000
9	Investments	Nil
10	Turnover	Nil
11	Profit before taxation	34,940
12	Provision for taxation (Current)	Nil
13	Profit after taxation	26,150
14	Proposed Dividend	Nil
15	Extent of shareholding	100%

Note:

1. Names of subsidiaries which are yet to commence operations: Nil
2. Names of subsidiaries which have been liquidated or sold during the year: Nil

Part “B”: Associates and Joint Ventures

Statement pursuant to Section 129 (3) of the Companies Act, 2013 related to Associate Companies and Joint Ventures

Sr. No.	Name of Associates or Joint Ventures
NIL	

Form No. MR-3
SECRETARIAL AUDIT REPORT
FOR THE FINANCIAL YEAR ENDED 31st March, 2026
[Pursuant to section 204(1) of the Companies Act, 2013 and rule No.9 of
the Companies (Appointment and Remuneration Personnel) Rules, 2014]

To,
 The Members,
INFLUX HEALTHTECH LIMITED
[CIN: L24299MH2020PLC346825]
 109, Ghanshyam Enclave Premises
 Co-Op Soc Plot No. 856, Laljipada,
 Kandivali West, Mumbai City,
 Maharashtra, India, 400067

I have conducted the secretarial audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by **INFLUX HEALTHTECH LIMITED [CIN: L24299MH2020PLC346825]** (hereinafter called the company). Secretarial Audit was conducted in a manner that provided me a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing my opinion thereon.

Based on my verification of the Company's books, papers, minute books, forms and returns filed and other records maintained by the Company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, I hereby report that in my opinion, the Company has, during the audit period covering the financial year ended on **31st March, 2026** ('Audit Period') complied with the statutory provisions listed hereunder and also that the Company has proper Board-processes and compliance-mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

I have examined the books, papers, minute books, forms and returns filed and other records maintained by the Company for the financial year ended on **31st March, 2026** according to the provisions of:

- i. The Companies Act, 2013 (**the Act**) and the rules made there under.
- ii. The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the rules made thereunder;
- iii. The Depositories Act, 1996 and the Regulations and Bye-laws framed thereunder;
- iv. Foreign Exchange Management Act, 1999 and the Rules and Regulations made thereunder to the extent of Foreign Direct Investment, Overseas Direct Investment and External Commercial Borrowing.
- v. The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ('SEBI Act'): -

☎ +91 8866021210 | ✉ info@csnayan.com

📍 805, Arizona, Nr. Hotel Hyatt Regency, Opp Gujarat Vidhyapith, Usmanpura, Ashram Road, Ahmedabad 380014



- a) The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;
- b) The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015;
- c) The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018;
- d) The Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 (Not Applicable to the Company during the Audit Period);
- e) The Securities and Exchange Board of India (Issue and Listing of Non-Convertible Securities) Regulations, 2021 (Not Applicable to the Company during the Audit Period);
- f) The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993;
- g) The Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2021 (Not Applicable to the Company during the Audit Period);
- h) The Securities and Exchange Board of India (Buy-back of Securities) Regulations, 2018 (Not Applicable to the Company during the Audit Period).

I have also examined compliance with the applicable clauses of the following:

- i. Secretarial Standards issued by the Institute of Company Secretaries of India.
- ii. Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

During the period under review, the Company has complied with the provisions of the Act, Rules, Regulations, Guidelines, Standards, etc. mentioned above.

I further report that:


The Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors and Independent Directors. The changes in the composition of the Board of Directors that took place during the period under review were carried out in compliance with the provisions of the Act.

Adequate notice is given to all the Directors to schedule the Board Meetings, agenda and detailed notes on agenda were sent at least seven days in advance, and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the meeting.

Majority decision is carried through while the dissenting members' views, if any, are captured and recorded as part of the minutes.

I further report that:

I further report that during the audit period, except for the below event, there was no event/action having a major bearing on the Company's affairs in pursuance of the above referred laws, rules, regulations, guidelines etc.



The following resolutions were approved through the postal ballot process, for which notice was dispatched on 01st April, 2026 and the results were declared on 02nd May, 2026.

1. Alteration in main object clause of the Memorandum of Association of the company.
2. Appointment And Approval of Sitting Fees of Mr. Mohmad Saleh Mutvalli (DIN: 07361078) As Independent Director of the Company:

**For. Pitroda Nayan & Co.,
Company Secretaries**

**Nayan P. Pitroda
Proprietor**

Mem.No.: 58473

C.P.No.: 23912

UDIN.: A058473H001220832

P/R No.: 5509/2024

Date.: 26/08/2026

Place.: Ahmedabad


Note: This report is to be read with my letter of even date which is annexed as Annexure herewith and forms and integral part of this report.

Annexure to Secretarial Audit Report

To,
The Members,
INFLUX HEALTHTECH LIMITED
[CIN: L24299MH2020PLC346825]
109, Ghanshyam Enclave Premises
Co-Op Soc Plot No. 856, Laljipada,
Kandivali West, Mumbai City,
Maharashtra, India, 400067

My report of even date is to be read along with this letter.

1. Maintenance of secretarial records is the responsibility of the management of the Company. My responsibility is to express an opinion on these secretarial records based on my audit.
2. I have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the correctness of the contents of the secretarial records. The verification was done on test basis to ensure that correct facts are reflected in secretarial records. I believe that the processes and practices, I followed provide a reasonable basis for my opinion.
3. I have not verified the correctness and appropriateness of financial records and Books of Accounts of the Company.
4. Wherever required, I have obtained the Management representations about the compliance of Laws, Rules and Regulations and happening of events etc.
5. The compliance of the provisions of corporate and other applicable Laws, Rules, Regulations, Standards is the responsibility of management. My examination was limited to the verification of procedures on test basis.
6. The Secretarial Audit report is neither an assurance as to the future viability of the Company nor of the efficacy or effectiveness with which the management has conducted the affairs of the Company.
7. With respect to compliance with Regulation 3(5) and 3(6) of the SEBI (Prohibition of Insider Trading) Regulations, 2015 relating to the maintenance of Structured Digital Database ("SDD"), we have considered the Compliance Certificate dated 21st April, 2026 issued by Deepti & Associates, Practicing Company Secretaries, appointed by the Company for the financial year ended 31st March, 2026. As stated in the said certificate, the Company was required to capture 41 events during the financial year ended 31st March, 2026 and all 41 events were captured in the SDD.



We have considered the aforesaid observation while conducting our Secretarial Audit and have verified the relevant records document made available to us in this regard. The said Compliance Certificate has been considered as one of the audit evidences for the limited purpose of assessing compliance relating to the SDD and UPSI requirements and has not been treated as a substitute for our own audit procedures.

Foř. Pitroda Nayan & Co.,
Company Secretaries

Nayan P. Pitroda
Proprietor

Mem.No.: 58473

C.P.No.: 23912

UDIN.: A058473H001220832

P/R No.: 5509/2024

Date.: 26/08/2026

Place.: Ahmedabad

ANNEXURE-III

Annual Report on Corporate Social Responsibility (CSR) Activities *[Pursuant to Section 135 of the Companies Act, 2013]*

1. Brief Outline of CSR Policy of the Company:

Corporate Social Responsibility (CSR) is a significant part of our overall sustainability policy, encompassing social, economic, and environmental actions. The policy aims to demonstrate care for the community through its focus on education, healthcare, community development projects/programs, etc., and to support local institutions/NGOs in addressing the needs of marginalized and underserved communities to help them become self-reliant. These efforts are preferably undertaken in the local area and around our work centers/project sites, or in other areas if public needs so demand.

The Company approaches CSR strategically to ensure a sustainable future for people and the planet. By focusing our talent, technology, and capital on social welfare, healthcare issues, and educational concerns, we strive to enact positive social change in society.

The Company demonstrate Its commitment to social development by dedicating resources and efforts to meaningful CSR programs. The initiatives are aligned with Indian legal requirements and focus on the fields of education and healthcare, executed through our implementing agencies:

- Womb Foundation
- Bombay North-west Rotary Public Charitable Trust
- Hasaniya Healthcare Sarvajanik Trust
- Madresa Moinul Islam Trust
- Rotary Club of Palghar

The projects/programmes/activities undertaken or to be undertaken will be within the broad framework of Schedule VII of the Companies Act, 2013.

2. Composition of CSR Committee:

The CSR Committee is responsible for overseeing the execution of the Company's CSR Policy. Pursuant to the provisions of Section 135(1) of the Act, the Board has set up the CSR Committee.

The Board of Directors of the Company, at its meeting held on March 31, 2026, approved the reconstitution of the Corporate Social Responsibility Committee, in view of the resignation tendered by Mr. Ashok Kumar Jain, which is effective from March 31, 2026. Accordingly, Mr. Ashok Kumar Jain shall cease to be a member of the Corporate Social Responsibility Committee from the said date, and Mr. Mohmad Saleh Mutvalli, Additional (Non-Executive) Independent Director, has been appointed as a member of the Committee with effect from the same date.

The revised composition of the Corporate Social Responsibility Committee and meetings held during the financial year 2025-26 are as follows:

Name of the Director	Status in the Committee	Nature of Directorship	No. of committee Meetings Held & Entitled to Attend	No. of committee Meetings Attended
Mr. Munir Abdul Ganee Chandniwala	Chairman	Chairman and Managing Director	1	1
Mr. Mohmad Saleh Mutvalli	Member	Non-Executive Independent Director	0	0
Mrs. Shirin Munir Ahmed Chandniwala	Member	Whole Time Director	1	1

3. Web-Link for CSR Disclosure:

The Composition of CSR Committee, CSR Policy, and CSR projects approved by the Board are disclosed on the company's website at: <https://influxhealthtech.com/wp-content/uploads/2024/08/Corporate-Social-Responsibility-Policy.pdf>

4. Impact Assessment of CSR Projects:

Details of the impact assessment of CSR projects carried out in pursuance of sub-rule (3) of rule 8 of the Companies (Corporate Social Responsibility Policy) Rules, 2014, if applicable (attach the report): **Not Applicable**

5. Details of Amount Available for Set-off:

Not Applicable

6. Average Net Profit of the Company:

Average net profit of the company as per Section 135(5): Rs. 14,16,00,383/-

7. CSR Obligation for the Financial Year:

Sr. No.	Particulars	Amount
a.	Two percent of average net profit of the company as per Section 135(5)	Rs. 28,32,007/-

b.	Surplus arising out of the CSR projects or programmes or activities of the previous financial years	Nil
c.	Amount required to be set off for the financial year, if any	Nil
d.	Total CSR obligation for the financial year (a+b-c)	Rs. 28,85,010/-

8. CSR Amount Spent:

(a) CSR Amount Spent or Unspent for the Financial Year:

Total Amount Spent for the Financial Year (in Rs.)	Amount Unspent (in Rs.)				
	Total Amount transferred to Unspent CSR Account as per section 135(6)		Amount transferred to any fund specified under Schedule VII as per second proviso to section 135(5)		
	Amount	Date of transfer	Name of fund	Amount	Date of transfer
28,85,010/-	N.A.				

(b) Details of CSR Amount Spent Against Ongoing Projects for the Financial Year: There are no ongoing projects of the company for the financial year.

N o.	Name of the Project	Item from the List of Activities in Schedule VII to the Act	Local Area (Yes/ No)	Location of the Project	Project Duration	Amount Allocated for the Project (in Rs.)	Amount Spent in the Current Financial Year (in Rs.)	Amount Transferred to Unspent CSR Account for the Project as per Section 135(6) (in Rs.)	Mode of Implementation - Direct (Yes/No)	Mode of Implementation - Through Implementing Agency	State	District	Name	CSR Registration Number
N.A.														

(c) Details of CSR Amount Spent Against Other than Ongoing Projects for the Financial Year:

S. No.	Name of the Project	Item from the List of Activities in Schedule VII to the Act	Local Area (Yes/No)	Location of the Project	Amount Spent for the Project (In Rs.)	Mode of Implementation - Direct (Yes/No)	Mode of Implementation - Through Implementing Agency	
							Name	CSR Registration Number
1.	Promoting Education	Item No. (ii)	Yes	Mumbai	2,85,010	No	WOMB Foundation	CSR00031098

2.	Promoting Education	Item No. (ii)	Yes	Mumbai	2,50,000	No	Bombay North-West Rotary Public Charitable Trust	CSR00060705
3.	Promoting healthcare	Item No. (i)	No	Himatnagar, Gujarat	12,50,000	No	Hasaniya Healthcare Sarvajanic Trust	CSR00007825
4.	Promoting Education	Item No. (ii)	No	Himatnagar, Gujarat	8,50,000	No	Madresa Moinul Islam Trust	CSR00099789
5.	Promoting Education	Item No. (ii)	Yes	Mumbai	2,50,000	No	Rotary Club of Palghar	CSR00071913

(d) Amount Spent in Administrative Overheads: Nil

(e) Amount Spent on Impact Assessment, if Applicable: Nil

(f) Total Amount Spent for the Financial Year (8b+8c+8d+8e): Rs. 28,85,010/-

(g) Excess Amount for Set-off, if Any: Rs. 1,15,500/-

Sr. No.	Particulars	Amount (In Rs.)
(i)	Two percent of average net profit of the company as per Section 135(5)	Rs. 28,32,007/-
(ii)	Total amount spent for the Financial Year (Amount available for set-off from preceding financial years is Rs. 1,15,500)	Rs. 28,85,010/-
(iii)	Excess amount spent for the financial year [(ii) - (i)]	Rs. 53,003/-
(iv)	Surplus arising out of the CSR projects or programmes or activities of the previous financial years, if any	NIL
(v)	Amount available for set-off in succeeding financial years [(iii) - (iv)]	Rs. 1,68,503/-

9. Details of Unspent CSR Amount:

(a) Details of Unspent CSR Amount for the Preceding Three Financial Years: Nil

(b) Details of CSR Amount Spent in the Financial Year for Ongoing Projects of the Preceding Financial Year(s): Nil

10. Creation or Acquisition of Capital Assets:

(a) Date of creation or acquisition of the capital asset(s): Not Applicable

(b) Amount of CSR Spent for Creation or Acquisition of Capital Asset: Nil

(c) Details of the entity or public authority or beneficiary under whose name such capital asset is registered, their address etc.: Not Applicable

(d) Details of the capital asset(s) created or acquired (including complete address and location of the capital asset): Not Applicable

Specify the reason(s), if the company has failed to spend two percent of the average net profit as per Section 135(5): Not Applicable

ANNEXURE- IV

FORM NO. AOC-2

(Pursuant to clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014

Form for Disclosure of particulars of contracts/arrangements entered into by the company with related parties referred to in sub section (1) of section 188 of the Companies Act, 2013 including certain arm's length transaction under third proviso thereto.

1. Details of contracts or arrangements or transactions not at Arm's length basis

All contracts/arrangements entered into by the Company with related parties referred to in sub-section (1) of Section 188 of the Companies Act, 2013 are at arm's length basis.

2. Details of material contracts or arrangement or transactions at arm's length basis

All the transactions were entered by the Company in ordinary course of business and were in arm's length basis:

(Rs. in Lakhs, unless otherwise stated)

Name of Related Party and Nature of relationship	Nature of Contract / agreement / transactions	Amount	Duration of contracts / agreements / transactions	Salient terms of contracts or agreements, or transactions including the value	Date(s) of approval by the Board, if any:	Amount paid as advances
Mr. Munir Abdul Ganee Chandniwala (Managing Director)	Remuneration	96.00	April 1, 2025 to March 31, 2026	-	May 7, 2025	-
	Repayment of Loan	21.92	April 1, 2025 to March 31, 2026	-	May 7, 2025	-
	Rent	90.00	April 1, 2025 to March 31, 2026	-	May 7, 2025	-
	Acquisition of Fixed Asset	219.00	April 1, 2025 to March 31, 2026	-	May 7, 2025	-
Mrs. Shirin Munir Ahmed Chandniwala (Whole Time Director)	Remuneration	24.00	April 1, 2025 to March 31, 2026	-	May 7, 2025	-
	Rent	12.00	April 1, 2025 to March 31, 2026	-	May 7, 2025	-

Mr. Ashish Ghanshyam Shah (Chief Financial Officer)	Remuneration	12.55	April 1, 2025 to March 31, 2026	-	May 7, 2025	-
Mr. Atul Kumar Ashok Kumar Shukla (Company Secretary)	Remuneration	7.20	April 1, 2025 to March 31, 2026	-	May 7, 2025	-
Trusan Printpack Private Limited (Other Related Party)	Sale of Products	2.28	April 1, 2025 to March 31, 2026	-	May 7, 2025	-
	Purchase of Products	314.54	April 1, 2025 to March 31, 2026	-	May 7, 2025	-
	Rent income	3.60	April 1, 2025 to March 31, 2026	-	May 7, 2025	-
Influx Foundation (Other Related Party)	Donation	2.16	April 1, 2025 to March 31, 2026	-	May 7, 2025	-
Nutraceutical India (Other Related Party)	Sale of Product	0.29	April 1, 2025 to March 31, 2026	-	May 7, 2025	-

The Company has entered into contracts or arrangements with related parties as referred to in Section 188(1) of the Companies Act, 2013. However, all such transactions are entered into in the ordinary course of business and in the option of the Board all such transaction are at arm's length. Accordingly, by virtue of third proviso to Section 188(1) of the Act, no approval of the Board or General Meeting as referred to in Section 188(1) and its first proviso is required for such transactions. However, as part of good corporate governance, all related party transactions covered under section 188 of the Act are approved by the Audit committee.

ANNEXURE- V

PARTICULARS OF EMPLOYEE

Information required under Section 197 of the Companies Act, 2013 read with Rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Amendment Rules, 2016

- i. The Ratio of the remuneration of each Director to the median remuneration of the employees of the Company for the financial year 2025-26 and
- ii. The percentage Increase in remuneration of each Director, Managing Director, Chief Financial Officer and Company Secretary of the Company in the financial year 2025-26.

(Rs. In Lakhs, unless otherwise Stated)

Name & Designation	Remuneration of each Director & KMP for Financial 2025-26	Remuneration of each Director & KMP for Financial 2024-25	% increase / decrease in remuneration each Financial Year 2025-26	Ratio of remuneration of each Directors to median remuneration employees
Mr. Munir Abdul Ganee Chandniwala (MD)	96.00	84.00	14.29%	36.99
Mrs. Shirin Munir Ahmed Chandniwala (WTD)	24.00	16.00	50.00%	9.25
Mr. Ashish Shah (CFO)	12.55	10.03	25.12%	4.84
Mr. Atul Shukla (CS)	7.20	4.60	56.52%	2.77

MD - Managing Director, WTD – Whole-time Director, CFO – Chief Financial Officer; CS – Company Secretary.

- iii. The percentage increase / decrease in the median remuneration of employees in the financial year 2025-26.

Particular	Financial year 2025-26	Financial year 2024-25	Increase /(Decrease)
Median remuneration of all employees	2,59,524	2,46,000	5.50%

Note: The calculation of % Increase/decrease in the median remuneration has been done based on comparable employees.

- iv. The number of permanent employees on the rolls of Company.

There were 278 permanent employees on the rolls of Company as on March 31, 2026.

- v. Average percentiles increase already made in the salaries of employees other than the managerial personnel in the last financial year and its comparison with the percentile increase in the managerial remuneration and justification thereof and point out if there are any exceptional circumstances for increase in the managerial remuneration.**

Average percentiles increase already made in the salaries of employees other than the managerial personnel in the last financial year: 16.82%

Average increase in remuneration of KMPs: 36.48%.

Comparison with the percentile increase in the managerial remuneration:

The average increase in remuneration of Key Managerial Personnel (KMPs) was 36.48%, as compared to an average increase of 16.82% in the salaries of employees other than managerial personnel during the financial year.

- vi. Affirmation that the remuneration is as per the Remuneration Policy of the Company**

Pursuant to Rule 5(1)(xii) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, it is affirmed that the remuneration paid to the Directors, KMPs, Senior Management and other employees of the Company is as per the Remuneration Policy of the Company.

ANNEXURE - VI

DECLARATION REGARDING CODE OF CONDUCT

We hereby confirm that, all the Directors and Senior Management Personnel have affirmed compliance with Influx Healthtech Limited Code of Business conduct and Ethics for the year ended March 31, 2026.

Registered Office:

109, Ghanshyam Enclave
Premises Co-op Soc Plot No.
856, Laljipada, Kandivali West,
Mumbai - 400067 Maharashtra,
India.

**By Order of the Board of Directors of
Influx Healthtech Limited**

Sd/-

Mrs. Shirin Munir Ahmed Chandniwala
Whole-time Director
DIN: 08459623

Sd/-

Mr. Munir Abdul Ganee Chandniwala
Chairman and Managing Director
DIN: 08459582

Date: August 26, 2026

Place: Mumbai

MANAGEMENT DISCUSSION AND ANALYSIS REPORT

(a) Industry Structure and Developments

India's healthcare and wellness industry is evolving rapidly, with growing demand for certified, innovation led manufacturing across nutraceuticals, cosmetics, ayurvedic, veterinary, and homecare products. Influx Healthtech Limited, operating in the contract development and manufacturing (CDMO) space, is well positioned to capitalize on this trend, leveraging its globally certified facilities, strong R&D capabilities, and presence across four continents. Industry shifts toward clean-label formulations, functional cosmetics, and AYUSH-backed herbal products offer significant growth opportunities, while Influx's investments in automation, capacity expansion, and sustainability ensure it remains a competitive leader in this dynamic sector.

(b) Opportunities and Threats

Opportunities:

1. **Growing Consumer Demand for Innovation:** Consumer demand for new, innovative products continues to grow, particularly in the dietary/nutritional and cosmetics segments. The Company is well-positioned to capitalize on this trend by focusing on R&D and product innovation.
2. **Rising Demand in Emerging Markets:** The Company has identified emerging markets, particularly covered all Indian market and then in Asia and Africa, as areas for significant growth. These markets are experiencing an increase in disposable income and consumer demand for health-related and wellness products.
3. **Geographic and Market Expansion:** The Company plans to expand its footprint in international markets. As part of its strategy, it is exploring entry into additional countries, where demand for the Company's products is expected to rise.
4. **Innovation and New Product Development:** Continuous innovation and new product launches represent a major growth opportunity. The Company has a robust pipeline of products slated for release in the coming fiscal years, which are gaining traction.

Threats:

1. **Low Consumer Awareness:** In certain markets, especially emerging economies, consumer awareness of the Company's products is still developing. This could pose a challenge to sales growth, especially in new geographic regions.
2. **Government Scheme Delays:** The Company's business in certain segments, such as veterinary feeds, may be impacted by delays in the implementation of government schemes and regulations, which could affect the timely release of new products.

-
3. **Professional Skill Shortage:** The Company's ability to innovate and maintain high operational standards is challenged by the shortage of skilled professionals in certain markets. This can potentially slow down product development and impact growth.

(c) Segment-wise or Product-wise Performance

- **Nutraceuticals**
 - Contributed approximately 89.83% of total revenue
 - Growth driven by rising demand for functional supplements, gummies, protein bars, and wellness products
 - Strong export traction due to clean-label and certified formulations
- **Cosmetics**
 - Accounted for 5.06% of revenue
 - Increased sales of skincare creams, personal care items, and cosmetic jellies
 - Benefited from rising interest in premium, herbal, and vegan beauty products
- **Ayurvedic & Herbal Products**
 - Contributed 4.17% of revenue
 - Boosted by government AYUSH initiatives and consumer preference for natural remedies
 - Includes herbal tablets, oils, and traditional formulations
- **Veterinary Feed Supplements**
 - Represented 0.91% of revenue
 - Steady growth in animal health solutions, especially for poultry and livestock
 - Includes mineral mixtures and nutritional additives
- **Homecare Products**
 - Minimal but emerging segment at 0.03% of revenue
 - Includes eco-friendly cleaning solutions and personal hygiene items
 - Niche formulations with potential for strategic expansion

(d) Outlook

Influx Healthtech Limited enters the upcoming fiscal year with a strong foundation and a clear growth trajectory. The company aims to expand its manufacturing capacity across nutraceuticals, veterinary feed supplements, cosmetics, and homecare products, supported by proceeds from its successful IPO. With increasing global demand for certified, clean-label wellness products and rising interest in preventive healthcare, Influx is well-positioned to deepen its international footprint and diversify its client base. Strategic investments in automation, R&D, and sustainable packaging will further enhance operational efficiency and product innovation. Backed by robust financials and a scalable business model, the company anticipates continued momentum in revenue growth and margin improvement, reinforcing its role as a leading CDMO in the wellness sector.

(e) Risk and Concerns

Influx Healthtech Limited faces competition and pricing pressure in the fragmented CDMO market, with revenue heavily concentrated in nutraceuticals and a limited client base. Margin volatility from raw-material, supply-chain

and forex swings, evolving FSSAI, AYUSH and US FDA regulations, plus execution risks in capacity expansion, automation and ESG compliance, underscore the need for agile innovation and robust quality controls.

(f) Internal Control Systems and Their Adequacy

The company has implemented robust internal control systems that ensure efficient operations, compliance with laws and regulations, and the reliability of financial reporting. Regular audits and reviews are conducted to assess the adequacy of these systems, with improvements made as necessary to address any identified weaknesses. The internal control framework is deemed adequate and effective in mitigating risks.

(g) Discussion on Financial Performance with Respect to Operational Performance

The company's financial performance has been strong, with revenue growth driven by increased sales across key product segments. Operational efficiency initiatives have resulted in improved margins, despite fluctuations in raw material prices. Investment in technology and production capacity has also contributed to better operational performance, enabling the company to meet growing demand.

(h) Material Developments in Human Resources / Industrial Relations Front, Including Number of People Employed

During the financial year, the company has made significant strides in strengthening its human resources. New training programs have been introduced to enhance employee skills, particularly in areas of quality control and production efficiency. Industrial relations have remained stable, with no major disruptions. The total number of employees as of the end of the financial year stands at 2025-26.

(i) Details of Significant Changes in Key Financial Ratios

Sr No.	Ratios	Numerator	Denominator	As at 31st March, 2026	As at 31st March, 2025	% change in Ratio
i.	Current Ratio (in Times)	Current Assets	Current Liabilities	3.59	1.44	148.22%
ii.	Debt-Equity Ratio (In Times)	Total Debt	Shareholder's Equity	-	0.01	-100.00%
iii.	Debt Service Coverage Ratio (in Times)	Earnings available for Debt Servicing	Total Debt service	-	22,523.99	-100.00%
iv.	Return on Equity Ratio (in %)	Profit After Taxes	Average Equity	20.39	36.72	-44.48%
v.	Inventory turnover ratio (in Times)	Cost of Goods Sold	Average Inventory	10.07	11.23	-10.29%
vi.	Trade Receivables turnover ratio	Revenue from Operations	Average Trade Receivables	4.43	4.34	2.26%

	(In Times)					
vii.	Trade payables turnover ratio (In Times)	Purchase of Goods & services and other expense	Average Trade Payables	4.45	3.84	15.92%
viii.	Net Capital Turnover Ratio (In Times)	Revenue from Operations	Working Capital	3.98	9.17	-56.64%
ix.	Net Profit Ratio (in %)	Net Profit After Taxes	Revenue from Operations	14.08%	12.76%	10.42%
x.	Return on Capital Employed (in %)	Earnings Before Interest and Tax	Capital Employed	27.21%	49.17%	-44.66%

❖ **Remark - Any change in the ratio by more than 25% as compared to the preceding year.**

Sr. No. of Ratio	Reason of Variance
i.	The company had made fresh issue of shares through public offer and the pending utilisation the funds have been temporarily parked in short term fixed deposits and hence there has been a significant improvement in the current ratio as compared to the previous year.
ii.	The company has repaid all its debts in the current year resulting in Debt-Equity ratio to be Nil.
iii.	The company has repaid all its debts in the current year resulting in Debt-Service Coverage Ratio to be Nil.
iv.	The decline in Return on Equity (ROE) from the previous year is primarily due to a temporary mismatch between capital infusion and its deployment. During the current financial year, the Company raised fresh equity capital through an Initial Public Offering (IPO), significantly increasing the shareholders' funds (the denominator). However, these funds were only partially deployed in operations by the end of the year. Because this newly raised capital has not yet reached full productive capacity, net profit did not grow in proportion to the expanded equity base, resulting in a lower ROE for the current period.
viii.	This expansion in the working capital base was primarily driven by higher current assets, specifically the unutilised proceeds from the Company's recent Initial Public Offering (IPO) that are temporarily parked in Fixed Deposits awaiting deployment. Consequently, the growth in the capital base temporarily outpaced revenue growth, resulting in a lower turnover ratio for the current period.
x.	The decline in Return on Capital Employed (ROCE) from the previous year is primarily due to a temporary mismatch between capital infusion and its deployment. During the current financial year, the Company raised fresh equity capital through an Initial Public Offering (IPO), significantly increasing the capital employed base (the denominator). However, these funds were only partially deployed in operations by the end of the year. Because this newly raised capital has not yet reached full productive capacity, net profit did not grow in proportion to the expanded equity base, resulting in a lower ROCE for the current period.

FINACIAL INFORMATION

Particulars	Page No.
Standalone Financial Statements	
Independent Audit Report from V. B. Goel & Co.	SF1
Balance sheet	SF18
Profit and Loss Account	SF19
Cash flow Statement	SF20
Notes to Accounts	SF26
Consolidated Financial Statements	
Independent Audit Report from V. B. Goel & Co.	CF1
Balance sheet	CF13
Profit and Loss Account	CF14
Cash flow Statement	CF15
Notes to Accounts	CF22

INDEPENDENT AUDITORS' REPORT

TO THE MEMBERS OF INFLUX HEALTHTECH LIMITED

Report on the Audit of the Financial Statements

Opinion

We have audited the accompanying standalone financial statements of **INFLUX HEALTHTECH LIMITED** ("the Company"), which comprise the Balance Sheet as at March 31, 2026, the Statement of Profit and Loss Account and the Statement of Cash Flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies and other explanatory information (hereinafter referred to as the "standalone financial statement").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013 ("the Act") in the manner so required and give a true and fair view in conformity with the Accounting Standards prescribed under section 133 of the Act read with the Companies (Accounting Standard) Rules, 2021 and other accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2026, its profit and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit of the standalone financial statements in accordance with the Standards on Auditing (SAs) specified under Section 143(10) of the Act. Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Statements* section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("ICAI") together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matter

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the standalone financial statements of the current period. These matters were addressed in



the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

We have determined that there are no key audit matters to communicate in our report.

Other Information

The Company's Board of Directors is responsible for the other information. The other information comprises the information included in the Company's annual report but does not include the financial statements and our auditors' report thereon. The Company's annual report is expected to be made available to us after the date of this auditor's report.

Our opinion on the standalone financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the standalone financial statements, our responsibility is to read the other information identified above when it becomes available and, in doing so, consider whether the other information is materially inconsistent with the standalone financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

When we read the Company's annual report, if we conclude that there is a material misstatement therein, we are required to communicate the matter to Company's Board of Directors and determine the actions under the applicable laws and regulations.

Responsibilities of Management for the Standalone Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these standalone financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the accounting Standards specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.



In preparing the standalone financial statements, the Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations or has no realistic alternative but to do so.

Those Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the standalone financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- i) Identify and assess the risks of material misstatement of the standalone financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- ii) Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- iii) Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- iv) Conclude on the appropriateness of management's use of the going concern basis of



accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- v) Evaluate the overall presentation, structure and content of the standalone financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of the misstatement in the statement that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the statement may be influenced. We consider quantitative materiality and qualitative factors in; (i) planning the scope of our audit work and evaluating the results of our work; and (ii) to evaluate the effects of any identified misstatements in the standalone financial statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of these standalone financial statements of the current period and are therefore the key audit matters. We have determined that there are no key audit matters to communicate in our report.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2020 ("the order") issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act, we give in the "Annexure A" a statement on the matters specified in paragraph 3 and 4 of the Order,



to the extent applicable.

2. As required by section 143(3) of the Act, we report that:
- a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit;
 - b) In our opinion, proper books of account as required by law have been kept by the Company so far as appears from our examination of those books;
 - c) The Balance Sheet, the Statement of Profit & Loss, and the Cash Flow Statement dealt with by this Report are in agreement with the books of account;
 - d) In our opinion, the aforesaid standalone financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
 - e) On the basis of the written representations received from the directors as on March 31, 2026 taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2026 from being appointed as a director in terms of Section 164(2) of the Act.
 - f) With respect to the adequacy of the internal financial controls with reference to the financial statements of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure B" to this report. Our report expresses an unmodified opinion on the adequacy and operating effectiveness of the Company's internal financial controls with reference to financial statements.
 - g) According to the information and explanations given to us and verification of the records of the company, the company has paid/provided managerial remuneration in accordance with the provisions of section 197 read with Schedule V to the Act.
 - h) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
 - i) The Company has disclosed the impact of pending litigations on its financial position in its standalone financial statements as referred to in Note 21 to the standalone financial statements;



- ii) The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
- iii) There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.
- iv) (a) The Management has represented that, to the best of its knowledge and belief, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other persons or entities, including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;

(b) The Management has represented, that, to the best of its knowledge and belief, no funds have been received by the Company from any persons or entities, including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;

(c) Based on such audit procedures that have been considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) of Rule 11(e), as provided under (a) and (b) above, contain any material misstatement.
- v) The company has not paid neither declared any dividend during the year.
- vi) Based on our examination which included test checks, the company has used accounting softwares for maintaining its books of account for the period ended March 31, 2026 which has a feature of recording audit trail (edit log) facility and the same has operated throughout the period for all relevant transactions



recorded in the software. Further, during the course of our audit we did not come across any instance of audit trail feature being tampered with. Additionally, the audit trail has been preserved by the company as per the statutory requirements for record retention.



FOR V. B. GOEL & CO.
Chartered Accountants
Firm Reg. No. 115906 W

Wz

(Vikas Goel)
Partner

Membership No. : 39287

UDIN: 26039287 HJRRAW9645

Place: Mumbai

Date: 20-05-2026

‘ANNEXURE A’ TO THE INDEPENDENT AUDITOR’S REPORT

Report on Companies (Auditor’s Report) Order, 2020 (‘the Order’) issued by the Central Government in terms of Sub-section 11 of Section 143 of the Companies Act, 2013

- (i) In respect of the Company’s Property, Plant and Equipment and Intangible Assets:
- a) (A) The company has maintained proper records to show full particulars including quantitative details and the situation of its property, plant and equipment.
 - (B) The company has maintained proper records to show full particulars of its intangible assets.
- b) The Company has a program of physical verification of property, plant and equipment whereby all the items of property, plant and equipment are verified once in three years. The physical verification of property, plant and equipment was due in the current year and no material discrepancies were noticed on such verification during the year by the Management. In our opinion, the periodicity of the physical verification is reasonable having regard to the size of the Company and the nature of its assets.
- c) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the title deeds of all the immovable properties disclosed in the financial statements are held in the name of the Company.
- d) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not revalued any of its Property, Plant and Equipment and intangible assets during the year.
- e) According to the information and explanations given to us and on the basis of our examination of the records of the Company, there are no proceedings initiated during the year or are pending against the Company as at March 31, 2026 for holding any Benami property under the Benami Transactions (Prohibition) Act, 1988 (as amended in 2016) and rules made thereunder.
- (ii) a) The inventory has been physically verified by the management during the year. In our opinion, the frequency of such verification is reasonable and procedures and coverage as followed by management were appropriate. No discrepancies were noticed on verification between the physical stocks and the book records that were 10% or more



in the aggregate for each class of inventory.

- b) The Company has not been sanctioned working capital limits in excess of five crore rupees in aggregate from banks or financial institutions during the year on the basis of security of current assets of the Company. Accordingly, there is no requirement of filing quarterly returns or statements by the company to the banks or financial institutions. Hence, clause 3(ii)(b) of the Order is not applicable to the Company.
- (iii) According to the information and explanation given to us and based on the basis of our examination of the records of the Company, the Company has not provided any guarantee or security or granted any loan or advances in the nature of loans, secured or unsecured, to companies, firms, limited liability partnership or any other parties during the year. Further, the Company has made investments in companies, in respect of which requisite information is as below. Further, the Company has not made any investment in or granted any loans, secured or unsecured, to firms, limited liability partnership and other parties.
- (a) According to the information and explanations given to us and based on the audit procedures conducted by us, the company has not granted any loans or advances in the nature of loan or stood guarantee or provided security to companies, firms, limited liability partnership or any other parties during the year. Accordingly, reporting under clause 3(iii)(a) of the Order is not applicable to the company.
- (b) According to the information and explanations given to us and based on the audit procedures conducted by us, in our opinion the investments made are, prima facie, not prejudicial to the interest of the Company.

Further, the Company has not provided guarantees, given security or granted any loan or advance in the nature of loan to companies, firms, limited liability partnership or any other parties during the year.

- (c) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not granted any loan or advance in the nature of loan to companies, firms, limited liability partnership or any other parties during the year. Accordingly, reporting under clauses 3(iii) (c) to (f) of the Order is not applicable to the company.



- (iv) The company has not granted any loans or provided any guarantees or security to the parties covered under section 185 of the Act. In our opinion and according to the explanation given to us, the company has complied with the provisions of section 186 of the Act to the extent applicable to investments made by the company.
- (v) The Company has neither accepted any deposits from the public nor accepted any amounts which are deemed to be deposits within the meaning of sections 73 to 76 of the Act and the rules framed thereunder, to the extent applicable. Accordingly, the requirement to report on clause 3(v) of the Order is not applicable to the Company.
- (vi) We have broadly reviewed the books of account maintained by the company pursuant to the Rules made by the Central Government for the maintenance of cost records under section 148 of the Act, and are of the opinion that prima facie, the prescribed accounts and records have been made and maintained.
- (vii) a) The Company does not have liability in respect of Service tax, Duty of excise, Sales tax and Value added tax during the year since effective July 1, 2017, these statutory dues have been subsumed into Goods and Services Tax.

According to the information and explanations given to us and on the basis of our examination of the records of the Company, amounts deducted / accrued in the books of account in respect of undisputed statutory dues including Goods and Services Tax, Provident fund, Employees' State Insurance, Income-Tax, Cess and other statutory dues have not been regularly deposited by the Company with the appropriate authorities.

According to the information and explanations given to us, there were no undisputed amounts payable in respect of Goods and Services Tax, Provident fund, Employees' State Insurance, Income-Tax, Cess and other statutory dues were in arrears as at March 31, 2026 for a period of more than six months from the date they became payable except for the details mentioned below :

Name of the Statute	Nature of the dues	Amount (Rs.)	Period to which the amount relates	Due date	Date of payment
Income Tax Act, 1961(IT Act)	Income Tax	26,463	A.Y. 2024-25	31.10.2024	NA



- (b) According to the information and explanations given to us, the following dues have not been deposited by the Company on account of disputes and the details are as under:

Name of the Statute	Nature of the dues	Amount (Rs.)	Period to which the amount relates	Forum where Dispute is Pending
Goods & Service Tax	Goods & Service Tax Demand	17,58,268*	July 2025	GST Appellate Authority

*The amount has been deposited with the respective tax authorities under dispute

- (viii) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not surrendered or disclosed any transactions, previously unrecorded as income in the books of account, in the tax assessments under the Income-tax Act, 1961 as income during the year.
- (ix) a) According to the information and explanation given to us and based on examination of records of the company, the company has not taken any loans or other borrowings from bank or financial institution or any other lender during the year. Accordingly, clause 3(ix)(a) of the Order is not applicable to the Company.
- b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not been declared Wilful Defaulter by any bank or financial institution or government or any government authority.
- c) According to the information and explanation given to us on the basis of our examination of the Company, the Company has not availed any term loan from any lender. Accordingly, clause 3(ix)(c) of the Order is not applicable to the Company.
- d) According to the information and explanation given to us, and the procedures performed by us and on an overall examination of the financial statements of the company, we report that no funds raised on short term basis have, prima facie, been used for long-term purposes by the company during the year.
- e) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not taken any funds



from any entity or person on account of or to meet the obligations of its subsidiaries. The Company does not hold any investment in any associate or joint venture (as defined under the Act) during the year ended March 31, 2026.

- f) According to the information and explanations given to us and on an overall examination of the financial statements of the Company, the Company has not raised loans during the year on the pledge of securities held in its subsidiaries. The Company does not hold any investment in associate or joint venture (as defined under the Act) during the year ended March 31, 2026.
- (x) a) According to the information and explanations given to us and on an overall examination of the financial statements of the Company, the moneys raised by the company by way of initial public offer during the year have been applied for the purposes for which those were raised. Further, no debt instruments were issued during the year by the company.
- b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not made any preferential allotment or private placement of shares or fully or partly convertible debentures during the year. Accordingly, clause 3(x)(b) of the Order is not applicable.
- (xi) a) Based on examination of the books and records of the Company and according to the information and explanations given to us, considering the principles of materiality as outlined in the Standards on Auditing, we report that no fraud by the Company or on the Company has been noticed or reported during the year.
- b) According to the information and explanations given to us, no report under sub-section (12) of Section 143 of the Companies Act, 2013 has been filed in Form ADT-4 as prescribed under Rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government.
- c) As represented to us by the management, there are no whistle blower complaints received by the company during the year.
- (xii) According to the information and explanations given to us, the Company is not a Nidhi Company. Accordingly, clause 3(xii) (a) to (c) of the Order is not applicable to the Company.



- (xiii) According to the information and explanations given to us and based on examination of records of the company, the company has entered into transactions with related parties in compliance with the provisions of sections 177 and 188 of the Act, where applicable, and the details of the related party transactions have been disclosed in the financial statements as required by the applicable accounting standards.
- (xiv) a) In our opinion and based on our examination, the company has an internal audit system commensurate with the size and nature of its business.
- b) We have considered the internal audit reports of the company issued till date, for the period under audit
- (xv) In our opinion and according to the information and explanations given to us, the Company has not entered into any non-cash transactions with its directors or persons connected to its directors and hence, provisions of Section 192 of the Companies Act, 2013 are not applicable to the Company.
- (xvi) a) In our opinion, the Company is not required to be registered under section 45-IA of the Reserve Bank of India Act, 1934. Accordingly, the reporting under clause 3(xvi)(a) of the order is not applicable.
- b) The company has not conducted any Non-Banking Financial or Housing Finance activities during the year. Accordingly, the reporting under clause 3(xi)(b) of the Order is not applicable to the Company.
- c) The Company is not a Core Investment Company (CIC) as defined in the regulations made by the Reserve Bank of India. Accordingly, clause 3(xvi)(c) of the Order is not applicable to the Company.
- d) According to the information and explanations provided to us during the course of audit, the Group does not have any CICs. Accordingly, the requirements of clause 3(xvi)(d) are not applicable.
- (xvii) The Company has not incurred cash losses in the current and in the immediately preceding financial year.
- (xviii) There has been no resignation of the statutory auditors during the year. Accordingly, clause 3(xviii) of the Order is not applicable to the Company.



- (xix) According to the information and explanations given to us and on the basis of the financial ratios, ageing and expected dates of realisation of financial assets and payment of financial liabilities, other information accompanying the financial statements, our knowledge of the Board of Directors and management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report that Company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the Company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the Company as and when they fall due.
- (xx) (a) In our opinion and according to the information and explanations given to us, in respect of other than ongoing projects, there are no unspent amounts that are required to be transferred to a fund specified in Schedule VII of the Companies Act (the Act), in compliance with second proviso to sub-section (5) of Section 135 of the Act. Accordingly, reporting under clause 3(xx)(a) of the Order is not applicable.
- (b) In our opinion and according to the information and explanations given to us, in respect of ongoing projects, there are no on-going projects and hence transferring unspent amount to a special account in compliance with provisions of sub-section (6) of section 135 of the Act is not applicable to the company. Accordingly, reporting under clause 3(xx)(b) of the Order is not applicable.



FOR V. B. GOEL & CO.
Chartered Accountants
Firm Reg. No. 115906 W

W2

(Vikas Goel)
Partner
Membership No. : 39287
UDIN : 26039287 HJRRAW 9645

Place : Mumbai
Date : 20-05-2026

‘ANNEXURE B’ TO THE INDEPENDENT AUDITOR’S REPORT

Report on the Internal Financial Controls with reference to standalone financial statements under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 (“the Act”)

We have audited the internal financial controls with reference to standalone financial statements of **INFLUX HEALTHTECH LIMITED** (“the Company”) as of March 31, 2026 in conjunction with our audit of the standalone financial statements of the Company for the year ended on that date.

Management’s Responsibility for Internal Financial Controls

The Company’s management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (“the Guidance Note”) issued by the Institute of Chartered Accountants of India (“ICAI”). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company’s policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

Auditors’ Responsibility

Our responsibility is to express an opinion on the Company’s internal financial controls with reference to standalone financial statements based on our audit. We conducted our audit in accordance with the Guidance Note and the Standards on Auditing specified under section 143(10) of the Act, to the extent applicable to an audit of internal financial controls, both applicable to an audit of internal financial controls and both issued by the ICAI. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls with reference to standalone financial statements was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system with reference to standalone financial statements and their operating effectiveness. Our audit of internal financial controls with reference to standalone financial statements included obtaining an understanding of internal financial controls with reference to standalone financial statements, assessing the risk that a material weakness exists, and testing and evaluating the



design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system with reference to standalone financial statements.

Meaning of internal financial controls with reference to standalone financial statements

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that

- (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company;
- (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and
- (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent limitations of internal financial controls with reference to standalone financial statements

Because of the inherent limitations of internal financial controls with reference to standalone financial statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls with reference to standalone financial statements to future periods are subject to the risk that the internal financial control with reference to standalone financial statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.



Opinion

In our opinion, the Company has, in all material respects, an adequate internal financial controls system with reference to standalone financial statements and such internal financial controls with reference to standalone financial statements were operating effectively as at March 31, 2026, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note issued by ICAI.



FOR V. B. GOEL & CO.
Chartered Accountants
Firm Reg. No. 115906 W

V. B.

(Vikas Goel)
Partner

Membership No. : 39287

UDIN: 26039287 HJRRAW 9645

Place : Mumbai

Date : 20-05-2026

(Rs. in lakhs, unless otherwise stated)

Particulars	Note No.	As at 31 March, 2026	As at 31 March, 2025
<u>EQUITY AND LIABILITIES</u>			
<u>1. Shareholders' fund</u>			
(a) Share Capital	2	2,315.04	1,815.00
(b) Reserves and Surplus	3	7,760.93	1,799.55
<u>2. Non-Current Liabilities</u>			
(a) Other Long-Term Liabilities	4	-	5.26
(b) Long Term Provision	5	23.43	17.73
<u>3. Current Liabilities</u>			
(a) Short Term Borrowing	6	-	21.92
(b) Trade Payables	7		
- Dues to Micro, Small and Medium Enterprises ('MSME')		500.66	2,140.80
- Dues to Creditors Other than MSMEs		1,411.45	801.15
(c) Other Current Liabilities	8	305.73	271.03
(d) Short-term Provisions	9	53.17	157.48
TOTAL		12,370.41	7,029.91
<u>ASSETS</u>			
<u>1. Non-Current Assets</u>			
(a) Property, Plant & Equipment and Intangible Assets	10		
- Property, plant & Equipment		2,755.22	1,872.50
- Intangible assets		2.83	3.81
- Capital WIP		346.91	-
- Intangible asset under development		1.69	-
(b) Non Current Investments	11	1.00	-
(c) Deferred Tax Asset (Net)	12	61.17	18.25
(d) Long term loans and advances	13	919.01	62.81
(e) Other non current assets	14	137.10	170.57
<u>2. Current Assets</u>			
(a) Current Investments	15	229.99	-
(b) Inventories	16	1,593.27	1,321.73
(c) Trade receivables	17	3,378.04	3,244.09
(d) Cash and Cash Equivalents	18	2,515.74	191.06
(e) Short-term loans and advances	19	393.49	76.56
(f) Other current assets	20	34.95	68.52
TOTAL		12,370.41	7,029.91

Notes to Accounts forming integral part of standalone financial statements

01-44

As per our attached report of even date.

For and on behalf of the Board of Directors of Influx Healthtech Limited

For V.B.GOEL & CO
Chartered Accountants
Firm Registration No.: 115906W

Vikas Goel
Partner
Membership. No. 39287
Place: Mumbai
Date : 20-05-2026


Munir Chandniwala
(Managing Director)
DIN: 08459582
Place: Mumbai
Date: 20-05-20

Shirin Chandniwala
(Whole - Time Director)
DIN: 08459623
Place: Mumbai
Date : 20-05-2026

Ashish Shah
(Chief Financial Officer)

Place: Mumbai
Date : 20-05-2026

Atul Shukla
(Company Secretary)
Membership Number :
ACS46854
Place: Mumbai
Date : 20-05-2026



Standalone Statement of Profit and Loss account for the year ended 31st March, 2026

(Rs. in lakhs, unless otherwise stated)

Particulars	Note No.	For the year ended 31 March, 2026	For the year ended 31 March, 2025
I. INCOME			
Revenue from Operations	22	14,683.36	10,485.36
Other Income	23	133.49	13.31
TOTAL INCOME		14,816.85	10,498.68
II. EXPENDITURE			
Cost of Materials Consumed	24	8,921.72	6,340.78
Changes in inventories of Finished Goods	25	(252.61)	1.16
Employee Benefit Expenses	26	1,175.47	879.45
Finance Cost	27	18.42	16.60
Depreciation & Amortization	10	377.80	282.45
Other Expenses	28	1,852.65	1,206.83
TOTAL EXPENSES		12,093.45	8,727.27
III. Net Profit before tax (I-II)		2,723.40	1,771.41
IV. Tax Expenses			
Current Tax		710.47	440.99
Deferred Tax		(42.93)	10.32
Short/(Excess) Provision for Income tax		1.73	(7.22)
V. Net Profit after tax (III-IV)		2,054.13	1,327.32
VI. Earning per Equity Share	30		
Basic (in Rs.)		9.35	7.31
Diluted (in Rs.)		9.35	7.31

Notes to Accounts forming integral part of standalone financial statements

01-44

As per our attached report of even date

For V.B.GOEL & CO
Chartered Accountants
Firm Registration No.: 115906W

Vikas Goel
Partner
Membership. No. 39287
Place: Mumbai
Date : 20-05-2026



For and on behalf of the Board of Directors of Influx Healthtech Limited

M.A. Chandniwala
Munir Chandniwala
(Managing Director)
DIN: 08459582
Place: Mumbai
Date : 20-05-2026

Ashish Shah
(Chief Financial Officer)

Place: Mumbai
Date : 20-05-2026

S.M. Chandniwala
Shirin Chandniwala
(Whole - Time Director)
DIN: 08459623
Place: Mumbai
Date : 20-05-2026

Atul Shukla
(Company Secretary)

Membership Number : ACS46854
Place: Mumbai
Date : 20-05-2026

Standalone Statement of Cash flows for the year ended 31st March, 2026

(Rs. in lakhs, unless otherwise stated)

Particulars	For the year ended 31 March, 2026	For the year ended 31 March, 2025
A) Cash Flow from Operating Activities		
Net Profit before tax & extraordinary items	2,723.40	1,771.41
Adjustment For :		
Depreciation & Amortization Expenses	377.80	282.45
Bad Debts Written Off	36.09	8.49
Provision for bad and doubtful debts	10.24	-
Reversal of Doubtful Debts (net of provision)	-	(4.00)
Interest Expenses & other finance cost	18.42	16.60
Interest Income	(16.66)	(5.62)
Income from Investments	(112.47)	-
Operating Profit Before Working Capital Changes	3,036.82	2,069.32
Adjusted for :		
Increase/(Decrease) in Trade payables	(1,029.85)	1,543.92
Increase/(Decrease) in Other Current Liabilities	26.56	59.69
Increase/(Decrease) in Other Non - Current Liabilities	(5.26)	-
Increase/(Decrease) in Provision	5.70	(10.94)
(Increase)/Decrease in Trade Receivables	(180.27)	(1,656.99)
(Increase)/Decrease in Inventories	(271.54)	(776.11)
(Increase)/Decrease in Loans and Advances	(316.93)	(11.64)
(Increase)/Decrease in Other Current and Non-current Assets	(41.45)	(67.45)
Net Cash generated from Operating activities (before tax)	1,223.78	1,149.80
(Tax Paid)/ Tax Refund - Net	(834.92)	(444.18)
Net Cash Generated from Operating Activities (A)	388.86	705.62
B) Cash Flow from Investing Activities		
Purchase of Property, Plant and Equipment, Capital Work-in-Progress, Intangible under development and Intangible Assets	(2,456.19)	(821.11)
Cash Outflow from Investments	(118.52)	-
Maturity of fixed deposit	50.00	(50.00)
Interest Income	7.70	6.64
Net Cash used in Investment Activities (B)	(2,517.01)	(864.47)
C) Cash Flow from Financing Activities		
Interest Expenses & other finance cost	-	(0.09)
Proceeds from Initial Public Offer (net of issue expenses)	4,474.75	-
(Repayment)/ Proceeds of Short Term Borrowings	(21.92)	(10.56)
Net cash generated from / (used in) Financing Activities (C)	4,452.83	(10.66)
Net Increase / (Decrease) in Cash and Cash Equivalents (A+B+C)	2,324.68	(169.50)
Cash and Cash Equivalents at the beginning of the Year		
Cash and cash equivalents	191.06	290.56
Short term bank deposits	-	70.00
Cash and Cash Equivalents at the end of the Year	2,515.74	191.06
Cash and cash equivalents comprise of:		
Cash on Hand	4.69	0.94
Bank Balances:		
In Current Accounts	207.18	190.13
Short Term Bank Deposit	2,303.87	-
Cash and cash equivalents at the end of the Year	2,515.74	191.06

Note:

- The above Cash Flow Statement has been prepared under the 'Indirect Method' as set out in the Accounting Standard - 3 on Cash Flow Statement issued by ICAI.
- Previous year's figures have been regrouped where ever necessary to align with the current year's classification.

As per our attached report of even date.

For and on behalf of the Board of Directors of
Influx Healthtech Limited

For V.B.GOEL & CO
Chartered Accountants
Firm Registration No.: 115906W

Vikas Goel
Partner
Membership. No. 39287
Place : Mumbai
Date : 20-05-2026



Munir Chandniwala
(Managing Director)
DIN: 08459582
Place : Mumbai
Date : 20-05-2026

Shirin Chandniwala
(Whole - Time Director)
DIN: 08459623
Place : Mumbai
Date : 20-05-2026

Ashish Shah
(Chief Financial Officer)

Atul Shukla
(Company Secretary)

Membership Number :
ACS46854
Place: Mumbai
Date : 20-05-2026

SUMMARY STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES & NOTES TO STANDALONE FINANCIAL INFORMATION

COMPANY OVERVIEW

Influx Healthtech Limited is a limited company incorporated on 28th September, 2020 under The Companies Act, 2013. The Company was converted From Private Limited Company to Public limited w.e.f. 23.05.2022. It has its registered office situated at 109, Ghanshyam Enclave Premises Co-op Society Plot no. 856, Lalipada, Kandivali West, Mumbai 400067. The company is engaged in the business of manufacturing and trading of Nutra Products and other related business activities.

The Company has its manufacturing unit at Plot no. 1,9,10 and 57, at Genesis Industrial Compound, Kolgaon, Palghar, Maharashtra - 401404

1 SIGNIFICANT ACCOUNTING POLICIES & NOTES TO ACCOUNTS

A Basis of Preparation of Financial statements

These financial statements have been prepared in accordance with the generally accepted accounting principles in India under the historical cost convention on accrual basis. These financial statements have been prepared to comply in all material aspects with the accounting standards notified under the Companies (Accounting Standards) Rules, 2021 (as amended), specified under section 133 and other relevant provisions of the Companies Act, 2013.

All assets and liabilities have been classified as current or non-current as per the Company's operating cycle and other criteria set out in the Schedule III (Division I) to the Companies Act, 2013. Based on the nature of products and the time between the acquisition of assets for processing and their realisation in cash and cash equivalents, the Company has ascertained its operating cycle as 12 months for the purpose of current – non-current classification of assets and liabilities.

B Use of Estimates

The preparation of Financial Statements in conformity with Generally Accepted Accounting Principles in India requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses and disclosure of contingent assets and liabilities at the end of the reporting period. The estimates and assumptions used in the accompanying Financial Statements are based upon management's evaluation of the relevant facts and circumstances as of the date of the Financial Statements. Actual results may differ from the estimates and assumptions used in preparing the accompanying Financial Statements. Any revisions to accounting estimates are recognized prospectively in current and future periods.

C Accounting Convention

The Company follows the mercantile system of accounting, recognizing income and expenditure on accrual basis. The accounts are prepared on historical cost basis and as a going concern.

Accounting policies not referred to specifically otherwise, are consistent with the generally accepted accounting principles.

The following significant accounting policies are adopted in the preparation and presentation of these financial statements:

D Current versus non-current classification

The assets and liabilities in the balance sheet are presented based on current and non-current classification:

An asset is current when it is:

- Expected to be realised or intended to be sold or consumed in normal operating cycle, or
- Held primarily for the purpose of trading, or
- Expected to be realised within twelve months after the reporting period, or
- Cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. All other assets are classified as non-current.

A liability is current when it is:

- Expected to be settled in normal operating cycle, or
- Held primarily for the purpose of trading, or
- Due to be settled within twelve months after the reporting period, or
- There is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period

All other liabilities are treated as non-current. Deferred tax assets / liabilities are classified as non-current assets and liabilities respectively.

E Property, Plant & Equipment and Intangible Assets

(a) Tangible Assets

Property, Plant and Equipment are stated at cost, net of accumulated depreciation and accumulated impairment losses, if any. Cost comprises of the purchase price including import duties and non-refundable taxes, and directly attributable expenses incurred to bring the asset to the location and condition necessary for it to be capable of being operated in the manner intended by management. Subsequent costs related to an item of Property, Plant and Equipment are recognised in the carrying amount of the item if the recognition criteria are met.

Items of Property, Plant and Equipment that have been retired from active use and are held for disposal are stated at the lower of their net carrying amount and net realisable value and are shown separately in the financial statements under the head 'Other current assets'. Any write-down in this regard is recognised immediately in the Statement of Profit and Loss.

An item of Property, Plant and Equipment is derecognised on disposal or when no future economic benefits are expected from its use or disposal. The gain or loss arising on derecognition is recognised in the Statement of Profit and Loss.

(b) Intangible Assets

(i) Acquired Intangible Assets

Intangible assets are stated at acquisition cost, net of accumulated amortization and accumulated impairment losses, if any. Gains or losses arising from the retirement or disposal of an intangible asset are determined as the difference between the net disposal proceeds and the carrying amount of the asset and recognised as income or expense in the Statement of Profit and Loss.

(ii) Impairment of Assets

Assessment is done at each balance sheet date as to whether there is any indication that an asset (tangible and intangible) may be impaired. If any such indication exists, an estimate of the recoverable amount of the asset/cash generating unit is made. Recoverable amount is higher of an asset's or cash generating unit's net selling price and its value in use. Value in use is the present value of estimated future cash flows expected to arise from the continuing use of an asset and from its disposal at the end of its useful life. For the purpose of assessing impairment, the recoverable amount is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or groups of assets. The smallest identifiable group of assets that generates cash inflows from continuing use that are largely independent of the cash inflows from other assets or groups of assets, is considered as a cash generating unit (CGU). An asset or CGU whose carrying value exceeds its recoverable amount is considered impaired and is written down to its recoverable amount. Assessment is also done at each balance sheet date as to whether there is any indication that an impairment loss recognised for an asset in prior accounting periods may no longer exist or may have decreased. An impairment loss is reversed to the extent that the asset's carrying amount does not exceed the carrying amount that would have been determined if no impairment loss had previously been recognised.

(c) Capital Work-in-Progress (CWIP)

Capital Work-in-Progress comprises the cost of assets that are in the process of construction/erection and are not yet ready for their intended use as at the Balance Sheet date. CWIP is carried at cost, which includes direct costs and other directly attributable expenditures. Upon completion and readiness for intended use, the accumulated cost is transferred to the respective head of Property, Plant and Equipment.

(d) Intangible Assets Under Development

Intangible Assets Under Development represents expenditure incurred on intangible assets that are under development and not yet ready for their intended use as at the Balance Sheet date. Such expenditure is capitalised only when the Company can demonstrate technical feasibility, intention and ability to complete the asset. Upon completion readiness for intended use, the accumulated cost is transferred to Intangible Assets.

(e) Depreciation

Depreciation on tangible assets is provided to the extent depreciable amount on the Written Down Value(WDV) Method. Depreciation is provided based on useful life of assets as prescribed in Schedule II to the Companies Act, 2013.

Intangible assets are amortised on a straight line basis over their estimated useful lives. A rebuttable presumption that the useful life of an intangible asset will not exceed ten years from the date when the asset is available for use is considered by the management. The amortisation period and the amortisation method are reviewed at least at each financial year end. If the expected useful life of the asset is significantly different from previous estimates, the amortisation period is changed accordingly.

The estimates of useful lives of property plant and equipment are as follows :

Types Of Asset	Useful life as per Schedule II
Building	30
Plant and Machinery	15
Furniture and Fixtures	10
Office Equipment	5
Motor Vehicles	8
Computer Software	3 to 10

F Non-Current Investments

Non-current investments are investments other than current investments and are intended to be held for more than one year from the date of acquisition. Non-current investments are carried at cost less provision for diminution, if any.

Provision for diminution in value is made only if such diminution is considered other than temporary in nature, and is determined separately for each individual investment.

On disposal, the difference between the carrying amount and net disposal proceeds is recognised in the Statement of Profit and Loss.

G Current Investments

Current investments are investments that are by nature readily realisable and intended to be held for not more than one year from the date of acquisition.

Current investments are carried at the lower of cost and fair value, determined on an individual investment basis.

Any reduction to fair value and any reversals of such reductions are recognised in the Statement of Profit and Loss.

H Inventories

Inventories of Raw Materials are valued at lower of cost or net realizable value. The method used for valuation or determination of cost is as per First-in-First-Out (FIFO) basis.

Inventories of stores, regular spares, fuel and packing material are valued at cost or net realizable value whichever is lower. First-in-First-Out (FIFO) method is used for valuation purpose. Inventories of finished goods are valued at lower of factory cost (including material, labour and related overheads and depreciation) and net realizable value.

Goods and Service Tax ('GST') Input, being tax which is set-off against GST output, does not form a part of cost of inventory as prescribed in AS – 2 on "Valuation of Inventories".

I Cash and Cash Equivalents

In the cash flow statement, cash and cash equivalents include cash in hand, demand deposits with banks, other short-term highly liquid investments with original maturities of three months or less.

J Provisions and Contingent Liabilities

(a) Provisions

Provisions are recognised when there is a present obligation as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and there is a reliable estimate of the amount of the obligation. Provisions are measured at the best estimate of the expenditure required to settle the present obligation at the Balance sheet date and are not discounted to its present value.

(b) Contingent Liabilities

Contingent liabilities are disclosed when there is a possible obligation arising from past events, the existence of which will be confirmed only by the occurrence or non occurrence of one or more uncertain future events not wholly within the control of the Company or a present obligation that arises from past events where it is either not probable that an outflow of resources will be required to settle or a reliable estimate of the amount cannot be made.

K Revenue Recognition

Sales are recognised when the significant risks and rewards of ownership in the goods are transferred to the buyer as per the terms of the contract, which coincides with the delivery of goods and are recognised net of trade discounts, rebates, Goods and Service tax.

Service income is accounted as and when services are rendered and are net of Goods and Service tax.

L Other Income

Interest income is recognised on a time proportion basis taking into account the amount outstanding and the rate applicable.

Export benefits, incentives and licenses: Export incentives are recognized as income when the right to receive credit as per the terms of the scheme is established in respect of the exports made and where there is no significant uncertainty regarding the ultimate collection of the relevant export proceeds.

Rental income is recognised in the statement of profit and loss on the straight line basis over the period of lease term.

M Borrowing costs

Borrowing costs include interest, other costs incurred in connection with borrowing and exchange differences arising from foreign currency borrowings to the extent that they are regarded as an adjustment to the interest cost. General and specific borrowing costs directly attributable to the acquisition, construction or production of qualifying assets, which are assets that necessarily take a substantial period of time to get ready for their intended use or sale, are added to the cost of those assets, until such time as the assets are substantially ready for their intended use or sale. All other borrowing costs are recognised in Statement of Profit and Loss in the period in which they are incurred.

N Employees Benefits

(a) Provident Fund

Contribution towards provident fund for employees is made to the regulatory authorities, where the Company has no further obligations. Such benefits are classified as Defined Contribution Schemes as the Company does not carry any further obligations, apart from the contributions made on a monthly basis.

(b) Gratuity

The Company provides for gratuity, a defined benefit plan (the "Gratuity Plan") covering eligible employees in accordance with the Payment of Gratuity Act, 1972. The Gratuity Plan provides a lump sum payment to vested employees at retirement, death, incapacitation or termination of employment, of an amount based on the respective employee's salary and the tenure of employment. The Company's liability is actuarially determined (using the Projected Unit Credit method) at the end of each year. Actuarial losses/ gains are recognised in the Statement of Profit and Loss in the year in which they arise.

(c) Termination Benefits

Termination benefits in the nature of voluntary retirement benefits are recognised in the Statement of Profit and Loss as and when incurred.

O Current and Deferred Tax

Tax expense for the period, comprising current tax and deferred tax, are included in the determination of the net profit or loss for the period. Current tax is measured at the amount expected to be paid to the tax authorities.

Deferred tax is recognised for all the timing differences, subject to the consideration of prudence in respect of deferred tax assets. Deferred tax assets are recognised and carried forward only to the extent that there is a reasonable certainty that sufficient future taxable income will be available against which such deferred tax assets can be realised. Deferred tax assets and liabilities are measured using the tax rates and tax laws that have been enacted or substantively enacted by the Balance Sheet date. In situations, where the Company has unabsorbed depreciation or carry forward losses under tax laws, all deferred tax assets are recognised only to the extent that there is virtual certainty supported by convincing evidence that they can be realised against future taxable profits. At each Balance Sheet date, the Company re-assesses unrecognised deferred tax assets, if any.

Current tax assets and current tax liabilities are offset when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle the asset and the liability on a net basis. Deferred tax assets and deferred tax liabilities are offset when there is a legally enforceable right to set off assets against liabilities representing current tax and where the deferred tax assets and the deferred tax liabilities relate to taxes on income levied by the same governing taxation laws.

P Foreign Currency Transaction

(a) Initial Recognition

On initial recognition, all foreign currency transactions are recorded by applying to the foreign currency amount the exchange rate between the reporting currency and the foreign currency at the date of the transaction.

(b) Subsequent Recognition

As at the reporting date, non-monetary items which are carried in terms of historical cost denominated in a foreign currency are reported using the exchange rate at the date of the transaction. All non-monetary items which are carried at fair value or other similar valuation denominated in a foreign currency are reported using the exchange rates that existed when the values were determined.

All monetary assets and liabilities in foreign currency are restated at the end of accounting period. With respect to long-term foreign currency monetary items, the Company has adopted the following policy:

- Foreign exchange difference on account of a depreciable asset, is adjusted in the cost of the depreciable asset, which would be depreciated over the balance life of the asset

- In other cases, the foreign exchange difference is accumulated in a Foreign Currency Monetary Item Translation Difference Account, and amortised over the balance period of such long term asset/ liability

A monetary asset or liability is termed as a long-term foreign currency monetary item, if the asset or liability is expressed in a foreign currency and has a term of 12 months or more at the date of origination of the asset or liability.

Exchange differences on restatement of all other monetary items are recognised in the Statement of Profit and Loss.

Q Earning / (loss) Per Share

Basic earnings / (loss) per share is calculated by dividing the net profit or loss for the period attributable to equity shareholders by the weighted average number of equity shares outstanding during the period. Earnings considered in ascertaining the Company's earnings per share is the net profit for the period after deducting preference dividends and any attributable tax thereto for the period. The weighted average number of equity shares outstanding during the period and for all periods presented is adjusted for events, such as bonus shares, other than the conversion of potential equity shares that have changed the number of equity shares outstanding, without a corresponding change in resources. For the purpose of calculating diluted earnings per share, the net profit or loss for the period attributable to equity shareholders and the weighted average number of shares outstanding during the period is adjusted for the effects of all dilutive potential equity shares.

(Rs. in lakhs, unless otherwise stated)

Note No.	Particulars	As at 31 March, 2026		As at 31 March, 2025	
		Number	Amount	Number	Amount
2	SHARE CAPITAL				
(a)	Authorised Capital				
	Equity Shares Of Rs. 10 Each	25,000,000	2,500.00	25,000,000	2,500.00
(b)	Issued, Subscribed & Fully Paid Up Capital				
	Equity Shares of Rs. 10 each fully Paid	23,150,400	2,315.04	18,150,000	1,815.00
	Total		2,315.04		1,815.00

(c) **Par value per share:**

The Company has only one class of Equity Shares having a par value Rs. 10 per share.

(d) **A reconciliation of the number of shares and amount outstanding at the beginning and at the end of the reporting period:**

Particulars	31 March, 2026		31 March, 2025	
	No. of Shares	Amount	No. of Shares	Amount
Equity Shares at the beginning of the year	18,150,000	181,500,000	25,000	250,000
Add: Share issued during the year	5,000,400	50,004,000	18,125,000	181,250,000
Less: Shares bought back during the year	-	-	-	-
Equity Shares at the end of the year	23,150,400	231,504,000	18,150,000	181,500,000

(e) **The rights, preferences and restrictions attaching to each class of shares including restrictions on the distribution of dividends and the repayment of capital:**

The Company has issued only one class of equity shares having a par value of Rs. 10 each. Each equity shareholders is entitled to one vote per share. Dividend, if any, is declared and paid in Indian Rupees. Dividend, if any, proposed by the Board of Director is subject to the approval of the share holders in the ensuing Annual General Meeting.

In the event of liquidation of the Company, the holders of equity shares will be entitled to receive remaining assets of the Company, after distribution of all preferential amounts, if any. The distribution will be proportion to the number of equity shares held by the shareholders.

(f) **Shares in respect of each class in the company held by its holding company or its ultimate holding company including shares held by or by subsidiaries or associates of the holding company or the ultimate holding company in aggregate:**

There are no holding or associate companies. Accordingly repoting to that extent under this clause is not applicable. Futher, no shares have been held by the subsidiary company.

(g) **Shares in the company held by each shareholder holding more than 5 per cent. shares specifying the number of shares held:**

Name of Shareholders	31 March, 2026		31 March, 2025	
	No. of Shares	% Held	No. of Shares	% Held
Munir Chandniwala	16,142,100	69.73%	17,242,500	95.00%

(h) **Aggregate number of bonus shares issued or shares issued for consideration other than cash and shares bought back during the period of five years immediately preceeding the reporting date.**

Particulars	As at 31.03.2026 (No. of Shares)	As at 31.03.2025 (No. of Shares)
a) Equity shares allotted as fully paid up pursuant to contracts for consideration other than cash	Nil	Nil
b) Subscription amount is adjusted against a bona fide debt payable in money at once by the company.	Nil	Nil
c) Conversion of loan into shares in the event of default in repayment.	Nil	Nil
d) Conversion of loan into shares in the event of default in repayment.	Nil	Nil
e) Equity Shares allotted as fully paid bonus shares by capitalisation of reserves.	Nil	18,125,000

(i) **Shareholding of Promoters**

The details of the shares held by promoters as at March 31, 2026 are as follows :

Promoter Name	No. of Shares	% of Total Shares	% change during the year
Munir Chandniwala	16,142,100	69.73%	-25.27%
Shirin Chandniwala	880,638	3.80%	-1.05%
Abdul Ganee Chandniwala	726	0.00%	0.00%
Total	17,023,464	73.53%	

The details of the shares held by promoters as at March 31, 2025 are as follows :

Promoter Name	No. of Shares	% of Total Shares
Munir Chandniwala	17,242,500	95.00%
Shirin Chandniwala	880,638	4.85%
Abdul Ganee Chandniwala	726	0.00%
Total	18,123,864	99.86%

Note No.	Particulars	As at	As at
		31 March, 2026	31 March, 2025
3	RESERVES & SURPLUS		
	General Reserve		
	Opening Balance	-	650.00
	Less: Transferred on account of bonus issue of shares	-	(650.00)
	Total (A)	-	-
	Profit & Loss Account		
	Opening Balance	1,799.55	1,634.72
	Add: Profit/(Loss) for the year	2,054.13	1,327.32
	Less: Transferred on account of bonus issue of shares	-	(1,162.50)
	Total (B)	3,853.67	1,799.55
	Securities Premium		
	Opening Balance	-	-
	Add: Received During the year	4,300.34	-
	Less : Share Issue Expenses	(393.09)	-
	Total (C)	3,907.26	-
	Total (A+B+C)	7,760.93	1,799.55
4	OTHER LONG TERM LIABILITIES		
	<u>Security Deposits</u>		
	From Customer	-	5.26
	Total	-	5.26
5	LONG TERM PROVISION		
	<u>Provision for Employee Benefits</u>		
	- Gratuity	23.43	17.73
	Total	23.43	17.73
6	SHORT TERM BORROWINGS		
	Unsecured		
	<u>Repayable on demand - interest free</u>		
	<u>From Directors</u>		
	Munir Chandniwala	-	21.92
	Total	-	21.92

Note No.	Particulars	As at 31 March, 2026	As at 31 March, 2025
7	TRADE PAYABLES		
	(a) Total outstanding dues of micro enterprises and small enterprises*	500.66	2,140.80
	(b) Total outstanding dues of creditors other than micro enterprises and small enterprises	1,411.45	801.15
	Total	1,912.11	2,941.95

* The information regarding Micro and Small enterprises have been determined to the extent such parties have been identified on the basis of information available with the Company.

(a) Trade payable ageing schedule

Figures for Reporting Period ended 31 March, 2026

Particulars	Outstanding for following periods from due date of payment					Total
	Unbilled Due	Less than 1 Year	1-2 years	2-3 years	More than 3years	
Undisputed Dues-MSME	2.43	498.23	-	-	-	500.66
Undisputed Dues-Other than MSME	29.25	1,382.20	-	-	-	1,411.45
Disputed Dues-MSME	-	-	-	-	-	-
Disputed Dues-Others	-	-	-	-	-	-
Total	31.67	1,880.43	-	-	-	1,912.11

Figures for Reporting Period ended 31 March, 2025

Particulars	Outstanding for following periods from due date of payment					Total
	Unbilled Due	Less than 1 Year	1-2 years	2-3 years	More than 3years	
Undisputed Dues-MSME	12.46	2,127.85	0.49	-	-	2,140.80
Undisputed Dues-Other than MSME	14.69	758.98	26.96	0.52	-	801.15
Disputed Dues-MSME	-	-	-	-	-	-
Disputed Dues-Others	-	-	-	-	-	-
Total	27.15	2,886.83	27.45	0.52	-	2,941.95

(b) Dues to Micro and Small Enterprises

The disclosure pursuant to the said Micro, Small and Medium Enterprises Development Act, 2006 ('MSMED Act') are as follows: -

Particulars	As at 31 March, 2026	As at 31 March, 2025
i) Principal amount due to suppliers registered under the MSMED Act and remaining unpaid as at year end.	498.23	2,128.34
ii) Interest due thereon to suppliers registered under the MSMED Act and remaining unpaid as at year end.	-	-
iii) Principal amounts paid to suppliers registered under the MSMED Act, beyond the appointed day during the year.	-	-
iv) Interest paid under Section 16 of MSMED Act to suppliers registered under the MSMED Act, beyond the appointed day during the year.	-	-
v) Amount of interest due and payable for the period (where the principal has been paid but interest under the MSMED Act, 2006 not paid)	-	-
vi) Interest accrued and remaining unpaid at the end of each accounting year	-	-

Note No.	Particulars	As at	As at
		31 March, 2026	31 March, 2025
8	OTHER CURRENT LIABILITIES		
	Statutory dues Payable	24.95	59.62
	Income received in advance	155.36	110.18
	Employee Dues Payable	74.71	58.65
	Payable for Capital Goods	50.71	42.58
	Total	305.73	271.03
9	SHORT TERM PROVISIONS		
	Provision for Tax (Net of advances)	53.17	157.48
	Total	53.17	157.48

10 PROPERTY, PLANT AND EQUIPMENT

(All Amounts in Rs. Lakhs, unless otherwise stated)

SR. No.	DESCRIPTION OF ASSET	GROSS BLOCK				DEPRECIATION				NET BLOCK	
		AS AT 01/04/2025	ADDITION DURING THE PERIOD	DEDUCTION DURING THE PERIOD	AS AT 31/03/2026	UP TO 31/03/2025	ADDITION DURING THE PERIOD	DEDUCTIONS DURING THE PERIOD	AS AT 31/03/2026	AS AT 31/03/2026	
a)	TANGIBLE ASSETS										
	Land	-	260.25	-	260.25	-	-	-	-	260.25	
	Premises (includes Capital cost on Rented Property)	750.54	221.65	-	972.19	82.40	76.90	-	159.30	812.88	
	Plant & Machinery	1,414.16	688.40	-	2,102.56	387.35	233.73	-	621.08	1,481.48	
	Office Equipment	40.29	15.42	-	55.72	24.72	11.29	-	36.01	19.70	
	Furniture & Fixtures	198.07	30.92	-	228.99	54.38	43.09	-	97.47	131.52	
	Motor Vehicle	30.71	38.85	-	69.55	14.59	9.67	-	24.26	45.29	
	Computer Hardware	10.50	4.04	-	14.54	8.33	2.12	-	10.45	4.09	
	Sub Total (A)	2,444.27	1,259.53	-	3,703.80	571.77	376.81	-	948.58	2,755.22	
b)	INTANGIBLE ASSETS										
	Computer Software	5.86	-	-	5.86	2.05	0.99	-	3.04	2.83	
	Sub Total (B)	5.86	-	-	5.86	2.05	0.99	-	3.04	2.83	
	Total (A)+(B)	2,450.13	1,259.53	-	3,709.66	573.81	377.80	-	951.61	2,758.05	
c)	Capital Work in Progress (CWIP)										
	Capital Work in Progress	-	346.91	-	346.91	-	-	-	-	346.91	
	Sub Total (C)	-	346.91	-	346.91	-	-	-	-	346.91	
d)	Intangible asset under development										
	Intangible asset under development	-	1.69	-	1.69	-	-	-	-	1.69	
	Sub Total (D)	-	1.69	-	1.69	-	-	-	-	1.69	
	Total (A)+(B)+(C)+(D)	2,450.13	1,608.13	-	4,058.26	573.81	377.80	-	951.61	3,106.64	

(i) The Company has not revalued its Property, Plant and Equipment since the Company has adopted cost model as its accounting policy to an entire class of Property, Plant and Equipment in accordance with AS 10.

(ii) The company does not hold any immovable property whose title deeds are not held in the name of the company.

Capital work-in-progress(CWIP)
Ageing as at March 31, 2026

Particulars	Amount in CWIP for a period of				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
Projects in progress	346.91	-	-	-	346.91
Projects temporarily suspended	-	-	-	-	-
Total	346.91	-	-	-	346.91

Intangible asset under development
Ageing as at March 31, 2026

Particulars	Amount in CWIP for a period of				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
Projects in progress	1.69	-	-	-	1.69
Projects temporarily suspended	-	-	-	-	-
Total	1.69	-	-	-	1.69

Previous Year

(All Amounts in Rs. Lakhs, unless otherwise stated)

SR. No.	DESCRIPTION OF ASSET	GROSS BLOCK				DEPRECIATION				NET BLOCK	
		AS AT 01/04/2024	ADDITION DURING THE PERIOD	DEDUCTION DURING THE PERIOD	AS AT 31/03/2025	UP TO 31/03/2024	ADDITION DURING THE PERIOD	DEDUCTIONS DURING THE PERIOD	AS AT 31/03/2025	AS AT 31/03/2025	
a)	<u>TANGIBLE ASSETS</u>										
	Premises (the above asset is Capital cost on Rented Property)	406.54	344.00	-	750.54	29.60	52.80	-	82.40	668.14	
	Plant & Machinery	1,080.01	334.15	-	1,414.16	207.96	179.39	-	387.35	1,026.82	
	Office Equipment	29.19	11.10	-	40.29	15.16	9.56	-	24.72	15.57	
	Furniture & Fixtures	117.21	80.86	-	198.07	23.16	31.22	-	54.38	143.69	
	Motor Vehicle	18.87	11.83	-	30.71	9.05	5.55	-	14.59	16.11	
	Computer Hardware	8.85	1.65	-	10.50	5.15	3.18	-	8.33	2.17	
	Sub Total (A)	1,660.67	783.59	-	2,444.27	290.08	281.69	-	571.77	1,872.50	
b)	<u>INTANGIBLE ASSETS</u>										
	Computer Software	3.68	2.18	-	5.86	1.29	0.75	-	2.05	3.81	
	Sub Total (B)	3.68	2.18	-	5.86	1.29	0.75	-	2.05	3.81	
	Total (A)+(B)	1,664.35	785.78	-	2,450.13	291.37	282.45	-	573.81	1,876.31	
c)	<u>Capital Work in Progress (CWIP)</u>										
	Capital Work in Progress	-	-	-	-	-	-	-	-	-	
	Sub Total (C)	-	-	-	-	-	-	-	-	-	
d)	<u>Intangible asset under development</u>										
	Intangible asset under development	-	-	-	-	-	-	-	-	-	
	Sub Total (D)	-	-	-	-	-	-	-	-	-	
	Total (A)+(B)+(C)+(D)	1,664.35	785.78	-	2,450.13	291.37	282.45	-	573.81	1,876.31	

* The Company has not revalued its Property, Plant and Equipment since the Company has adopted cost model as its accounting policy to an entire class of Property, Plant and Equipment in accordance with AS 10.

Note No.	Particulars	As at 31 March, 2026	As at 31 March, 2025
11	Non-Current Investment		
	<u>Trade Investment, At Cost</u>		
	Investment in Equity Instruments - Unquoted, Fully paid up		
	Olahey Wellness Private Limited	1.00	-
	(10,000 equity shares of Rs. 10 each)		
	Total	1.00	-
	The aggregate amount of non-current unquoted investment	1.00	-
	The aggregate amount of provision for diminution in value of non-current unquoted investment	-	-
12	DEFERRED TAX ASSET (NET)		
	<u>Deferred Tax Asset</u>		
	- On account of Depreciation	15.44	8.07
	- On account of provision for doubtful debts	6.23	3.65
	- On account of disallowance u/s 35D	31.54	-
	- On account of disallowance u/s 43B	6.70	6.52
	- On account of disallowance u/s 40(a)(ia)	1.26	-
	Total	61.17	18.25
13	LONG TERM LOANS AND ADVANCES		
	<u>Unsecured & Considered Good</u>		
	Capital Advances	919.01	62.81
	Total	919.01	62.81
	(a) Loans and Advances due by directors or other officers of the company or any of them either severally or jointly with any other person	Nil	21.00
	(b) Loans and Advances due by firm or private companies in which director is a partner or director or member	Nil	Nil
	(c) Loans or advances in the nature of loans granted to Promoters, Directors, Kmps and their related parties (as defined under Companies Act, 2013), either severally or jointly with any other person, that are:		
	(i) repayable on demand; or	Nil	Nil
	(ii) without specifying any terms or period of repayment	Nil	Nil
	(d) In line with Circular No. 04/2015 issued by the Ministry of Corporate Affairs dated March 10, 2015, loans given to employees as per the Company's policy are not considered for the purpose of disclosure under section 186(4) of the Companies Act, 2013.	Nil	Nil
14	OTHER NON CURRENT ASSETS		
	<u>Unsecured, Considered good</u>		
	Rental Deposits	122.09	118.49
	Security deposits	15.01	2.08
	Bank Deposits with maturity more than 12 months	-	50.00
	Total	137.10	170.57
	(a) Debts due by directors or other officers of the company or any of them either severally or jointly with any other person	115.00	115.00
	(b) Debts due by firm or private companies in which director is a partner or director or member	Nil	Nil

Note No.	Particulars	As at	
		31 March, 2026	31 March, 2025

15 Current Investment

Unquoted Investments

Investment in Mutual Funds
(at lower of cost and market value)

Particulars	No. of units		As at 31 March, 2026	As at 31 March, 2025
	As at March 31, 2026	As at March 31, 2025		
Aditya Birla Sun Life Arbitrage Fund	181,735.74	-	50.00	-
Aditya Birla Sun Life Savings Fund	22,884.22	-	129.99	-
WhiteOak Capital Arbitrage Fund	456,973.77	-	50.00	-
Total			229.99	-

The aggregate amount of unquoted investments

229.99

-

The aggregate amount of provision for diminution in value of investments

Nil

Nil

16 INVENTORIES

(Valued at lower of cost or estimated net realisable value)

Raw Materials	964.22	1,048.87
Packing Materials	298.75	195.18
Finished Goods	330.30	77.69
Total	1,593.27	1,321.73

17 TRADE RECEIVABLES

Secured, Considered Good	-	5.26
Unsecured, Considered Good	3,378.04	3,238.84
Doubtful	24.75	14.52
Less: Allowance for Bad and Doubtful Debts	(24.75)	(14.52)
Total	3,378.04	3,244.09

Debts Due by firm or private companies in which director is partner, director or member

1.78

4.99

Debts Due by directors or other officers of the company

Nil

Nil

Figures for Reporting Period ended 31 March, 2026

Particulars	Outstanding for following periods from due date of payment					Total
	Less than 6 months	6 months -1 year	1-2 years	2-3 years	More than 3 years	
Undisputed Trade receivables						
considered good	2,690.29	339.01	345.20	-	-	3,374.49
considered doubtful	-	-	9.10	15.66	-	24.75
Disputed Trade						
considered good	-	3.55	-	-	-	3.55
considered doubtful	-	-	-	-	-	-
Less: Allowance for Bad and Doubtful Debts	-	-	(9.10)	(15.66)	-	(24.75)
Total	2,690.29	342.55	345.20	-	-	3,378.04

Figures for Reporting Period ended 31 March, 2025

Particulars	Outstanding for following periods from due date of payment					Total
	Less than 6 months	6 months -1 year	1-2 years	2-3 years	More than 3 years	
Undisputed Trade receivables						
considered good	2,877.20	351.89	15.00	-	-	3,244.09
considered doubtful	-	-	14.52	-	-	14.52
Disputed Trade						
considered good	-	-	-	-	-	-
considered doubtful	-	-	-	-	-	-
Less: Allowance for Bad and Doubtful Debts	-	-	(14.52)	-	-	(14.52)
Total	2,877.20	351.89	15.00	-	-	3,244.09

Note No.	Particulars	As at	As at
		31 March, 2026	31 March, 2025
18	CASH AND CASH EQUIVALENTS		
	Balances with banks		
	In Current Account	207.18	190.13
	Deposits with maturity less than 3 months*	2,303.87	-
	Cash on hand	4.69	0.94
	Total	2,515.74	191.06
*Deposits include Rs. 2,289.19 lakhs representing unutilized proceeds from the Initial Public Offering (IPO). These balances are earmarked specifically for the objects of the issue as stated in the Prospectus and are not available for use in the company's day-to-day operations.			
19	SHORT TERM LOANS AND ADVANCES		
	(Unsecured-Considered Good)		
	Advance paid against supply of goods & services	27.13	34.18
	Loans and advances to Employees	18.72	23.52
	Prepaid Expenses	18.33	11.32
	Input tax credit available for utilisation	329.30	7.54
	Total	393.49	76.56
	Loans and Advances due by directors or other officers of the company or any of them either severally or jointly with any other person	Nil	Nil
	Loans and Advances due by firm or private companies in which director is a partner or director or member	Nil	Nil
	Loans or advances in the nature of loans granted to Promoters, Directors, KMPs and their related parties (as defined under Companies Act, 2013), either severally or jointly with any other person, that are:		
	(i) repayable on demand; or	Nil	Nil
	(ii) without specifying any terms or period of repayment	Nil	Nil
	In line with Circular No. 04/2015 issued by the Ministry of Corporate Affairs dated March 10, 2015, loans given to employees as per the Company's policy are not considered for the purpose of disclosure under section 186(4) of the Companies Act, 2013.	Nil	Nil
20	OTHER CURRENT ASSETS		
	Unsecured, Considered good		
	Deferred Share Issue expenses	-	67.45
	Interest accrued on fixed deposits	10.03	0.81
	Interest accrued on security deposits	-	0.26
	Deposit paid under GST litigation	17.59	-
	Refund under GST law	7.33	-
	Total	34.95	68.52
21	CONTINGENT LIABILITIES & COMMITMENTS		
a)	Contingent Liabilities		
	GST Penalty under dispute for non-compliance of E-way Bill provision (Amount paid under dispute Rs. 17.59 lakhs)	17.59	Nil
b)	Commitments		
	Estimated amounts of contracts remaining to be executed on capital account and not provided for	1,532.30	Nil

(Rs. in lakhs, unless otherwise stated)

Note No.	Particulars	For the year ended 31 March, 2026	For the year ended 31 March, 2025
22	REVENUE FROM OPERATION		
	Sale of products	14,584.43	10,405.84
	Other Operating revenues	98.93	79.53
	Total	14,683.36	10,485.36
23	OTHER INCOME		
	Reversal of Doubtful Debts (net of provision)	-	4.00
	Interest received on Fixed Deposit	16.66	5.30
	Interest received on Security Deposit	-	0.33
	Rent Received	3.60	3.60
	Duty Drawback Income Received	0.09	0.09
	Gain on variation in foreign exchange rate	0.66	-
	Net gain on sale of investments	112.47	-
	Total	133.49	13.31
24	COST OF MATERIAL CONSUMED		
	Opening Stock		
	Raw Material	1,048.87	307.82
	Packing Material	195.18	158.95
		1,244.04	466.77
	Add: Purchases		
	Raw Material	6,100.66	5,062.18
	Packing Material	2,839.98	2,055.88
		8,940.64	7,118.06
	Less: Closing Stock		
	Raw Material	(964.22)	(1,048.87)
	Packing Material	(298.75)	(195.18)
		(1,262.97)	(1,244.04)
	Total	8,921.72	6,340.78
25	CHANGES IN INVENTORIES OF FINISHED GOODS		
	Opening Stock of Goods		
	Finished Goods	77.69	78.85
	Total (I)	77.69	78.85
	Closing Stock of Goods		
	Finished Goods	330.30	77.69
	Total (II)	330.30	77.69
	Net Impact (I-II)	(252.61)	1.16
26	EMPLOYEE BENEFIT EXPENSES		
	Salaries, Wages & Allowances	934.00	699.73
	Directors Remuneration	120.00	100.00
	Contribution to Provident fund and other fund	59.07	40.84
	Group Insurance for Staff	5.79	4.98
	Staff Welfare Expenses	33.18	16.18
	Contribution to Gratuity fund	23.42	17.73
	Total	1,175.47	879.45
27	FINANCE COSTS		
	Interest Expenses		
	Secured Loan	-	0.09
	Interest on income tax	18.42	16.50
	Total	18.42	16.60

(Rs. in lakhs, unless otherwise stated)

Note No.	Particulars	For the year ended 31 March, 2026	For the year ended 31 March, 2025
28	OTHER EXPENSES		
	<u>Manufacturing Expenses</u>		
	Labour Charges	591.96	404.93
	Power & Fuel Charges	183.07	123.58
	Transportation Expenses	142.27	107.59
	Factory Rent	89.46	84.96
	Factory Expenses	83.16	75.00
	Cartridge Filling Expenses	29.09	16.25
	Packing & Forwarding	15.18	14.88
	Laboratory Expenses	12.93	13.16
		1,147.11	840.35
	<u>Administrative & Other Expenses</u>		
	Legal, Professional, Listing and License Fees	77.74	64.65
	Listing related Expenses	141.31	-
	Repair & Maintenance	111.29	52.89
	Office Rent	42.61	36.57
	Travelling & Conveyance Expenses	31.61	31.65
	Corporate Social Responsibility Expenses	28.85	21.72
	Provision for Doubtful Debts (net of reversal)	10.24	-
	Vehicle Expenses	7.64	9.63
	Courier Charges	9.64	6.94
	Bad Debts	36.09	8.49
	Printing & Stationery	10.50	3.98
	Insurance Expenses	7.18	3.38
	Electricity Expenses	3.49	3.32
	Donation	4.06	2.57
	Society Maintenance Charges	2.88	2.82
	<u>Auditor's Remuneration</u>		
	for Statutory Audit	2.50	2.50
	for Limited Review	0.75	-
	for other services	1.31	0.15
	Computer & Internet Expenses	4.44	2.58
	Loss on variation in foreign exchange rate	-	2.22
	Mobile & Telephone charges	2.01	1.64
	Rates & Taxes	0.03	1.06
	Office Expenses	4.67	0.97
	Membership & Subscription Fees	0.85	0.77
	Advertisement Expense	1.45	0.60
	Bank Charges	1.00	0.41
	Charges on investments	0.23	-
	Software & Website Expenses	7.82	3.42
	Director Sitting Fees	1.80	-
	Fines and Penalties	1.10	-
		555.06	264.93
	<u>Selling & Marketing Expenses</u>		
	Exhibition Expenses	80.42	68.59
	Commission	55.41	31.61
	Sales Promotion Expenses	14.64	1.34
		150.47	101.55
Total		1,852.65	1,206.83

29 Disclosures as required by AS 18 "Related Parties" issued by the ICAI

List of Related Parties

Sr.No	Name of Related Party	Relationship
1	Munir Chandniwala	Managing Director
2	Shirin Chandniwala	Whole Time Director
3	Abdul Ganee Chandniwala	Director
4	Ashish Shah	Chief Financial Officer
5	Atul Shukla	Company Secretary
6	Olahey Wellness Private Limited	Subsidiary
7	ESLP Digital LLP	Other Related Party
8	Trusan Printpack Private Limited	Other Related Party
9	Chandniwala Clinic	Other Related Party
10	Influx Foundation	Other Related Party
11	Nutraceutical India	Other Related Party
12	Shinai Enterprise	Other Related Party

Summary of significant related party transactions carried out in the ordinary course of business are as under:

(Rs. in lakhs, unless otherwise stated)

Sl.	Nature of Transaction	Year Ended March 31, 2026	Year Ended March 31, 2025
I	Key Management Personnel		
(i)	Munir Chandniwala		
	Remuneration	96.00	84.00
	Loan taken	-	15.16
	Loan repaid	21.92	20.44
	Rent Paid	90.00	90.00
	Advance for fixed Asset	-	21.00
	Acquisition of fixed Asset	219.00	-
(ii)	Shirin Chandniwala		
	Remuneration	24.00	16.00
	Loan Repaid	-	2.00
	Rent Paid	12.00	12.00
(iii)	Ashish Shah		
	Remuneration	12.55	10.03
	Loan Given	-	2.00
	Loan Recovered	-	2.00
(iv)	Atul Shukla		
	Remuneration	7.20	4.60
II	Other Related Party		
(i)	Trusan Printpack Private Limited		
	Sale of product	2.28	1.70
	Purchase of product	314.54	220.21
	Rent Income	3.60	3.60
	Reimbursement of Expense	-	0.09
(iii)	Influx Foundation		
	Donation	2.16	0.85
(iv)	Nutraceutical India		
	Sale of product	0.29	0.02

Balance at the Year End

Sr.No	Name	Nature of Transaction	As at 31 March, 2026	As at 31 March, 2025
1	Munir Chandniwala	Remuneration	-	1.35
2	Munir Chandniwala	Unsecured Loan	-	21.92
3	Munir Chandniwala	Security Deposit	115.00	115.00
4	Munir Chandniwala	Advance for Acquisition of Fixed Asset	-	21.00
5	Shirin Chandniwala	Remuneration	0.15	1.62
6	Trusan Printpack Private Limited	Purchase of product	8.21	44.03
7	Nutraceutical India	Sale of product	1.78	4.99
8	Ashish Shah	Remuneration	0.45	-
9	Atul Shukla	Remuneration	0.60	-

30 Disclosure as required by AS 20 "Earnings Per Share" issued by the ICAI
Earning Per Share (EPS)

The earning considered in ascertaining the Company's EPS comprises the net profit after tax the number of shares used in Computation of Basic EPS is the weighted average number of share outstanding during the year which is calculated as below:

(Rs. in lakhs, unless otherwise stated)

Particular	For the Year Ended March 31, 2026	For the Year Ended March 31, 2025
Calculation of weighted average no. equity shares :		
No. of Shares at the beginning of the year fully paid	18,150,000	25,000
No. of Shares to issued fully paid	5,000,400	18,125,000
Total Equity Shares outstanding at the end of the year	23,150,400	18,150,000
Total Equity Shares outstanding at the end of the year (considering the impact of bonus and fresh issue of equity shares for all periods)	21,972,224	18,150,000
Net Profit after tax / (loss) available for equity share holder (Rs. in Lakhs)	2,054.13	1,327.32
Basic / Diluted earnings per share of Rs. 10 (Rs.) (considering the impact of bonus issue for all periods)	9.35	7.31

31 Disclosure related to Corporate Social Responsibility (as per Section 135 of the Act)

(Rs. in lakhs, unless otherwise stated)

Particulars	For the Year Ended March 31, 2026	For the Year Ended March 31, 2025
(a) Gross amount required to be spent by the Company during the year	28.32	20.56
(b) Amount of expenditure incurred on :		
(i) Construction/Acquisition of asset	-	-
(ii) On purposes other than (i) above	28.85	21.72
(c) Shortfall at the end of the year	N.A	N.A
(d) Total amount of previous years shortfall	N.A	N.A
(e) Reason for shortfall	N.A	N.A
(f) Contribution to a trust controlled by the company in relation to CSR Expenditure	N.A	N.A
(g) Where a provision is made with respect to a liability incurred by entering into a contractual obligation	N.A	N.A

The Company undertakes the following activities in Corporate social responsibility (CSR):

(i) Promoting of education, including special education and employment enhancing vocation skills especially among children, women, elderly, and the differently abled and livelihood enhancement projects.

(ii) eradicating hunger, poverty and malnutrition, promoting health care including preventive health and sanitation Including contribution to the Swatch Bharat Kosh set-up by the Central Government for the promotion of sanitation and making available safe drinking water.

(iii) ensuring environmental sustainability, ecological balance, protection of flora and fauna, animal welfare, agroforestry, conservation of natural resources and maintaining quality of soil, air and water including contribution to the Clean Ganga Fund setup by the Central Government for rejuvenation of river Ganga.

Note No.	Particulars	(Rs. in lakhs, unless otherwise stated)	
		For the year ended	For the year ended
		March 31, 2026	March 31, 2025
32	Employee Benefit Expenses		
	(a) Defined Contribution Plans		
	Amount recognised in the Statement of Profit and Loss		
(i)	Employers' Contribution to Provident Fund *	45.96	31.75
	[Includes Employers' Contribution to Employee's Pension Scheme 1995]		
(ii)	Employers' Contribution to Employee's State Insurance Commission*	12.81	8.76
		58.77	40.51

* Included in Contribution to Provident and Other Funds(Refer Note 26)

(b) Defined Benefit Plan

Gratuity

The Company has a defined benefit gratuity plan for its employees ("Gratuity Scheme"). The gratuity plan is governed by the Payment of Gratuity Act, 1972. Under the Act, every employee who has completed five years of service is entitled to specific benefit. The level of benefits provided depends on the employee's length of service and salary at retirement age. Every employee except chairman and managing director who has completed five years or more of service gets a gratuity on departure at 15 days salary (last drawn) for each completed year of service as per the provisions of the Payment of Gratuity Act, 1972. The scheme is funded with an insurance company.

(i) Change in Defined Benefit Obligation

Sr No.	Particulars	For the Year Ended March 31, 2026	For the Year Ended March 31, 2025
1	DBO at the beginning of the period	46.39	28.66
2	Acquisition adjustment	-	-
3	Interest cost	3.19	2.00
4	Past Service Cost/(credit) – vested benefits	0.84	-
5	Past Service Cost/(credit) – Non vested benefits	-	-
6	Current Service Cost	12.69	9.70
7	Curtailment Cost/ (credit)	-	-
8	Settlement Cost/ (credit)	-	-
9	Plan Amendments	-	-
10	Benefit payments from Company	-	-
11	Benefit payments from fund	-	-
12	Actuarial (gains) loss on Obligation	7.14	6.03
13	DBO at the end of the period	70.25	46.39

(ii) Fair Value of Plan Assets

S.No	Particulars	For the Year Ended March 31, 2026	For the Year Ended March 31, 2025
1	Fair value of plan assets (beginning)	28.66	-
2	Acquisition Adjustment	-	-
3	Charges and Taxes	-	-
4	Expected return on plan assets	2.58	-
5	Employer's contributions	17.71	28.66
6	Employee's contributions	-	-
7	Benefit payments	-	-
8	Actuarial Gain/ (Loss) on Plan Assets	(2.13)	-
9	Fair value of plan assets (end)	46.83	28.66

(Rs. in lakhs, unless otherwise stated)

(iii) Change in Fair Value of Plan Assets

S.No	Particulars	For the Year Ended March 31, 2026	For the Year Ended March 31, 2025
1	Fair value of plan assets (beginning)	28.66	-
2	Acquisition Adjustment	-	-
3	Charges and Taxes	-	-
4	Actual return on plan assets	0.45	-
5	Employer's contributions	17.71	28.66
6	Employee's contributions	-	-
7	Benefit payments	-	-
8	Actuarial Gain/ (Loss) on Plan Assets	-	-
9	Fair value of plan assets (end)	46.83	28.66

(iv) Amount Recognition in the Statement of Profit and Loss

S.No	Particulars	For the Year Ended March 31, 2026	For the Year Ended March 31, 2025
1	Current Service Cost	12.69	9.70
2	Interest Cost	3.19	2.00
3	Past Service Cost	0.84	-
4	Expected Return on Plan Assets	(2.58)	-
5	Curtailment Cost	-	-
6	Settlement Cost	-	-
7	Amortisation of Past Service Cost	-	-
8	Net Actuarial (Gains)/ Losses	9.28	6.03
9	Total Employer Expense in P&L	23.42	17.73

(v) Recognition of Actuarial Gain/ Loss

S.No	Particulars	For the Year Ended March 31, 2026	For the Year Ended March 31, 2025
1	Unrecognized Actuarial Loss/(Gain) start	7.14	6.03
2	Actuarial loss/(gain) – Plan Assets	2.13	-
3	Total Actuarial Loss/(Gain)	9.28	6.03
4	(Gain)/Loss recognized	9.28	6.03
5	Unrecognized Loss/(Gain) end	-	-

(vi) Actuarial (Gain)/ Loss on Obligation

S.No	Particulars	For the Year Ended March 31, 2026	For the Year Ended March 31, 2025
1	Experience Adjustment	12.08	5.51
2	Financial Change	(4.94)	0.52
3	Assumption Change	-	-

(vii) Recognition of Past Service Cost

S.No	Particulars	For the Year Ended March 31, 2026	For the Year Ended March 31, 2025
1	Unrecognized Past Service Cost (start)	-	-
2	Past Service Cost (Credit)	-	-
3	Recognized Past Service Cost	-	-
4	Unrecognized Past Service Cost (end)	-	-

(Rs. in lakhs, unless otherwise stated)

(viii) Balance Sheet Reconciliation

S.No	Particulars	For the Year Ended March 31, 2026	For the Year Ended March 31, 2025
1	Net (Asset)/Liability (beginning)	17.73	28.66
2	Employer Expense	23.42	17.73
3	Employer Contributions	(17.71)	(28.66)
4	Net (Asset)/Liability (end)	23.43	17.73

(ix) P&L Reconciliation

S.No	Particulars	For the Year Ended March 31, 2026	For the Year Ended March 31, 2025
1	DBO at end of year	70.25	46.39
2	DBO at beginning of year	(46.39)	(28.66)
3	Benefits Paid	-	-
4	Actual Return on Plan Assets	(0.45)	-
5	Expenses deducted by the Insurer	0.01	-
6	Expense Recognized in P&L	23.43	17.73

(x) Major Categories of Plan Assets

S.No	Asset Categories	For the Year Ended March 31, 2026	For the Year Ended March 31, 2025
1	Government of India Securities	0.00%	0.00%
2	State Government Securities	0.00%	0.00%
3	High Quality Corporate Bonds	0.00%	0.00%
4	Equity shares (listed)	0.00%	0.00%
5	Property	0.00%	0.00%
6	Special Deposit Scheme	0.00%	0.00%
7	Funds managed by Insurer	100.00%	100.00%
8	Others	0.00%	0.00%
9	Total	0.00%	0.00%

(xi) Contribution Estimate

Description	Estimate	Estimate
Company's Best Estimate of Contribution (Next Year)	23.43	46.39

33 Impairment of Assets

There is no such impairable asset for the year as ended on 31.03.2026 in terms of AS-28. Hence company has not made any provision for impairment loss.

34 Segment Reporting

The company is engaged in single segment and there are no separate reportable segments as defined in Accounting standard – 17 “Segment Reporting”.

35 Foreign Exchange transactions :

(Rs. in lakhs, unless otherwise stated)

Particular	For the Year Ended March 31, 2026	For the Year Ended March 31, 2025
Export of goods on F.O.B Basis	21.51	61.03
CIF Value of Import of Capital Goods	33.68	-
Remittance of Dividend in Foreign Currency	-	-
Expenditure in Foreign Currency	0.90	27.47

36 Additional Information required to be disclosed as per Schedule III.

i) Details of Raw Materials Consumed

Particulars	For the Year Ended March 31, 2026	For the Year Ended March 31, 2025
Powder	5,737.44	4,046.19
Capsule	110.74	184.47
Oil	337.14	90.46
Others	-	-
TOTAL	6,185.32	4,321.13

37 IPO Funds and Application of Funds

The company has completed fresh issue of Equity Shares by Initial Public Offer (“IPO”) of 50,00,400 Equity Shares of face value Rs.10 each at an issue price of Rs. 96 per equity share. The Equity Shares of the company were listed on National Stock Exchange of India Limited (“NSE”) Emerge Platform on June 25, 2025. The details of utilization of the net proceeds as mentioned below:

Sr No.	Objects as disclosed in the offer document	Amount disclosed in offer document	Amount utilized upto 31.03.2026	Unutilized amount as on 31.03.2026
1	Funding Capital expenditure requirements for setting up of manufacturing facilities	3,673.34	1,384.15	2,289.19
2	General Corporate Purpose	667.40	667.40	-
3	Public Issue Expenses	583.24	583.24	-
	Total	4,923.98	2,634.79	2,289.19

38 Disclosure of transactions with struck off companies :

The Company did not have any material transactions with companies struck off under Section 248 of the Companies Act, 2013 or Section 560 of Companies Act, 1956 during the financial year.

39 Registration of Charges or Satisfaction with Registrar of Companies(ROC)

There are no charges or satisfaction which are yet to be registered with the Registrar of Companies beyond the statutory period.

40 Compliance with number of layers of Companies

The Company has complied with the requirements of the number of layers prescribed under clause (87) of section 2 of the Companies Act, 2013 read with Companies (Restriction on number of Layers) Rules, 2017.

41 Disclosure in relation to undisclosed income

During the year, the Company has not surrendered or disclosed any income in the tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961). Accordingly, there are no transactions which are not recorded in the books of accounts.

Notes forming part of Standalone Financial Statements

42 Financial Ratio

Sr no.	Particulars	Numerator	Denominator	March 31,2026	March 31,2025	Variance
I	Current Ratio (in times)	Total Current Asset	Total Current Liabilities	3.59	1.44	148.22%
II	Debt - Equity Ratio (in times)	Total Debt	Shareholders' Equity	-	0.01	-100.00%
III	Debt - Service Coverage Ratio (in times)	Earnings available for debt service	Debt Service	-	22,523.99	-100.00%
IV	Return on equity ratio (in %)	Net Profits after taxes	Shareholder's Equity	20.39	36.72	-44.48%
V	Inventory turnover ratio (in times)	Revenue from operations	Average Inventory	10.07	11.23	-10.29%
VI	Trade receivable turnover ratio (in times)	Total Sales	Average Accounts Receivable	4.43	4.34	2.26%
VII	Trade payables turnover ratio (in times)	Total Purchases+Other Expenses	Average Trade Payables	4.45	3.84	15.92%
VIII	Net Capital Turnover ratio (in times)	Revenue from operations	Average Working Capital	3.98	9.17	-56.64%
IX	Net Profit Ratio (in %)	Net Profit	Net Sales	14.08%	12.76%	10.42%
X	Return on capital employed (in %)	Earning before interest and taxes	Capital Employed	27.21%	49.17%	-44.66%

Notes :

- (i) Earnings available for debt service = Net Profit before taxes + non-cash operating expenses + interest + other non-cash adjustments
- (ii) Debt Service = Finance cost + Principal repayments (only term loans and not demand loans)
- (iv) Working Capital = Current Asset less Current liabilities
- (v) Capital employed = Shareholders' funds + deferred tax liability, if any

Reason for variance (where variance is more than 25% compared to the ratio of preceding year)

Reason for Variance more than 25% for the Financial Year ended March 31, 2026

Sr.No of Ratio	Reason of variance
I	The company had made fresh issue of shares through public offer and the pending utilisation the funds have been temporarily parked in short term fixed deposits and hence there has been a significant improvement in the current ratio as compared to the previous year.
II	The company has repaid all its debts in the current year resulting in Debt-Equity ratio to be Nil.
III	The company has repaid all its debts in the current year resulting in Debt - Service Coverage Ratio to be Nil.
IV	The decline in Return on Equity (ROE) from the previous year is primarily due to a temporary mismatch between capital infusion and its deployment. During the current financial year, the Company raised fresh equity capital through an Initial Public Offering (IPO), significantly increasing the shareholders' funds (the denominator). However, these funds were only partially deployed in operations by the end of the year. Because this newly raised capital has not yet reached full productive capacity, net profit did not grow in proportion to the expanded equity base, resulting in a lower ROE for the current period.
VIII	This expansion in the working capital base was primarily driven by higher current assets, specifically the unutilised proceeds from the Company's recent Initial Public Offering (IPO) that are temporarily parked in Fixed Deposits awaiting deployment. Consequently, the growth in the capital base temporarily outpaced revenue growth, resulting in a lower turnover ratio for the current period.
X	The decline in Return on Capital Employed (ROCE) from the previous year is primarily due to a temporary mismatch between capital infusion and its deployment. During the current financial year, the Company raised fresh equity capital through an Initial Public Offering (IPO), significantly increasing the capital employed base (the denominator). However, these funds were only partially deployed in operations by the end of the year. Because this newly raised capital has not yet reached full productive capacity, net profit did not grow in proportion to the expanded equity base, resulting in a lower ROCE for the current period.

43 Additional Disclosure Requirements

No transactions or disclosures to report against the following disclosure requirements as notified by MCA pursuant to amended Schedule III of the Act:

- (a) Benami Property held under Prohibition of Benami Property Transactions Act, 1988 and rules made thereunder
- (b) Wilful Defaulter
- (c) Scheme of arrangements in terms of section 230 to 237 of the Act
- (d) Crypto Currency or Virtual Currency
- (e) Borrowings from banks or financial institutions on the basis of security of current assets
- (f) Revaluation of investment property
- (g) Utilisation of borrowed funds/ share premium
- (h) Loans & Advances to promoters, directors, KMPs and related parties

44 Previous year figures have been re-grouped, re-classified where ever necessary

As per our attached report of even date.


For V.B.GOEL & CO
Chartered Accountants
Firm Registration No.: 115906W


Vikas Goel
Partner
Membership. No.39287
Place : Mumbai
Date : 20-05-2026



For and on behalf of the Board of Directors of Influx Healthtech Limited


Munir Chandniwala
(Managing Director)
DIN: 08459582
Place : Mumbai
Date : 20-05-2026


Shirin Chandniwala
(Whole - Time Director)
DIN: 08459623
Place : Mumbai
Date : 20-05-2026


Ashish Shah
(Chief Financial Officer)
Place: Mumbai
Date : 20-05-2026


Atul Shukla
(Company Secretary)
Membership Number : ACS46854
Place: Mumbai
Date : 20-05-2026

INDEPENDENT AUDITORS' REPORT

TO THE MEMBERS OF INFLUX HEALTHTECH LIMITED

Report on the Audit of the Consolidated Financial Statements

Opinion

We have audited the accompanying consolidated financial statements of **INFLUX HEALTHTECH LIMITED** (hereinafter referred to as “the Holding Company”) and its subsidiary (Holding Company and its subsidiary together referred to as “the Group”), which comprise the Consolidated Balance Sheet as at March 31, 2026, the Consolidated Statement of Profit and Loss Account, the Consolidated Cash Flows Statement for the year then ended, and notes to the consolidated financial statements, including a summary of significant accounting policies and other explanatory information (hereinafter referred to as “the consolidated financial statements”)

In our opinion and to the best of our information and according to the explanations given to us aforesaid consolidated financial statements give the information required by the Companies Act, 2013 (“the Act”) in the manner so required and give a true and fair view in conformity with the Accounting Standards prescribed under section 133 of the Act read with the Companies (Accounting Standard) Rules, 2021 and other accounting principles generally accepted in India, of the consolidated state of affairs of the Company as at March 31, 2026, consolidated profit and its consolidated cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit of the consolidated financial statements in accordance with the Standards on Auditing (SAs) specified under Section 143(10) of the Act (SAs). Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Consolidated Financial Statements* section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (“ICAI”) together with the ethical requirements that are relevant to our audit of the consolidated financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on the consolidated financial statements.



Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the consolidated financial statements of the current period. These matters were addressed in the context of our audit of the consolidated financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

We have determined that there are no key audit matters to communicate in our report.

Information other than the Consolidated Financial Statements and Auditor's Report thereon

The Holding Company's Board of Directors is responsible for the preparation of the other information. The other information comprises the information included in the Holding Company's annual report, but does not include the consolidated financial statements and our auditors' report thereon. The Holding Company's annual report is expected to be made available to us after the date of this auditor's report.

Our opinion on the consolidated financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the consolidated financial statements, our responsibility is to read the other information identified above when it becomes available and, in doing so, consider whether the other information is materially inconsistent with the consolidated financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

When we read the Holding Company's annual report, if we conclude that there is a material misstatement therein, we are required to communicate the matter to those charged with governance and determine the actions under the applicable laws and regulations.

Responsibilities of Management and those charged with governance for the consolidated financial statements

The Holding Company's Board of Directors is responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these consolidated financial statements that give a true and fair view of the consolidated financial position, consolidated financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the accounting Standards specified under section 133 of the Act. The respective board of directors of the



companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of presentation of the consolidated financial statements by the Directors of the Holding Company, as aforesaid.

In preparing the consolidated financial statements, the respective Board of Directors of the companies included in the Group are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group are responsible for overseeing the financial reporting process of the Group.

Auditor's Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- i) Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is



- higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- ii) Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the Holding company has adequate internal financial controls with reference to consolidated financial statements in place and the operating effectiveness of such controls.
 - iii) Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
 - iv) Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
 - v) Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
 - vi) Obtain sufficient appropriate audit evidence regarding the financial information of such entities or business activities within the Group of which we are independent auditors and to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the audit of financial information of such entities. For the other entities included in the consolidated financial statements, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

Materiality is the magnitude of the misstatement in the consolidated financial statement that,



individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the consolidated financial statement may be influenced. We consider quantitative materiality and qualitative factors in; (i) planning the scope of our audit work and evaluating the results of our work; and (ii) to evaluate the effects of any identified misstatements in the consolidated financial statements.

We communicate with those charged with governance of the Holding Company and such other entities included in the consolidated financial statements of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance of the Holding Company with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of these consolidated financial statements of the current period and are therefore the key audit matters. We have determined that there are no key audit matters to communicate in our report.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2020 ("the order") issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act, we give in the "Annexure A" a statement on the matters specified in paragraph 3(xxi) of the Order, to the extent applicable.
2. As required by section 143(3) of the Act, based on our audit, we report that:
 - a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit of the aforesaid consolidated financial statements.
 - b) In our opinion, proper books of account as required by law relating to preparation of the aforesaid consolidated financial statements have been kept so far as it appears from our examination of those books.
 - c) The Consolidated Balance Sheet, the Consolidated Statement of Profit & Loss and the



Consolidated Cash Flow Statement dealt with by this Report are in agreement with the books of account maintained for the purpose of preparation of the consolidated financial statements.

- d) In our opinion, the aforesaid consolidated financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
- e) On the basis of the written representations received from the directors of the Group as on March 31, 2026 taken on record by the Board of Directors of the Holding Company and Subsidiary Companies, none of the directors of the Group is disqualified as on March 31, 2026 from being appointed as a director in terms of Section 164 (2) of the Act.
- f) With respect to the adequacy of the internal financial controls with reference to the consolidated financial statements of the Group and the operating effectiveness of such controls, refer to our separate report in 'Annexure B' to this report. Our report expresses an unmodified opinion on the adequacy and operating effectiveness of the Group's internal financial controls with reference to consolidated financial statements.
- g) According to the information and explanations given to us and verification of the records of the company, the Holding Company has paid/provided managerial remuneration in accordance with the provisions of section 197 read with Schedule V to the Act. Further, provisions of section 197 is not applicable to subsidiary company.
- h) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
 - i) The Consolidated financial statements disclose the impact of pending litigations on the consolidated financial position of the Group as referred to in Note no. 18 to the consolidated financial statements;
 - ii) The Group did not have long-term contracts including derivative contracts for which there were no material foreseeable losses as at March 31, 2026;
 - iii) There were no amounts during the year which were required to be transferred to the Investor Education and Protection Fund by the Holding Company or its subsidiaries incorporated in India during the year ended March 31, 2026;



- iv) (a) The respective Managements of the Holding Company and its subsidiary which are companies incorporated in India whose financial statements have been audited under the Act have represented to us that, to the best of its knowledge and belief, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Holding Company or any of its subsidiary to or in any other persons or entities, including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Holding Company or any of its subsidiary ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;
- (b) The respective managements of the Holding Company and its subsidiary which are companies incorporated in India whose financial statements have been audited under the Act have represented to us, that, to the best of its knowledge and belief, no funds have been received by the Holding Company or its subsidiary from any persons or entities, including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Holding Company or any of such subsidiary shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries; and
- (c) Based on such audit procedures that have been considered reasonable and appropriate in the circumstances and according to the information and explanations provided to us by the management, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) of Rule 11(e), as provided under (a) and (b) above, contain any material misstatement.
- v) The Holding company or its subsidiary have not declared or paid any dividend during the year.



- vi) Based on our examination which included test checks, the Holding Company and its subsidiary companies incorporated in India have used accounting software(s) maintaining their respective books of account for the period ended March 31, 2026 which has a feature of recording audit trail (edit log) facility and the same has operated throughout the period for all relevant transactions recorded in the software(s). Further, during the course of our audit we did not come across any instance of audit trail feature being tampered with. Additionally, the audit trail has been preserved by the Group as per the statutory requirements for record retention.



FOR V. B. GOEL & CO.
Chartered Accountants
Firm Reg. No. 115906 W

Vr

(Vikas Goel)
Partner
Membership No. : 39287
UDIN: 26039287ZKSYGS6670

Place: Mumbai
Date: 20-05-2026

‘ANNEXURE A’ TO THE INDEPENDENT AUDITOR’S REPORT

Annexure A referred to in paragraph 21 under Report on Other Legal and Regulatory Requirements of our report of even date

According to information and explanations given to us, out of the companies incorporated in India, following companies are also included in consolidated financial statements, have certain remarks included in their reports under Companies (Auditors Report) Order, 2020 (“CARO”) which have been reproduced as per the requirement of the Guidance Note on CARO:

Sl. No.	Name of the entities	CIN	Holding Company/ Subsidiary Company	Clause number of CARO Report
1.	Influx Healthtech Limited	L24299MH2020PLC346825	Holding Company	3(vii)(a)
2.	Influx Healthtech Limited	L24299MH2020PLC346825	Holding Company	3(vii)(b)
3.	Olahey Wellness Private Limited	U21001MH2026PTC467374	Subsidiary Company	3(xvii)



FOR V. B. GOEL & CO.
Chartered Accountants
Firm Reg. No. 115906 W

W

(Vikas Goel)
Partner
Membership No. : 39287
UDIN : 26039287ZKSYGS6670

Place : Mumbai
Date : 20-05-2026

‘ANNEXURE B’ TO THE INDEPENDENT AUDITOR’S REPORT OF EVEN DATE ON THE CONSOLIDATED FINANCIAL STATEMENTS.

Report on the Internal Financial Controls with reference to consolidated financial statements under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 (“the Act”)

In conjunction with our audit of the consolidated financial statements of **INFLUX HEALTHTECH LIMITED** (hereinafter referred to as “the Holding Company”) as of and for the year ended March 31, 2026, we have audited the internal financial controls with reference to consolidated financial statements of the Holding Company and its subsidiary company which is incorporated in India (the Holding Company and its subsidiary together referred to as the “Group”), as of that date.

Management’s Responsibility for Internal Financial Controls

The respective Board of Directors of the Holding Company and its subsidiary company, to whom reporting under clause (i) of sub-section 3 of section 143 of the Act in respect of the adequacy of the internal financial controls with reference to consolidated financial statements is applicable, which are companies incorporated in India, are responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (“Guidance Note”) issued by the Institute of Chartered Accountants of India (“ICAI”). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to the respective company’s policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

Auditors’ Responsibility

Our responsibility is to express an opinion on the Holding Company's and its subsidiary company's internal financial controls with reference to consolidated financial statements based on our audit. We conducted our audit in accordance with the Guidance Note and the Standards on Auditing specified under section 143(10) of the Act, to the extent applicable to an audit of internal financial controls, both issued by the ICAI. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls with reference to consolidated financial statements was established and



maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system with reference to consolidated financial statements and their operating effectiveness. Our audit of internal financial controls with reference to consolidated financial statements included obtaining an understanding of internal financial controls with reference to consolidated financial statements, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Holding Company's and its subsidiary internal financial controls system with reference to consolidated financial statements.

Meaning of internal financial controls with reference to Consolidated financial statements

A company's internal financial control with reference to consolidated financial statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control with reference to consolidated financial statements includes those policies and procedures that

- (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company;
- (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and
- (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent limitations of internal financial controls with reference to consolidated financial statements

Because of the inherent limitations of internal financial controls with reference to consolidated financial statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls with reference to consolidated financial statements to




future periods are subject to the risk that the internal financial control with reference to consolidated financial statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, to the best of our information and according to the explanations given to us, the Holding Company, and its subsidiary company have maintained in all material respects, an adequate internal financial controls system with reference to consolidated financial statements and such internal financial controls with reference to consolidated financial statements were operating effectively as at March 31, 2026, based on the internal control over financial reporting criteria established by the Holding Company considering the essential components of internal control stated in the Guidance Note issued by the ICAI.

Place : Mumbai
Date : 20-05-2026



FOR V. B. GOEL & CO.
Chartered Accountants
Firm Reg. No. 115906 W

V. B. Goel

(Vikas Goel)
Partner
Membership No. : 39287
UDIN: 26039287ZKSYG56670

(Rs. in lakhs, unless otherwise stated)

Particulars	Note No.	As at 31 March, 2026
EQUITY AND LIABILITIES		
1. Shareholders' fund		
(a) Share Capital	2	2,315.04
(b) Reserves and Surplus	3	7,760.67
2. Non-Current Liabilities		
(a) Long Term Provision	4	23.43
3. Current Liabilities		
(a) Trade Payables	5	
- Dues to Micro, Small and Medium Enterprises ('MSME')		500.81
- Dues to Creditors Other than MSMEs		1,411.45
(b) Other Current Liabilities	6	305.73
(c) Short-term Provisions	7	53.17
TOTAL		12,370.30
ASSETS		
1. Non-Current Assets		
(a) Property, Plant & Equipment and Intangible Assets	8	
- Property, plant & Equipment		2,755.22
- Intangible assets		2.83
- Capital WIP		346.91
- Intangible asset under development		1.69
(b) Deferred Tax Asset (Net)	9	61.26
(c) Long term loans and advances	10	919.01
(d) Other non current assets	11	137.10
2. Current Assets		
(a) Current Investments	12	229.99
(b) Inventories	13	1,593.27
(c) Trade receivables	14	3,378.04
(d) Cash and Cash Equivalents	15	2,516.54
(e) Short-term loans and advances	16	393.49
(f) Other current assets	17	34.95
TOTAL		12,370.30

Notes to Accounts forming integral part of Consolidated financial statements

01-36

As per our attached report of even date.

For and on behalf of the Board of Directors of Influx Healthtech Limited

For V.B.GOEL & CO
Chartered Accountants
Firm Registration No.: 115906W



Vikas Goel
Partner
Membership. No. 39287
Place: Mumbai
Date: 20-05-2026

M.A. Chandniwala

Munir Chandniwala
(Managing Director)
DIN: 08459582
Place: Mumbai
Date: 20-05-2026

Shirin Chandniwala

Shirin Chandniwala
(Whole - Time Director)
DIN: 08459623
Place: Mumbai
Date: 20-05-2026

Ashish Shah

Ashish Shah
(Chief Financial Officer)

Place: Mumbai
Date: 20-05-2026

Atul Shukla

Atul Shukla
(Company Secretary)

Membership Number :
ACS46854
Place: Mumbai
Date: 20-05-2026

Consolidated Statement of Profit and Loss account for the year ended 31st March, 2026

(Rs. in lakhs, unless otherwise stated)

Particulars	Note No.	For the year ended 31 March, 2026
I. INCOME		
Revenue from Operations	19	14,683.36
Other Income	20	133.49
TOTAL INCOME		14,816.85
II. EXPENDITURE		
Cost of Materials Consumed	21	8,921.72
Changes in inventories of Finished Goods	22	(252.61)
Employee Benefit Expenses	23	1,175.47
Finance Cost	24	18.42
Depreciation & Amortization	8	377.80
Other Expenses	25	1,853.00
TOTAL EXPENSES		12,093.80
III. Net Profit before tax (I-II)		2,723.05
IV. Tax Expenses		
Current Tax		710.47
Deferred Tax		(43.02)
Short/(Excess) Provision for Income tax		1.73
V. Net Profit after tax (III-IV)		2,053.87
VI. Earning per Equity Share	28	
Basic (in Rs.)		9.35
Diluted (in Rs.)		9.35


Notes to Accounts forming integral part of Consolidated financial statements

01-36

As per our attached report of even date

For and on behalf of the Board of Directors of Influx Healthtech Limited

For V.B.GOEL & CO
Chartered Accountants
Firm Registration No.: 115906W



Vikas Goel
Partner
Membership. No. 39287
Place: Mumbai
Date: 20-05-2026

Munir Chandniwala

Munir Chandniwala
(Managing Director)
DIN: 08459582
Place: Mumbai
Date: 20-05-2026

Shirin Chandniwala

Shirin Chandniwala
(Whole - Time Director)
DIN: 08459623
Place: Mumbai
Date: 20-05-2026

Ashish Shah

Ashish Shah
(Chief Financial Officer)

Place: Mumbai
Date: 20-05-2026

Atul Shukla

Atul Shukla
(Company Secretary)

Membership Number : ACS46854
Place: Mumbai
Date: 20-05-2026

Consolidated Statement of Cash flows for the year ended 31st March, 2026

(Rs. in lakhs, unless otherwise stated)	
Particulars	For the year ended 31 March, 2026
A) Cash Flow from Operating Activities	
Net Profit before tax & extraordinary items	2,723.05
Adjustment For :	
Depreciation & Amortization Expenses	377.80
Bad Debts Written Off	36.09
Provision for bad and doubtful debts	10.24
Interest Expenses & other finance cost	18.42
Interest Income	(16.66)
Income from Capital Gains	(112.47)
Operating Profit Before Working Capital Changes	3,036.47
Adjusted for :	
Increase/(Decrease) in Trade payables	(1,029.70)
Increase/(Decrease) in Other Current Liabilities	26.56
Increase/(Decrease) in Other Non - Current Liabilities	(5.26)
Increase/(Decrease) in Provision	5.70
(Increase)/Decrease in Trade Receivables	(180.27)
(Increase)/Decrease in Inventories	(271.54)
(Increase)/Decrease in Loans and Advances	(316.93)
(Increase)/Decrease in Other Current and Non-current Assets	(41.45)
Net Cash generated from Operating activities (before tax)	1,223.58
(Tax Paid)/ Tax Refund - Net	(834.92)
Net Cash Generated from Operating Activities (A)	388.66
B) Cash Flow from Investing Activities	
Purchase of Property, Plant and Equipment, Capital Work-in-Progress, Intangible under development and Intangible Assets	(2,456.19)
Cash Outflow from Investments	(117.52)
Maturity of fixed deposit	50.00
Interest Income	7.70
Net Cash used in Investment Activities (B)	(2,516.01)
C) Cash Flow from Financing Activities	
Proceeds from Initial Public Offer (net of issue expenses)	4,474.75
(Repayment)/ Proceeds of Short Term Borrowings	(21.92)
Net cash generated from / (used in) Financing Activities (C)	4,452.83
Net Increase / (Decrease) in Cash and Cash Equivalents (A+B+C)	2,325.48
Cash and Cash Equivalents at the beginning of the Year	
Cash and cash equivalents	191.06
Short term bank deposits	-
Cash and Cash Equivalents at the end of the Year	2,516.54
Cash and cash equivalents comprise of:	
Cash on Hand	4.69
Bank Balances:	
In Current Accounts	207.98
Short Term Bank Deposit	2,303.87
Cash and cash equivalents at the end of the Year	2,516.54

Note:

i. The above Cash Flow Statement has been prepared under the 'Indirect Method' as set out in the Accounting Standard - 3 on Cash Flow Statement issued by ICAI.

As per our attached report of even date.

For and on behalf of the Board of Directors of Influx Healthtech Limited

For V.B.GOEL & CO
Chartered Accountants
Firm Registration No.: 115906W

Vikas Goel
Partner
Membership. No. 39287
Place : Mumbai
Date : 20-05-2026



Munir Chandniwala
(Managing Director)
DIN: 08459582
Place : Mumbai
Date : 20-05-2026

Ashish Shah
(Chief Financial Officer)
Place: Mumbai
Date : 20-05-2026

Shirin Chandniwala
(Whole - Time Director)
DIN: 08459623
Place : Mumbai
Date : 20-05-2026

Atul Shukla
(Company Secretary)
Membership Number : ACS46854
Place: Mumbai
Date : 20-05-2026

SUMMARY STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES & NOTES TO CONSOLIDATED FINANCIAL INFORMATION

COMPANY OVERVIEW

Influx Healthtech Limited ("the Holding Company") is a limited company incorporated on 28th September, 2020 under The Companies Act, 2013. The Company was converted From Private Limited Company to Public limited w.e.f. 23.05.2022. It has its registered office situated at 109, Ghanshyam Enclave Premises Co-op Society Plot no. 856, Laljipada, Kandivali West, Mumbai 400067. The company is engaged in the business of manufacturing and trading of Nutra Products and other related business activities.

The Company has its manufacturing unit at Plot no. 1,9,10 and 57, at Genesis Industrial Compound, Kolgaon, Palghar, Maharashtra - 401404

Principles of Consolidation

(i) The financial statements of the Company and its subsidiary are consolidated on a line-by-line basis by adding together the book values of like items of assets, liabilities, income and expenses, after fully eliminating intra-group balances and intra-group transactions in accordance with Accounting Standard 21 (AS 21) on 'Consolidated Financial Statements' notified under Section 133 and other relevant Provision of the Companies Act, 2013 'Companies (Accounting Standards) Rules, 2014 ("Accounting Standards Rules") as amended.

(ii) Investments in subsidiary is eliminated and differences between the cost of investments over the net assets on the date of investments or on the date of the financial statements immediately preceding the date of investments in subsidiaries are recognised as Goodwill or Capital Reserve, as the case may be.

(iii) The excess of the cost of acquisition over the Company's portion of equity and reserves of the subsidiary company at each time an investment is made in a subsidiary is recognized in the financial statements as Goodwill. Negative Goodwill is recognized as Capital Reserve.

(iv) Minority interest in the subsidiaries consists of

(A) The amount of equity attributable to minorities at the date on which investment in a subsidiary is made and

(B) The minority's share of movements in equity since the date the parent subsidiary relationship comes into existence.

(v) The Consolidated Financial Statements are prepared using uniform accounting policies for like transaction and other events in similar circumstances and are presented in the same manner as the Standalone Financial Statements of the Company.

(vi) Investments in subsidiaries not considered in consolidation are accounted as per AS - 13 "Accounting for Investments" as referred to in the Accounting Standard Rules.

a. Details of subsidiary with respective holdings thereof:

Name of Subsidiary	Country of incorporation	Date of acquisition	Percentage of holdings as of March 31, 2026
Olahey Wellness Private Limited	India	03-Feb-26	100%

(b) Disclosures mandated by Schedule III of the Companies Act, 2013 by way of additional information:

b) Disclosures mandated by Schedule III of the Companies Act, 2013 by way of additional information:

Name of the Entity	Net Assets		Share in Profit or Loss for the period	
	i.e. Total Assets Minus Total Liabilities			
	As a % of Consolidated Net Assets	Amount	As a % of Consolidated Profit	Amount
Parent				
Influx Healthtech Limited	99.99%	10,074.98	100.01%	2,054.13
Subsidiary				
Olahey Wellness Private Limited	0.01%	0.74	-0.01%	(0.26)

1 SIGNIFICANT ACCOUNTING POLICIES & NOTES TO ACCOUNTS

A Basis of Preparation of Financial statements

These financial statements have been prepared in accordance with the generally accepted accounting principles in India under the historical cost convention on accrual basis. These financial statements have been prepared to comply in all material aspects with the accounting standards notified under the Companies (Accounting Standards) Rules, 2006 (as amended), specified under section 133 and other relevant provisions of the Companies Act, 2013.

All assets and liabilities have been classified as current or non-current as per the Company's operating cycle and other criteria set out in the Schedule III (Division I) to the Companies Act, 2013. Based on the nature of products and the time between the acquisition of assets for processing and their realisation in cash and cash equivalents, the Company has ascertained its operating cycle as 12 months for the purpose of current – non-current classification of assets and liabilities.

B Use of Estimates

The preparation of Financial Statements in conformity with Generally Accepted Accounting Principles in India requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses and disclosure of contingent assets and liabilities at the end of the reporting period. The estimates and assumptions used in the accompanying Financial Statements are based upon management's evaluation of the relevant facts and circumstances as of the date of the Financial Statements. Actual results may differ from the estimates and assumptions used in preparing the accompanying Financial Statements. Any revisions to accounting estimates are recognized prospectively in current and future periods.

C Accounting Convention

The Company follows the mercantile system of accounting, recognizing income and expenditure on accrual basis. The accounts are prepared on historical cost basis and as a going concern.

Accounting policies not referred to specifically otherwise, are consistent with the generally accepted accounting principles.

The following significant accounting policies are adopted in the preparation and presentation of these financial statements:

D Current versus non-current classification

The assets and liabilities in the balance sheet are presented based on current and non-current classification:

An asset is current when it is:

- Expected to be realised or intended to be sold or consumed in normal operating cycle, or
- Held primarily for the purpose of trading, or
- Expected to be realised within twelve months after the reporting period, or
- Cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. All other assets are classified as non-current.

A liability is current when it is:

- Expected to be settled in normal operating cycle, or
- Held primarily for the purpose of trading, or
- Due to be settled within twelve months after the reporting period, or
- There is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period

All other liabilities are treated as non-current. Deferred tax assets / liabilities are classified as non-current assets and liabilities respectively.

E Property, Plant & Equipment and Intangible Assets

(a) Tangible Assets

Property, Plant and Equipment are stated at cost, net of accumulated depreciation and accumulated impairment losses, if any. Cost comprises of the purchase price including import duties and non-refundable taxes, and directly attributable expenses incurred to bring the asset to the location and condition necessary for it to be capable of being operated in the manner intended by management. Subsequent costs related to an item of Property, Plant and Equipment are recognised in the carrying amount of the item if the recognition criteria are met.

Items of Property, Plant and Equipment that have been retired from active use and are held for disposal are stated at the lower of their net carrying amount and net realisable value and are shown separately in the financial statements under the head 'Other current assets'. Any write-down in this regard is recognised immediately in the Statement of Profit and Loss.

An item of Property, Plant and Equipment is derecognised on disposal or when no future economic benefits are expected from its use or disposal. The gain or loss arising on derecognition is recognised in the Statement of Profit and Loss.

(b) **Intangible Assets**

(i) **Acquired Intangible Assets**

Intangible assets are stated at acquisition cost, net of accumulated amortization and accumulated impairment losses, if any.

Gains or losses arising from the retirement or disposal of an intangible asset are determined as the difference between the net disposal proceeds and the carrying amount of the asset and recognised as income or expense in the Statement of Profit and Loss.

(ii) **Impairment of Assets**

Assessment is done at each balance sheet date as to whether there is any indication that an asset (tangible and intangible) may be impaired. If any such indication exists, an estimate of the recoverable amount of the asset/cash generating unit is made. Recoverable amount is higher of an asset's or cash generating unit's net selling price and its value in use. Value in use is the present value of estimated future cash flows expected to arise from the continuing use of an asset and from its disposal at the end of its useful life. For the purpose of assessing impairment, the recoverable amount is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or groups of assets. The smallest identifiable group of assets that generates cash inflows from continuing use that are largely independent of the cash inflows from other assets or groups of assets, is considered as a cash generating unit (CGU). An asset or CGU whose carrying value exceeds its recoverable amount is considered impaired and is written down to its recoverable amount. Assessment is also done at each balance sheet date as to whether there is any indication that an impairment loss recognised for an asset in prior accounting periods may no longer exist or may have decreased. An impairment loss is reversed to the extent that the asset's carrying amount does not exceed the carrying amount that would have been determined if no impairment loss had previously been recognised.

(c) **Capital Work-in-Progress (CWIP)**

Capital Work-in-Progress comprises the cost of assets that are in the process of construction/erection and are not yet ready for their intended use as at the Balance Sheet date. CWIP is carried at cost, which includes direct costs and other directly attributable expenditures. Upon completion and readiness for intended use, the accumulated cost is transferred to the respective head of Property, Plant and Equipment.

(d) **Intangible Assets Under Development**

Intangible Assets Under Development represents expenditure incurred on intangible assets that are under development and not yet ready for their intended use as at the Balance Sheet date. Such expenditure is capitalised only when the Company can demonstrate technical feasibility, intention and ability to complete the asset. Upon completion readiness for intended use, the accumulated cost is transferred to Intangible Assets.

(e) **Depreciation**

Depreciation on tangible assets is provided to the extent depreciable amount on the Written Down Value(WDV) Method. Depreciation is provided based on useful life of assets as prescribed in Schedule II to the Companies Act, 2013.

Intangible assets are amortised on a straight line basis over their estimated useful lives. A rebuttable presumption that the useful life of an intangible asset will not exceed ten years from the date when the asset is available for use is considered by the management. The amortisation period and the amortisation method are reviewed at least at each financial year end. If the expected useful life of the asset is significantly different from previous estimates, the amortisation period is changed accordingly.

The estimates of useful lives of property plant and equipment are as follows :

Types Of Asset	Useful life as per Schedule II
Building	30
Plant and Machinery	15
Furniture and Fixtures	10
Office Equipment	5
Motor Vehicles	8
Computer Software	3 to 10

F Non-Current Investments

Non-current investments are investments other than current investments and are intended to be held for more than one year from the date of acquisition. Non-current investments are carried at cost less provision for diminution, if any.

Provision for diminution in value is made only if such diminution is considered other than temporary in nature, and is determined separately for each individual investment.

On disposal, the difference between the carrying amount and net disposal proceeds is recognised in the Statement of Profit and Loss.

G Current Investments

Current investments are investments that are by nature readily realisable and intended to be held for not more than one year from the date of acquisition.

Current investments are carried at the lower of cost and fair value, determined on an individual investment basis.

H Inventories

Inventories of Raw Materials are valued at lower of cost or net realizable value. The method used for valuation or determination of cost is as per First-in-First-Out (FIFO) basis.

Inventories of stores, regular spares, fuel and packing material are valued at cost or net realizable value whichever is lower. First-in-First-Out (FIFO) method is used for valuation purpose. Inventories of finished goods are valued at lower of factory cost (including material, labour and related overheads and depreciation) and net realizable value.

Goods and Service Tax ('GST') Input, being tax which is set-off against GST output, does not form a part of cost of inventory as prescribed in AS – 2 on "Valuation of Inventories".

I Cash and Cash Equivalents

In the cash flow statement, cash and cash equivalents include cash in hand, demand deposits with banks, other short-term highly liquid investments with original maturities of three months or less.

J Provisions and Contingent Liabilities

(a) Provisions

Provisions are recognised when there is a present obligation as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and there is a reliable estimate of the amount of the obligation. Provisions are measured at the best estimate of the expenditure required to settle the present obligation at the Balance sheet date and are not discounted to its present value.

(b) Contingent Liabilities

Contingent liabilities are disclosed when there is a possible obligation arising from past events, the existence of which will be confirmed only by the occurrence or non occurrence of one or more uncertain future events not wholly within the control of the Company or a present obligation that arises from past events where it is either not probable that an outflow of resources will be required to settle or a reliable estimate of the amount cannot be made.

K Revenue Recognition

Sales are recognised when the significant risks and rewards of ownership in the goods are transferred to the buyer as per the terms of the contract, which coincides with the delivery of goods and are recognised net of trade discounts, rebates, Goods and Service tax.

Service income is accounted as and when services are rendered and are net of Goods and Service tax.

L Other Income

Interest income is recognised on a time proportion basis taking into account the amount outstanding and the rate applicable.

Export benefits, incentives and licenses: Export incentives are recognized as income when the right to receive credit as per the terms of the scheme is established in respect of the exports made and where there is no significant uncertainty regarding the ultimate collection of the relevant export proceeds.

Rental income is recognised in the statement of profit and loss on the straight line basis over the period of lease term.

M Borrowing costs

Borrowing costs include interest, other costs incurred in connection with borrowing and exchange differences arising from foreign currency borrowings to the extent that they are regarded as an adjustment to the interest cost. General and specific borrowing costs directly attributable to the acquisition, construction or production of qualifying assets, which are assets that necessarily take a substantial period of time to get ready for their intended use or sale, are added to the cost of those assets, until such time as the assets are substantially ready for their intended use or sale. All other borrowing costs are recognised in Statement of Profit and Loss in the period in which they are incurred.

N Employees Benefits

(a) Provident Fund

Contribution towards provident fund for employees is made to the regulatory authorities, where the Company has no further obligations. Such benefits are classified as Defined Contribution Schemes as the Company does not carry any further obligations, apart from the contributions made on a monthly basis.

(b) Gratuity

The Company provides for gratuity, a defined benefit plan (the "Gratuity Plan") covering eligible employees in accordance with the Payment of Gratuity Act, 1972. The Gratuity Plan provides a lump sum payment to vested employees at retirement, death, incapacitation or termination of employment, of an amount based on the respective employee's salary and the tenure of employment. The Company's liability is actuarially determined (using the Projected Unit Credit method) at the end of each year. Actuarial losses/ gains are recognised in the Statement of Profit and Loss in the year in which they arise.

(c) Termination Benefits

Termination benefits in the nature of voluntary retirement benefits are recognised in the Statement of Profit and Loss as and when incurred.

O Current and Deferred Tax

Tax expense for the period, comprising current tax and deferred tax, are included in the determination of the net profit or loss for the period. Current tax is measured at the amount expected to be paid to the tax authorities.

Deferred tax is recognised for all the timing differences, subject to the consideration of prudence in respect of deferred tax assets. Deferred tax assets are recognised and carried forward only to the extent that there is a reasonable certainty that sufficient future taxable income will be available against which such deferred tax assets can be realised. Deferred tax assets and liabilities are measured using the tax rates and tax laws that have been enacted or substantively enacted by the Balance Sheet date. In situations, where the Company has unabsorbed depreciation or carry forward losses under tax laws, all deferred tax assets are recognised only to the extent that there is virtual certainty supported by convincing evidence that they can be realised against future taxable profits. At each Balance Sheet date, the Company re-assesses unrecognised deferred tax assets, if any.

Current tax assets and current tax liabilities are offset when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle the asset and the liability on a net basis. Deferred tax assets and deferred tax liabilities are offset when there is a legally enforceable right to set off assets against liabilities representing current tax and where the deferred tax assets and the deferred tax liabilities relate to taxes on income levied by the same governing taxation laws.

P Foreign Currency Transaction

(a) Initial Recognition

On initial recognition, all foreign currency transactions are recorded by applying to the foreign currency amount the exchange rate between the reporting currency and the foreign currency at the date of the transaction.

(b) Subsequent Recognition

As at the reporting date, non-monetary items which are carried in terms of historical cost denominated in a foreign currency are reported using the exchange rate at the date of the transaction. All non-monetary items which are carried at fair value or other similar valuation denominated in a foreign currency are reported using the exchange rates that existed when the values were determined.

All monetary assets and liabilities in foreign currency are restated at the end of accounting period. With respect to long-term foreign currency monetary items, the Company has adopted the following policy:

- Foreign exchange difference on account of a depreciable asset, is adjusted in the cost of the depreciable asset, which would be depreciated over the balance life of the asset

- In other cases, the foreign exchange difference is accumulated in a Foreign Currency Monetary Item Translation Difference Account, and amortised over the balance period of such long term asset/ liability

A monetary asset or liability is termed as a long-term foreign currency monetary item, if the asset or liability is expressed in a foreign currency and has a term of 12 months or more at the date of origination of the asset or liability.

Exchange differences on restatement of all other monetary items are recognised in the Statement of Profit and Loss.

Q Earning / (loss) Per Share

Basic earnings / (loss) per share is calculated by dividing the net profit or loss for the period attributable to equity shareholders by the weighted average number of equity shares outstanding during the period. Earnings considered in ascertaining the Company's earnings per share is the net profit for the period after deducting preference dividends and any attributable tax thereto for the period. The weighted average number of equity shares outstanding during the period and for all periods presented is adjusted for events, such as bonus shares, other than the conversion of potential equity shares that have changed the number of equity shares outstanding, without a corresponding change in resources. For the purpose of calculating diluted earnings per share, the net profit or loss for the period attributable to equity shareholders and the weighted average number of shares outstanding during the period is adjusted for the effects of all dilutive potential equity shares.

(Rs. in lakhs, unless otherwise stated)

Note No.	Particulars	As at 31 March, 2026	
		Number	Amount
2 SHARE CAPITAL			
(a) Authorised Capital			
	Equity Shares Of Rs. 10 Each	25,000,000	2,500.00
(b) Issued, Subscribed & Fully Paid Up Capital			
	Equity Shares of Rs. 10 each fully Paid	23,150,400	2,315.04
	Total		2,315.04

(c) **Par value per share:**

The Company has only one class of Equity Shares having a par value Rs. 10 per share.

(d) **A reconciliation of the number of shares and amount outstanding at the beginning and at the end of the reporting period:**

Particulars	31 March, 2026	
	No. of Shares	Amount
Equity Shares at the beginning of the year	18,150,000	181,500,000
Add: Share issued during the year	5,000,400	50,004,000
Less: Shares bought back during the year	-	-
Equity Shares at the end of the year	23,150,400	231,504,000

(e) **The rights, preferences and restrictions attaching to each class of shares including restrictions on the distribution of dividends and the repayment of capital:**

The Company has issued only one class of equity shares having a par value of Rs. 10 each. Each equity shareholders is entitled to one vote per share. Dividend, if any, is declared and paid in Indian Rupees. Dividend, if any, proposed by the Board of Director is subject to the approval of the share holders in the ensuing Annual General Meeting.

In the event of liquidation of the Company, the holders of equity shares will be entitled to receive remaining assets of the Company, after distribution of all preferential amounts, if any. The distribution will be proportion to the number of equity shares held by the shareholders.

(f) **Shares in respect of each class in the company held by its holding company or its ultimate holding company including shares held by or by subsidiaries or associates of the holding company or the ultimate holding company in aggregate:**

There are no holding or associate companies. Accordingly repoting to that extent under this clause is not applicable. Futher, no shares have been held by the subsidiary company.

(g) **Shares in the company held by each shareholder holding more than 5 per cent. shares specifying the number of shares held:**

Name of Shareholders	31 March, 2026	
	No. of Shares	% Held
Munir Chandniwala	16,142,100	69.73%

(h) **Aggregate number of bonus shares issued or shares issued for consideration other than cash and shares bought back during the period of five years immediately preceeding the reporting date.**

Particulars	As at 31.03.2026 (No. of Shares)
a) Equity shares allotted as fully paid up pursuant to contracts for consideration other than cash	Nil
b) Subscription amount is adjusted against a bona fide debt payable in money at once by the company.	Nil
c) Conversion of loan into shares in the event of default in repayment.	Nil
d) Conversion of loan into shares in the event of default in repayment.	Nil
e) Equity Shares allotted as fully paid bonus shares by capitalisation of reserves.	Nil

(i) Shareholding of Promoters

The details of the shares held by promoters as at March 31, 2026 are as follows :

Promoter Name	No. of Shares	% of Total Shares	% change during the year
Munir Chandniwala	16,142,100	69.73%	-25.27%
Shirin Chandniwala	880,638	3.80%	-1.05%
Abdul Ganee Chandniwala	726	0.00%	0.00%
Total	17,023,464	73.53%	

The details of the shares held by promoters as at March 31, 2025 are as follows :

Promoter Name	No. of Shares	% of Total Shares
Munir Chandniwala	17,242,500	95.00%
Shirin Chandniwala	880,638	4.85%
Abdul Ganee Chandniwala	726	0.00%
Total	18,123,864	99.86%

Note No.	Particulars	As at 31 March, 2026
3	RESERVES & SURPLUS	
	Surplus in Profit & Loss Account	
	Opening Balance	1,799.55
	Add: Profit/(Loss) for the year	2,053.87
	Total(B)	3,853.41
	Securities Premium	
	Opening Balance	-
	Add: Received During the year	4,300.34
	Less : Share Issue Expenses	(393.09)
	Total(C)	3,907.26
	Total(A+B+C)	7,760.67
4	LONG TERM PROVISION	
	Provision for Employee Benefits	
	- Gratuity	23.43
	Total	23.43

Note No.	Particulars	As at 31 March, 2026
5	TRADE PAYABLES	
	(a) Total outstanding dues of micro enterprises and small enterprises*	500.81
	(b) Total outstanding dues of creditors other than micro enterprises and small enterprises	1,411.45
	Total	1,912.26

* The information regarding Micro and Small enterprises have been determined to the extent such parties have been identified on the basis of information available with the Company.

(a) Trade payable ageing schedule

Figures for Reporting Period ended 31 March, 2026

Particulars	Outstanding for following periods from due date of payment					Total
	Unbilled Due	Less than 1 Year	1-2 years	2-3 years	More than 3years	
Undisputed Dues-MSME	2.58	498.23	-	-	-	500.81
Undisputed Dues-Other than MSME	29.25	1,382.20	-	-	-	1,411.45
Disputed Dues-MSME	-	-	-	-	-	-
Disputed Dues-Others	-	-	-	-	-	-
Total	31.82	1,880.43	-	-	-	1,912.26

(b) Dues to Micro and Small Enterprises

The disclosure pursuant to the said Micro, Small and Medium Enterprises Development Act, 2006 ('MSMED Act') are as follows: -

Particulars	As at 31 March, 2026
i) Principal amount due to suppliers registered under the MSMED Act and remaining unpaid as at year end.	498.23
ii) Interest due thereon to suppliers registered under the MSMED Act and remaining unpaid as at year end.	-
iii) Principal amounts paid to suppliers registered under the MSMED Act, beyond the appointed day during the year.	-
iv) Interest paid under Section 16 of MSMED Act to suppliers registered under the MSMED Act, beyond the appointed day during the year.	-
v) Amount of interest due and payable for the period (where the principal has been paid but interest under the MSMED Act, 2006 not paid)	-
vi) Interest accrued and remaining unpaid at the end of each accounting year	-

Note No.	Particulars	As at 31 March, 2026
6	OTHER CURRENT LIABILITIES	
	Statutory dues Payable	24.95
	Income received in advance	155.36
	Employee Dues Payable	74.71
	Payable for Capital Goods	50.71
	Total	305.73
7	SHORT TERM PROVISIONS	
	Provision for Tax (Net of advances)	53.17
	Total	53.17

8 PROPERTY, PLANT AND EQUIPMENT

(All Amounts in Rs. Lakhs, unless otherwise stated)

SR. No.	DESCRIPTION OF ASSET	GROSS BLOCK				DEPRECIATION				NET BLOCK	
		AS AT 01/04/2025	ADDITION DURING THE PERIOD	DEDUCTION DURING THE PERIOD	AS AT 31/03/2026	UP TO 31/03/2025	ADDITION DURING THE PERIOD	DEDUCTIONS DURING THE PERIOD	AS AT 31/03/2026	AS AT 31/03/2026	
a)	TANGIBLE ASSETS										
	Land	-	260.25	-	260.25	-	-	-	-	260.25	
	Premises	750.54	221.65	-	972.19	82.40	76.90	-	159.30	812.88	
	(includes Capital cost on Rented Property)										
	Plant & Machinery	1,414.16	688.40	-	2,102.56	387.35	233.73	-	621.08	1,481.48	
	Office Equipment	40.29	15.42	-	55.72	24.72	11.29	-	36.01	19.70	
	Furniture & Fixtures	198.07	30.92	-	228.99	54.38	43.09	-	97.47	131.52	
	Motor Vehicle	30.71	38.85	-	69.55	14.59	9.67	-	24.26	45.29	
	Computer Hardware	10.50	4.04	-	14.54	8.33	2.12	-	10.45	4.09	
	Sub Total (A)	2,444.27	1,259.53	-	3,703.80	571.77	376.81	-	948.58	2,755.22	
b)	INTANGIBLE ASSETS										
	Computer Software	5.86	-	-	5.86	2.05	0.99	-	3.04	2.83	
	Sub Total (B)	5.86	-	-	5.86	2.05	0.99	-	3.04	2.83	
	Total (A)+(B)	2,450.13	1,259.53	-	3,709.66	573.81	377.80	-	951.61	2,758.05	
c)	Capital Work in Progress (CWIP)										
	Capital Work in Progress	-	346.91	-	346.91	-	-	-	-	346.91	
	Sub Total (C)	-	346.91	-	346.91	-	-	-	-	346.91	
d)	Intangible asset under development										
	Intangible asset under development	-	1.69	-	1.69	-	-	-	-	1.69	
	Sub Total (D)	-	1.69	-	1.69	-	-	-	-	1.69	
	Total (A)+(B)+(C)+(D)	2,450.13	1,608.13	-	4,058.26	573.81	377.80	-	951.61	3,106.64	

(i) The Company has not revalued its Property, Plant and Equipment since the Company has adopted cost model as its accounting policy to an entire class of Property, Plant and Equipment in accordance with AS 10.

(ii) The company does not hold any immovable property whose title deeds are not held in the name of the company.

Capital work-in-progress(CWIP)
Ageing as at March 31, 2026

Particulars	Amount in CWIP for a period of				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
Projects in progress	346.91	-	-	-	346.91
Projects temporarily suspended	-	-	-	-	-
Total	346.91	-	-	-	346.91

Intangible asset under development
Ageing as at March 31, 2026

Particulars	Amount in CWIP for a period of				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
Projects in progress	1.69	-	-	-	1.69
Projects temporarily suspended	-	-	-	-	-
Total	1.69	-	-	-	1.69

Note No.	Particulars	As at 31 March, 2026
9	DEFERRED TAX ASSET (NET)	
	<u>Deferred Tax Asset</u>	
	- On account of Depreciation	15.44
	- On account of provision for doubtful debts	6.23
	- On account of disallowance u/s 35D	31.54
	- On account of disallowance u/s 43B	6.70
	- On account of disallowance u/s 40(a)(ia)	1.26
	- On account of Business loss	0.09
	Total	61.26
10	LONG TERM LOANS AND ADVANCES	
	<u>Unsecured & Considered Good</u>	
	Capital Advances	919.01
	Total	919.01
	(a) Loans and Advances due by directors or other officers of the company or any of them either severally or jointly with any other person	Nil
	(b) Loans and Advances due by firm or private companies in which director is a partner or director or member	Nil
	(c) Loans or advances in the nature of loans granted to Promoters, Directors, Kmps and their related parties (as defined under Companies Act, 2013), either severally or jointly with any other person, that are:	
	(i) repayable on demand; or	Nil
	(ii) without specifying any terms or period of repayment	Nil
	(d) In line with Circular No. 04/2015 issued by the Ministry of Corporate Affairs dated March 10, 2015, loans given to employees as per the Company's policy are not considered for the purpose of disclosure under section 186(4) of the Companies Act, 2013.	Nil
11	OTHER NON CURRENT ASSETS	
	<u>Unsecured, Considered good</u>	
	Rental Deposits	122.09
	Security deposits	15.01
	Bank Deposits with maturity more than 12 months	-
	Total	137.10
	(a) Debts due by directors or other officers of the company or any of them either severally or jointly with any other person	115.00
	(b) Debts due by firm or private companies in which director is a partner or director or member	Nil

Note No.	Particulars	As at 31 March, 2026															
12	Current Investment																
	Unquoted Investments																
	<u>Investment in Mutual Funds</u> (at lower of cost and market value)																
	<table> <tr> <th>Particulars</th><th>No. of units</th><th>As at 31 March, 2026</th></tr> <tr> <td>Aditya Birla Sun Life Arbitrage Fund</td><td>181,735.74</td><td>50.00</td></tr> <tr> <td>Aditya Birla Sun Life Savings Fund</td><td>22,884.22</td><td>129.99</td></tr> <tr> <td>WhiteOak Capital Arbitrage Fund</td><td>456,973.77</td><td>50.00</td></tr> <tr> <td>Total</td><td></td><td>229.99</td></tr> </table>	Particulars	No. of units	As at 31 March, 2026	Aditya Birla Sun Life Arbitrage Fund	181,735.74	50.00	Aditya Birla Sun Life Savings Fund	22,884.22	129.99	WhiteOak Capital Arbitrage Fund	456,973.77	50.00	Total		229.99	
Particulars	No. of units	As at 31 March, 2026															
Aditya Birla Sun Life Arbitrage Fund	181,735.74	50.00															
Aditya Birla Sun Life Savings Fund	22,884.22	129.99															
WhiteOak Capital Arbitrage Fund	456,973.77	50.00															
Total		229.99															
	The aggregate amount of unquoted investments	229.99															
	The aggregate amount of provision for diminution in value of investments	Nil															
13	INVENTORIES (Valued at lower of cost or estimated net realisable value)																
	Raw Materials	964.22															
	Packing Materials	298.75															
	Finished Goods	330.30															
	Total	1,593.27															
14	TRADE RECEIVABLES																
	Secured, Considered Good	-															
	Unsecured, Considered Good	3,378.04															
	Doubtful	24.75															
	Less: Allowance for Bad and Doubtful Debts	(24.75)															
	Total	3,378.04															
	Debts Due by firm or private companies in which director is partner, director or	1.78															
	Debts Due by directors or other officers of the company	Nil															

Figures for Reporting Period ended 31 March, 2026

Particulars	Outstanding for following periods from due date of payment					Total
	Less than 6 months	6 months -1 year	1-2 years	2-3 years	More than 3 years	
Undisputed Trade receivables						
considered good	2,690.29	339.01	345.20	-	-	3,374.49
considered doubtful	-	-	9.10	15.66	-	24.75
Disputed Trade						
considered good	-	3.55	-	-	-	3.55
considered doubtful	-	-	-	-	-	-
Less: Allowance for Bad and Doubtful Debts						
	-	-	(9.10)	(15.66)	-	(24.75)
Total	2,690.29	342.55	345.20	-	-	3,378.04

Note No.	Particulars	As at 31 March, 2026
15	CASH AND CASH EQUIVALENTS	
	Balances with banks	
	In Current Account	207.98
	Deposits with maturity less than 3 months*	2,303.87
	Cash on hand	4.69
	Total	2,516.54
*Deposits include Rs. 2,289.19 lakhs representing unutilized proceeds from the Initial Public Offering (IPO). These balances are earmarked specifically for the objects of the issue as stated in the Prospectus and are not available for use in the company's day-to-day operations.		
16	SHORT TERM LOANS AND ADVANCES (Unsecured-Considered Good)	
	Advance paid against supply of goods & services	27.13
	Loans and advances to Employees	18.72
	Prepaid Expenses	18.33
	Input tax credit available for utilisation	329.30
	Total	393.49
	<i>Loans and Advances due by directors or other officers of the company or any of them either severally or jointly with any other person</i>	<i>Nil</i>
	<i>Loans and Advances due by firm or private companies in which director is a partner or director or member</i>	<i>Nil</i>
	<i>Loans or advances in the nature of loans granted to Promoters, Directors, KMPs and their related parties (as defined under Companies Act, 2013), either severally or jointly with any other person, that are:</i>	
	<i>(i) repayable on demand; or</i>	<i>Nil</i>
	<i>(ii) without specifying any terms or period of repayment</i>	<i>Nil</i>
	<i>In line with Circular No. 04/2015 issued by the Ministry of Corporate Affairs dated March 10, 2015, loans given to employees as per the Company's policy are not considered for the purpose of disclosure under section 186(4) of the Companies Act, 2013.</i>	<i>Nil</i>
17	OTHER CURRENT ASSETS	
	Unsecured, Considered good	
	Interest accrued on fixed deposits	10.03
	Deposit paid under GST litigation	17.59
	Refund under GST law	7.33
	Total	34.95
18	CONTINGENT LIABILITIES & COMMITMENTS	
a)	Contingent Liabilities	
	GST Penalty under dispute for non-compliance of E-way Bill provision <i>(Amount paid under dispute Rs. 17.59 lakhs)</i>	17.59
b)	Commitments	
	Estimated amounts of contracts remaining to be executed on capital account and not provided for	1,532.30

(Rs. in lakhs, unless otherwise stated)

Note No.	Particulars	For the year ended 31 March, 2026
19	REVENUE FROM OPERATION	
	Sale of products	14,584.43
	Other Operating revenues	98.93
	Total	14,683.36
20	OTHER INCOME	
	Interest received on Fixed Deposit	16.66
	Rent Received	3.60
	Duty Drawback Income Received	0.09
	Gain on variation in foreign exchange rate	0.66
	Net gain on sale of investments	112.47
	Total	133.49
21	COST OF MATERIAL CONSUMED	
	Opening Stock	
	Raw Material	1,048.87
	Packing Material	195.18
		1,244.04
	Add: Purchases	
	Raw Material	6,100.66
	Packing Material	2,839.98
		8,940.64
	Less: Closing Stock	
	Raw Material	(964.22)
	Packing Material	(298.75)
		(1,262.97)
	Total	8,921.72
22	CHANGES IN INVENTORIES OF FINISHED GOODS	
	Opening Stock of Goods	
	Finished Goods	77.69
	Total (I)	77.69
	Closing Stock of Goods	
	Finished Goods	330.30
	Total (II)	330.30
	Net Impact (I-II)	(252.61)
23	EMPLOYEE BENEFIT EXPENSES	
	Salaries, Wages & Allowances	934.00
	Directors Remuneration	120.00
	Contribution to Provident fund and other fund	59.07
	Group Insurance for Staff	5.79
	Staff Welfare Expenses	33.18
	Contribution to Gratuity fund	23.42
	Total	1,175.47
24	FINANCE COSTS	
	Interest Expenses	
	Interest on income tax	18.42
	Total	18.42

(Rs. in lakhs, unless otherwise stated)

Note No.	Particulars	For the year ended 31 March, 2026
25	OTHER EXPENSES	
	<u>Manufacturing Expenses</u>	
	Labour Charges	591.96
	Power & Fuel Charges	183.07
	Transportation Expenses	142.27
	Factory Rent	89.46
	Factory Expenses	83.16
	Cartridge Filling Expenses	29.09
	Packing & Forwarding	15.18
	Laboratory Expenses	12.93
		1,147.11
	 Administrative & Other Expenses	
	Legal, Professional, Listing and License Fees	77.94
	Listing related Expenses	141.31
	Repair & Maintenance	111.29
	Office Rent	42.61
	Travelling & Conveyance Expenses	31.61
	Corporate Social Responsibility Expenses	28.85
	Provision for Doubtful Debts (net of reversal)	10.24
	Vehicle Expenses	7.64
	Courier Charges	9.64
	Bad Debts	36.09
	Printing & Stationery	10.50
	Insurance Expenses	7.18
	Electricity Expenses	3.49
	Donation	4.06
	Society Maintenance Charges	2.88
	<u>Auditor's Remuneration</u>	
	for Statutory Audit	2.65
	for Limited Review	0.75
	for other services	1.31
	Computer & Internet Expenses	4.44
	Mobile & Telephone charges	2.01
	Rates & Taxes	0.03
	Office Expenses	4.67
	Membership & Subscription Fees	0.85
	Advertisement Expense	1.45
	Bank Charges	1.00
	Charges on investments	0.23
	Software & Website Expenses	7.82
	Director Sitting Fees	1.80
	Fines and Penalties	1.10
		555.41
	 Selling & Marketing Expenses	
	Exhibition Expenses	80.42
	Commission	55.41
	Sales Promotion Expenses	14.64
		150.47
	 Total	1,853.00

26 Disclosures as required by AS 18 "Related Parties" issued by the ICAI
List of Related Parties

Sr.No	Name of Related Party	Relationship
1	Munir Chandniwala	Managing Director
2	Shirin Chandniwala	Whole Time Director
3	Abdul Ganee Chandniwala	Director
4	Ashish Shah	Chief Financial Officer
5	Atul Shukla	Company Secretary
6	ESLP Digital LLP	Other Related Party
7	Trusan Printpack Private Limited	Other Related Party
8	Chandniwala Clinic	Other Related Party
9	Influx Foundation	Other Related Party
10	Nutrapharm India	Other Related Party
11	Shinaf Enterprise	Other Related Party

Summary of significant related party transactions carried out in the ordinary course of business are as under :

(Rs. in lakhs, unless otherwise stated)

Sl.	Nature of Transaction	Year Ended March 31, 2026
I	Key Management Personnel	
(i)	Munir Chandniwala	
	Remuneration	96.00
	Loan taken	-
	Loan repaid	21.92
	Rent Paid	90.00
	Advance for fixed Asset	-
	Acquisition of fixed Asset	219.00
(ii)	Shirin Chandniwala	
	Remuneration	24.00
	Loan Repaid	-
	Rent Paid	12.00
(iii)	Ashish Shah	
	Remuneration	12.55
	Loan Given	-
	Loan Recovered	-
(iv)	Atul Shukla	
	Remuneration	7.20
II	Other Related Party	
(i)	Trusan Printpack Private Limited	
	Sale of product	2.28
	Purchase of product	314.54
	Rent Income	3.60
	Reimbursement of Expense	-
(iii)	Influx Foundation	
	Donation	2.16
(iv)	Nutrapharm India	
	Sale of product	0.29

Balance at the Year End

Sr.No	Name	Nature of Transaction	As at 31 March, 2026
1	Munir Chandniwala	Remuneration	-
2	Munir Chandniwala	Unsecured Loan	-
3	Munir Chandniwala	Security Deposit	115.00
4	Munir Chandniwala	Advance for Acquisition of Fixed Asset	-
5	Shirin Chandniwala	Remuneration	0.15
6	Trusan Printpack Private Limited	Purchase of product	8.21
7	Nutrapharm India	Sale of product	1.78
8	Ashish Shah	Remuneration	0.45
9	Atul Shukla	Remuneration	0.60

(Rs. in lakhs, unless otherwise stated)

Note No.	Particulars	For the year ended March 31, 2026
----------	-------------	-----------------------------------

27 Employee Benefit Expenses

(a) Defined Contribution Plans

Amount recognised in the Statement of Profit and Loss

(i) Employers' Contribution to Provident Fund *	45.96
[Includes Employers' Contribution to Employee's Pension Scheme 1995]	
(ii) Employers' Contribution to Employee's State Insurance Commission*	12.81

58.77

* Included in Contribution to Provident and Other Funds(Refer Note 26)

(b) Defined Benefit Plan

Gratuity

The Company has a defined benefit gratuity plan for its employees ("Gratuity Scheme"). The gratuity plan is governed by the Payment of Gratuity Act, 1972. Under the Act, every employee who has completed five years of service is entitled to specific benefit. The level of benefits provided depends on the employee's length of service and salary at retirement age. Every employee except chairman and managing director who has completed five years or more of service gets a gratuity on departure at 15 days salary (last drawn) for each completed year of service as per the provisions of the Payment of Gratuity Act, 1972. The scheme is funded with an insurance company.

(i) Change in Defined Benefit Obligation

Sr No.	Particulars	For the Year Ended March 31, 2026
1	DBO at the beginning of the period	46.39
2	Acquisition adjustment	-
3	Interest cost	3.19
4	Past Service Cost/(credit) – vested benefits	0.84
5	Past Service Cost/(credit) – Non vested benefits	-
6	Current Service Cost	12.69
7	Curtailment Cost/ (credit)	-
8	Settlement Cost/ (credit)	-
9	Plan Amendments	-
10	Benefit payments from Company	-
11	Benefit payments from fund	-
12	Actuarial (gains) loss on Obligation	7.14
13	DBO at the end of the period	70.25

(ii) Fair Value of Plan Assets

S.No	Particulars	For the Year Ended March 31, 2026
1	Fair value of plan assets (beginning)	28.66
2	Acquisition Adjustment	-
3	Charges and Taxes	-
4	Expected return on plan assets	2.58
5	Employer's contributions	17.71
6	Employee's contributions	-
7	Benefit payments	-
8	Actuarial Gain/ (Loss) on Plan Assets	(2.13)
9	Fair value of plan assets (end)	46.83

(Rs. in lakhs, unless otherwise stated)

(iii) Change in Fair Value of Plan Assets

S.No	Particulars	For the Year Ended March 31, 2026
1	Fair value of plan assets (beginning)	28.66
2	Acquisition Adjustment	-
3	Charges and Taxes	-
4	Actual return on plan assets	0.45
5	Employer's contributions	17.71
6	Employee's contributions	-
7	Benefit payments	-
8	Actuarial Gain/ (Loss) on Plan Assets	-
9	Fair value of plan assets (end)	46.83

(iv) Amount Recognition in the Statement of Profit and Loss

S.No	Particulars	For the Year Ended March 31, 2026
1	Current Service Cost	12.69
2	Interest Cost	3.19
3	Past Service Cost	0.84
4	Expected Return on Plan Assets	(2.58)
5	Curtailment Cost	-
6	Settlement Cost	-
7	Amortisation of Past Service Cost	-
8	Net Actuarial (Gains)/ Losses	9.28
9	Total Employer Expense in P&L	23.42

(v) Recognition of Actuarial Gain/ Loss

S.No	Particulars	For the Year Ended March 31, 2026
1	Unrecognized Actuarial Loss/(Gain) start	7.14
2	Actuarial loss/(gain) – Plan Assets	2.13
3	Total Actuarial Loss/(Gain)	9.28
4	(Gain)/Loss recognized	9.28
5	Unrecognized Loss/(Gain) end	-

(vi) Actuarial (Gain)/ Loss on Obligation

S.No	Particulars	For the Year Ended March 31, 2026
1	Experience Adjustment	12.08
2	Financial Change	(4.94)
3	Assumption Change	-

(vii) Recognition of Past Service Cost

S.No	Particulars	For the Year Ended March 31, 2026
1	Unrecognized Past Service Cost (start)	-
2	Past Service Cost (Credit)	-
3	Recognized Past Service Cost	-
4	Unrecognized Past Service Cost (end)	-

(Rs. in lakhs, unless otherwise stated)

(viii) Balance Sheet Reconciliation

S.No	Particulars	For the Year Ended March 31, 2026
1	Net (Asset)/Liability (beginning)	17.73
2	Employer Expense	23.42
3	Employer Contributions	(17.71)
4	Net (Asset)/Liability (end)	23.43

(ix) P&L Reconciliation

S.No	Particulars	For the Year Ended March 31, 2026
1	DBO at end of year	70.25
2	DBO at beginning of year	(46.39)
3	Benefits Paid	-
4	Actual Return on Plan Assets	(0.45)
5	Expenses deducted by the Insurer	0.01
6	Expense Recognized in P&L	23.43

(x) Major Categories of Plan Assets

S.No	Asset Categories	For the Year Ended March 31, 2026
1	Government of India Securities	0.00%
2	State Government Securities	0.00%
3	High Quality Corporate Bonds	0.00%
4	Equity shares (listed)	0.00%
5	Property	0.00%
6	Special Deposit Scheme	0.00%
7	Funds managed by Insurer	100.00%
8	Others	0.00%
9	Total	0.00%

(xi) Contribution Estimate

Description	Estimate
Company's Best Estimate of Contribution (Next Year)	23.43

28 Disclosure as required by AS 20 "Earnings Per Share" issued by the ICAI
Earning Per Share (EPS)

The earning considered in ascertaining the Company's EPS comprises the net profit after tax the number of shares used in Computation of Basic EPS is the weighted average number of share outstanding during the year which is calculated as below:

(Rs. in lakhs, unless otherwise stated)

Particular	For the Year Ended March 31, 2026
Calculation of weighted average no. equity shares :	
No. of Shares at the beginning of the year fully paid	18,150,000
No. of Shares to issued fully paid	5,000,400
Total Equity Shares outstanding at the end of the year	23,150,400
Total Equity Shares outstanding at the end of the year	21,972,224
Net Profit after tax / (loss) available for equity share holder (Rs. in Lakhs)	2,053.87
Basic / Diluted earnings per share of Rs. 10 (Rs.)	9.35
Basic / Diluted earnings per share of Rs. 10 (Rs.)	9.35

29 Impairment of Assets

There is no such impairable asset for the year as ended on 31.03.2026 in terms of AS-28. Hence company has not made any provision for impairment loss.

30 Segment Reporting

The company is engaged in single segment and there are no separate reportable segments as defined in Accounting standard – 17 "Segment Reporting".

31 IPO Funds and Application of Funds

The holding company has completed fresh issue of Equity Shares by Initial Public Offer ("IPO") of 50,00,400 Equity Shares of face value Rs.10 each at an issue price of Rs. 96 per equity share. The Equity Shares of the company were listed on National Stock Exchange of India Limited ("NSE") Emerge Platform on June 25, 2025. The details of utilization of the net proceeds as mentioned below:

Sr No.	Objects as disclosed in the offer document	Amount disclosed in offer document	Amount utilized upto 31.03.2026	Unutilized amount as on 31.03.2026
1	Funding Capital expenditure requirements for setting up of manufacturing facilities	3,673.34	1,384.15	2,289.19
2	General Corporate Purpose	667.40	667.40	-
3	Public Issue Expenses	583.24	583.24	-
	Total	4,923.98	2,634.79	2,289.19

32 Disclosure of transactions with struck off companies :

The Company did not have any material transactions with companies struck off under Section 248 of the Companies Act, 2013 or Section 560 of Companies Act, 1956 during the financial year.

33 Compliance with number of layers of Companies

The Company has complied with the requirements of the number of layers prescribed under clause (87) of section 2 of the Companies Act, 2013 read with Companies (Restriction on number of Layers) Rules, 2017.

34 Disclosure in relation to undisclosed income

During the year, the Company has not surrendered or disclosed any income in the tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961). Accordingly, there are no transactions which are not recorded in the books of accounts.

35 Additional Disclosure Requirements

No transactions or disclosures to report against the following disclosure requirements as notified by MCA pursuant to amended Schedule III of the Act:

- (a) Benami Property held under Prohibition of Benami Property Transactions Act, 1988 and rules made thereunder
- (b) Wilful Defaulter
- (c) Scheme of arrangements in terms of section 230 to 237 of the Act
- (d) Crypto Currency or Virtual Currency
- (e) Borrowings from banks or financial institutions on the basis of security of current assets
- (f) Revaluation of investment property
- (g) Utilisation of borrowed funds/ share premium

36 Comparative figures for the previous year have not been presented since the consolidated financial statements are prepared for the first time in accordance with the transition provision stated in paragraph 30 of Accounting Standard 21 "Consolidated Financial Statements".

As per our attached report of even date.

For V.B.GOEL & CO
Chartered Accountants
Firm Registration No.: 115906W

Vikas Goel
Partner

Membership. No.39287

Place : Mumbai

Date : 20-05-2026



For and on behalf of the Board of Directors of Influx Healthtech Limited

M.A. Chandniwala
Munir Chandniwala
(Managing Director)
DIN: 08459582
Place : Mumbai
Date : 20-05-2026

Ashish Shah
Ashish Shah
(Chief Financial Officer)

Place: Mumbai
Date : 20-05-2026

Shirin Chandniwala
Shirin Chandniwala
(Whole - Time Director)
DIN: 08459623
Place : Mumbai
Date : 20-05-2026

Atul Shukla
Atul Shukla
(Company Secretary)
Membership Number : ACS46854
Place: Mumbai
Date : 20-05-2026